|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Pemetrexed Disodium
Description of pemetrexed disodium:
Pemtrexed disodium is the disodium salt of a synthetic pyrimidine-based
antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate
synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate
(dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential
precursor in DNA synthesis. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
|
MedKoo Code#: 100710
|
|
Name:
Pemetrexed
Disodium
|
|
CAS#: 150399-23-8
(Pemetrexed
Disodium); 357166-29-1 (Pemetrexed
Disodium heptahydrate)
Synonym: US
brand name: ALIMTA. Abbreviation: MTA. Code name: LY231514.
IUPAC/Chemical name:
sodium
(S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
heptahydrate
|
|
Chemical structure:
|
Theoretical analysis
:
|
|
|
Pemetrexed (free
acid)
Chemical Formula: C20H21N5O6
Exact Mass: 427.14918
Elemental Analysis: C, 56.20; H, 4.95; N, 16.39; O, 22.46
Pemetrexed
Disodium
Chemical Formula: C20H19N5Na2O6
Molecular Weight: 471.37
Elemental Analysis: C, 50.96; H, 4.06;
N, 14.86; Na, 9.75; O, 20.37
Pemetrexed
Disodium heptahydrate
Chemical Formula: C20H33N5Na2O13
Molecular Weight: 597.48
Elemental Analysis: C, 40.20; H, 5.57;
N, 11.72; Na, 7.70; O, 34.81
|
|
Availability and price:
Pemetrexed disodium
heptahydrate (99%) is in
stock.
100 mg
/ $190.00
500mg / $350.00
1 g
$480.00
For questions and orders, please send email to
sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
Pemetrexed disodium heptahydrate has the chemical
name L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H
pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt,
heptahydrate. It is a white to almost-white solid with a molecular
formula of C20H19N5Na2O6•7H2O
and a molecular weight of 597.49. ALIMTA is supplied as a sterile
lyophilized powder for intravenous infusion available in single-dose
vials. The product is a white to either light yellow or green-yellow
lyophilized solid. Each 100-mg or 500-mg vial of ALIMTA contains
pemetrexed disodium equivalent to 100 mg pemetrexed and 106 mg mannitol
or 500 mg pemetrexed and 500 mg mannitol, respectively. Hydrochloric
acid and/or sodium hydroxide may have been added to adjust pH.
ALIMTA, pemetrexed for injection, is a folate analog
metabolic inhibitor that exerts its action by disrupting folate-dependent
metabolic processes essential for cell replication. In vitro studies
have shown that pemetrexed inhibits thymidylate synthase (TS),
dihydrofolate reductase (DHFR), and glycinamide ribonucleotide
formyltransferase (GARFT), which are folate-dependent enzymes involved
in the de novo biosynthesis of thymidine and purine nucleotides.
Pemetrexed is taken into cells by membrane carriers such as the reduced
folate carrier and membrane folate binding protein transport systems.
Once in the cell, pemetrexed is converted to polyglutamate forms by the
enzyme folylpolyglutamate synthetase. The polyglutamate forms are
retained in cells and are inhibitors of TS and GARFT. Polyglutamation is
a time- and concentration-dependent process that occurs in tumor cells
and, is thought to occur to a lesser extent, in normal tissues.
Polyglutamated metabolites are thought to have an increased
intracellular half-life resulting in prolonged drug action in malignant
cells.
According to
http://en.wikipedia.org/wiki/Pemetrexed: the
molecular structure of pemetrexed was developed by Edward C. Taylor at
Princeton University and clinically developed by Indianapolis based drug
maker, Eli Lilly and Company in 2004.
In February 2004, the Food and Drug Administration approved
pemetrexed for treatment of malignant pleural mesothelioma, a type of
tumor of the lining of the lung, in combination with cisplatin. In
September 2008, the FDA granted approval as a first-line treatment, in
combination with cisplatin, against of locally-advanced and metastatic
non-small cell lung cancer, or NSCLC, in patients with non-squamous
histology. A Phase III study showed benefits of maintenance use of
pemetrexed for non-squamous NSCLC. Trials are currently testing it
against esophagus and other cancers.
1: Klein R, Wielage R, Muehlenbein C,
Liepa AM, Babineaux S, Lawson A, Schwartzberg L. Cost-Effectiveness of
Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous
Non-small Cell Lung Cancer. J Thorac Oncol. 2010 Jun 24. [Epub ahead of
print] PubMed PMID: 20581708.
2: Stinchcombe TE, Bogart J, Wigle DA, Govindan R. Annual review of
advances in lung cancer clinical research: a report for the year 2009. J
Thorac Oncol. 2010 Jul;5(7):935-9. PubMed PMID: 20581576.
3: Davies JM, Dhruva NS, Walko CM, Socinski MA, Bernard S, Hayes DN, Kim
WY, Ivanova A, Keller K, Hilbun LR, Chiu M, Dees EC, Stinchcombe TE. A
phase I trial of sorafenib combined with cisplatin/etoposide or
carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer.
2010 Jun 24. [Epub ahead of print] PubMed PMID: 20580118.
4: Ostoros G, Döme B, Strausz J, Tímár J. [Changes in the diagnostic and
therapeutic strategies of non-small cell lung cancer.]. Magy Onkol. 2010
Jun;54(2):137-43. Hungarian. PubMed PMID: 20576590.
5: Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, Chang JT, Ko
JL. Genetic Determinants of Pemetrexed Responsiveness and
Nonresponsiveness in Non-small Cell Lung Cancer Cells. J Thorac Oncol.
2010 Jun 16. [Epub ahead of print] PubMed PMID: 20559153.
6: Anraku M, Tagawa T, Wu L, Yun Z, Keshavjee S, Zhang L, Johnston MR,
de Perrot M. Synergistic Antitumor Effects of Regulatory T Cell Blockade
Combined with Pemetrexed in Murine Malignant Mesothelioma. J Immunol.
2010 Jun 14. [Epub ahead of print] PubMed PMID: 20548032.
7: Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y,
Dickson R, Tudur Smith C, Davis H, Green J, Pearson M. Pemetrexed for
the first-line treatment of locally advanced or metastatic non-small
cell lung cancer. Health Technol Assess. 2010 May;14 Suppl 1:47-53.
PubMed PMID: 20507803.
8: Kim ST, Park JY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.
The Efficacy of the Frontline Platinum-based Combination Chemotherapy in
Malignant Peritoneal Mesothelioma. Jpn J Clin Oncol. 2010 Jun 9. [Epub
ahead of print] PubMed PMID: 20534685.
9: Muto O, Munakata M, Iino C, Sakata Y. Successful Treatment of Gastric
Adenocarcinoma in a Meckel's Diverticulum with Pemetrexed Plus
Carboplatin. Jpn J Clin Oncol. 2010 Jun 9. [Epub ahead of print] PubMed
PMID: 20534684.
10: Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M,
Nishio K, Nakagawa K. Enhanced anticancer effect of the combination of
BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung
cancer with the T790M mutation of epidermal growth factor receptor. Mol
Cancer Ther. 2010 Jun;9(6):1647-56. Epub 2010 Jun 8. PubMed PMID:
20530710.
11: Park KY, Jung JW, Nam SB, Lee HJ, Kim HS, Choi YH, Lee JC. Two lung
masses with different responses to pemetrexed. Korean J Intern Med. 2010
Jun;25(2):213-6. Epub 2010 Jun 1. PubMed PMID: 20526397; PubMed Central
PMCID: PMC2880697.
12: Van Schil PE, Baas P, Gaafar R, Maat AP, van de Pol M, Hasan B,
Klomp HM, Abdelrahman AM, Welch J, Van Meerbeeck J; on behalf of the
EORTC Lung Cancer Group. Phase II trial of trimodality therapy for
malignant pleural mesothelioma (EORTC 08031). Eur Respir J. 2010 Jun 4.
[Epub ahead of print] PubMed PMID: 20525721.
13: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2010 May;32(4):247-88. PubMed PMID: 20508873.
14: Wang ZK, Hu Y, Zhao H, Fu C. [Thymidylate synthase expression and
therapeutic effect analysis of pemetrexed in advanced lung
adenocarcinoma.]. Nan Fang Yi Ke Da Xue Xue Bao. 2010 May;30(5):978-80.
Chinese. PubMed PMID: 20501373.
15: Lee JH, Yu CJ, Chen KY, Shih JY, Lin YL, Yang CH. Pemetrexed for
heavily pretreated patients with advanced non-small cell lung cancer. J
Formos Med Assoc. 2010 May;109(5):338-44. PubMed PMID: 20497866.
16: Guhl G, Diaz-Ley B, Sanchez-Perez J, Jimenez U, Garcia-Diez A.
Pemetrexed-induced edema of the eyelid. Lung Cancer. 2010 May 18. [Epub
ahead of print] PubMed PMID: 20488577.
17: Grřnberg BH, Sundstrřm S, Kaasa S, Bremnes RM, Flřtten O, Amundsen
T, Hjelde HH, Plessen CV, Jordhřy M. Influence of comorbidity on
survival, toxicity and health-related quality of life in patients with
advanced non-small-cell lung cancer receiving platinum-doublet
chemotherapy. Eur J Cancer. 2010 May 12. [Epub ahead of print] PubMed
PMID: 20471248.
18: Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I
open-label study of continuous treatment with BIBF 1120, a triple
angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung
cancer patients. Clin Cancer Res. 2010 May 15;16(10):2881-9. Epub 2010
May 11. PubMed PMID: 20460487.
19: Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE,
Schneck KB, Yuan Z, Sanchez-Torres JM. Pemetrexed safety and
pharmacokinetics in patients with third-space fluid. Clin Cancer Res.
2010 May 15;16(10):2872-80. Epub 2010 May 11. PubMed PMID: 20460481.
20: Tanai C, Yamamoto N, Ohe Y, Takahashi T, Kunitoh H, Murakami H,
Yamamoto N, Nakamura Y, Nokihara H, Shukuya T, Baldwin JR, Koshiji M,
Tamura T. A Phase I Study of Enzastaurin Combined with Pemetrexed in
Advanced Non-small Cell Lung Cancer. J Thorac Oncol. 2010
Jul;5(7):1068-74. PubMed PMID: 20453691.
21: Sherman SI. Cytotoxic Chemotherapy for Differentiated Thyroid
Carcinoma. Clin Oncol (R Coll Radiol). 2010 May 8. [Epub ahead of print]
PubMed PMID: 20452757.
22: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2010 Apr;32(3):193-215. PubMed PMID: 20448862.
23: Zucali PA, Giovannetti E, Assaraf YG, Ceresoli GL, Peters GJ,
Santoro A. New tricks for old biomarkers: thymidylate synthase
expression as a predictor of pemetrexed activity in malignant
mesothelioma. Ann Oncol. 2010 Jul;21(7):1560-1. Epub 2010 May 5. PubMed
PMID: 20447928.
24: Fuld AD, Dragnev KH, Rigas JR. Pemetrexed in advanced non-small-cell
lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. PubMed
PMID: 20446853.
25: Ranson M, Reck M, Anthoney A, Hanauske AR, Dean E, Melezinek I,
Klingelschmitt G, Kletzl H, Blatter J, Twelves C. Erlotinib in
combination with pemetrexed for patients with advanced non-small-cell
lung cancer (NSCLC): a phase I dose-finding study. Ann Oncol. 2010 May
5. [Epub ahead of print] PubMed PMID: 20444843.
26: Malhotra B, Evans T, Weiss J, Eaby B, Stonehouse-Lee S, Sherry V,
Langer CJ. Carboplatin/pemetrexed/bevacizumab in the treatment of
patients with advanced non-small-cell lung cancer: a single-institution
experience. Clin Lung Cancer. 2010 May;11(3):192-7. PubMed PMID:
20439196.
27: Zhang GZ, Jiao SC, Meng ZT. Pemetrexed plus cisplatin/carboplatin in
previously treated locally advanced or metastatic non-small cell lung
cancer patients. J Exp Clin Cancer Res. 2010 Apr 27;29:38. PubMed PMID:
20423465; PubMed Central PMCID: PMC2876099.
28: Spigel DR, Hainsworth JD, Barton JH, Patton JF, Zubkus JD, Simons L,
Griner P, Burris HA 3rd, Greco FA. Phase II study of biweekly pemetrexed
and gemcitabine in patients with previously untreated advanced non-small
cell lung cancer. J Thorac Oncol. 2010 Jun;5(6):841-5. PubMed PMID:
20421819.
29: Bastos DA, Calabrich A, Katz A. Pemetrexed-induced fluid retention.
J Thorac Oncol. 2010 May;5(5):752. PubMed PMID: 20421771.
30: Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM,
Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia
Viganň M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi
P, Lambiase A, Bordignon C. Phase II study of asparagine-glycine-arginine-human
tumor necrosis factor alpha, a selective vascular targeting agent, in
previously treated patients with malignant pleural mesothelioma. J Clin
Oncol. 2010 May 20;28(15):2604-11. Epub 2010 Apr 20. PubMed PMID:
20406925.
31: Velez M, Belalcazar A, Domingo G, Blaya M, Raez LE, Santos ES.
Accelerated second-line or maintenance chemotherapy versus treatment at
disease progression in NSCLC. Expert Rev Anticancer Ther. 2010
Apr;10(4):549-57. PubMed PMID: 20397920.
32: Louvet C, André T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, Rassam
H, de Gramont A. Phase II Study of Biweekly Pemetrexed Plus Irinotecan
as Second-Line Therapy for Metastatic Colorectal Cancer. J Oncol.
2010;2010:785934. Epub 2010 Apr 8. PubMed PMID: 20396391; PubMed Central
PMCID: PMC2852604.
33: Zain JM, Marchi E. Pralatrexate - from bench to bedside. Drugs Today
(Barc). 2010 Feb;46(2):91-9. PubMed PMID: 20393637.
34: Owonikoko TK, Ramalingam SS, Belani CP. Maintenance therapy for
advanced non-small cell lung cancer: current status, controversies, and
emerging consensus. Clin Cancer Res. 2010 May 1;16(9):2496-504. Epub
2010 Apr 13. PubMed PMID: 20388843.
35: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346.
36: Richards DA, Loesch D, Vukelja SJ, Wu H, Hyman WJ, Nieves J, Wang Y,
Hu S, Shonukan OO, Tai DF. Phase I study of pemetrexed and pegylated
liposomal doxorubicin in patients with refractory breast, ovarian,
primary peritoneal, or fallopian tube cancer. Invest New Drugs. 2010 Mar
30. [Epub ahead of print] PubMed PMID: 20352294.
37: Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R,
Obasaju CK; for the Alpha Oncology Research Network. A retrospective
analysis of outcomes across histological subgroups in a three-arm phase
III trial of gemcitabine in combination with carboplatin or paclitaxel
versus paclitaxel plus carboplatin for advanced non-small cell lung
cancer. Lung Cancer. 2010 Mar 26. [Epub ahead of print] PubMed PMID:
20347506.
38: Steer J, Bough G, Razak AR, Meachery GJ, Hughes A. Life after
first-line chemotherapy in malignant pleural mesothelioma: a North-East
England experience. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):231-5.
PubMed PMID: 20346340.
39: Hansen O, Schytte T. [Maintenance treatment of non-small cell lung
cancer]. Ugeskr Laeger. 2010 Mar 22;172(12):954. Danish. PubMed PMID:
20334788.
40: Shukuya T, Takahashi T, Nakamura Y, Yamamoto N. [A case of malignant
pleural mesothelioma that responded to cisplatin plus pemetrexed
rechallenge]. Gan To Kagaku Ryoho. 2010 Mar;37(3):487-90. Japanese.
PubMed PMID: 20332689.
41: Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando
M, Shonukan O, Muscato J, O'Shaughnessy JA, Gralow J. A phase II trial
of pemetrexed and gemcitabine in patients with metastatic breast cancer
who have received prior taxane therapy. Clin Breast Cancer. 2010
Apr;10(2):148-53. PubMed PMID: 20299319.
42: Okamoto I, Takeda K, Daga H, Miyazaki M, Yonesaka K, Kiyota H,
Tsurutani J, Ueda S, Ichikawa Y, Takeda M, Sekiguchi R, Tominaga K,
Enatsu S, Nambu Y, Nakagawa K. Dose-escalation study of pemetrexed in
combination with carboplatin followed by pemetrexed maintenance therapy
for advanced non-small cell lung cancer. Lung Cancer. 2010 Mar 16. [Epub
ahead of print] PubMed PMID: 20236726.
43: Emmanouilides C, Yermetaki T, Serpanou A, Sapountzi E, Mantziari P,
Titopoulos I, Filippou D. Feasibility study of dose-dense biweekly
administered pemetrexed in patients with non-small cell lung cancer.
Hematol Oncol Stem Cell Ther. 2010;3(1):34-8. PubMed PMID: 20231811.
44: Hayashi H, Okamoto I, Ichikawa Y, Miyazaki M, Yoshioka H, Kunimasa
K, Nakagawa K. Retreatment of recurrent malignant pleural mesothelioma
with cisplatin and pemetrexed. Int J Clin Oncol. 2010 Mar 12. [Epub
ahead of print] PubMed PMID: 20224880.
45: Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C.
Treatment rationale and study design for a phase III, double-blind,
placebo-controlled study of maintenance pemetrexed plus best supportive
care versus best supportive care immediately following induction
treatment with pemetrexed plus cisplatin for advanced nonsquamous
non-small cell lung cancer. BMC Cancer. 2010 Mar 8;10:85. PubMed PMID:
20211022; PubMed Central PMCID: PMC2847958.
46: Chee CE, Jett JR, Bernath AM Jr, Foster NR, Nelson GD, Molina J,
Nikcevich DA, Steen PD, Flynn PJ, Rowland KM Jr. Phase 2 trial of
pemetrexed disodium and carboplatin in previously untreated
extensive-stage small cell lung cancer, N0423. Cancer. 2010 May
15;116(10):2382-9. PubMed PMID: 20209614.
47: Li J, Merl MY, Saif MW. Any second-line therapy for advanced
pancreatic cancer? Highlights from the "2010 ASCO Gastrointestinal
Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP. 2010 Mar
5;11(2):151-3. Review. PubMed PMID: 20208325.
48: Tsai LY, Yang YL, Lu MY, Lin DT, Huang HY, Lin KH. Deciduoid
mesothelioma of the pleura in an adolescent boy. Pediatr Hematol Oncol.
2010 Mar;27(2):132-7. PubMed PMID: 20201694.
49: Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.
Comparison of patient outcomes according to histology among pemetrexed-treated
patients with stage IIIB/IV non-small-cell lung cancer in two phase II
trials. Clin Lung Cancer. 2010 Mar 1;11(2):126-31. PubMed PMID:
20199979.
50: Müller C, Reddy JA, Leamon CP, Schibli R. Effects of the antifolates
pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in
xenografted and syngeneic tumor-bearing mice. Mol Pharm. 2010 Apr
5;7(2):597-604. PubMed PMID: 20199053.
51: Kao SC, McCaughan B, Muljono A, Boyer M. A pathological complete
response in malignant pleural mesothelioma after combination
chemotherapy with Carboplatin and pemetrexed. J Thorac Oncol. 2010
Mar;5(3):405-6. PubMed PMID: 20186029.
52: Kim HO, Lee SY, Shim JJ, Kang KH, Shin BK. A case of pemetrexed-induced
acute lung injury in non-small cell lung cancer. J Thorac Oncol. 2010
Mar;5(3):401-2. PubMed PMID: 20186027.
53: Righi L, Papotti MG, Ceppi P, Billč A, Bacillo E, Molinaro L,
Ruffini E, Scagliotti GV, Selvaggi G. Thymidylate synthase but not
excision repair cross-complementation group 1 tumor expression predicts
outcome in patients with malignant pleural mesothelioma treated with
pemetrexed-based chemotherapy. J Clin Oncol. 2010 Mar 20;28(9):1534-9.
Epub 2010 Feb 22. PubMed PMID: 20177021.
54: Rossi A, Maione P, Bareschino MA, Schettino C, Sacco PC, Ferrara ML,
Castaldo V, Gridelli C. The emerging role of histology in the choice of
first-line treatment of advanced non-small cell lung cancer: implication
in the clinical decision-making. Curr Med Chem. 2010;17(11):1030-8.
PubMed PMID: 20156162.
55: Marulli G, Rea F, Nicotra S, Favaretto AG, Perissinotto E,
Chizzolini M, Vianello A, Braccioni F. Effect of induction chemotherapy
on lung function and exercise capacity in patients affected by malignant
pleural mesothelioma. Eur J Cardiothorac Surg. 2010 Jun;37(6):1464-9.
Epub 2010 Feb 12. PubMed PMID: 20153664.
56: Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M. Efficacy
and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as
first-line treatment in East Asian patients with advanced non-small cell
lung cancer: results of an exploratory subgroup analysis of a phase III
trial. J Thorac Oncol. 2010 May;5(5):688-95. PubMed PMID: 20150825.
57: Marmé F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, Lichter P,
Hahn M, Schneeweiss A. FGFR4 Arg388 genotype is associated with
pathological complete response to neoadjuvant chemotherapy for primary
breast cancer. Ann Oncol. 2010 Feb 10. [Epub ahead of print] PubMed
PMID: 20147743.
58: StatBite: FDA oncology drug product approvals in 2009. J Natl Cancer
Inst. 2010 Feb 24;102(4):219. Epub 2010 Feb 9. PubMed PMID: 20145211.
59: Stark AL, Zhang W, Mi S, Duan S, O'Donnell PH, Huang RS, Dolan ME.
Heritable and non-genetic factors as variables of pharmacologic
phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Feb 9.
[Epub ahead of print] PubMed PMID: 20142840.
60: Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I,
Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K. Phase II Study of
Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural
Mesothelioma: A Single Institution Study. Am J Clin Oncol. 2010 May 3. [Epub
ahead of print] PubMed PMID: 20142722.
61: Sheth S. Current and emerging therapies for patients with advanced
non-small-cell lung cancer. Am J Health Syst Pharm. 2010 Jan 1;67(1
Suppl 1):S9-14. Review. PubMed PMID: 20044378.
62: Adams VR, Harvey RD. Histological and genetic markers for
non-small-cell lung cancer: customizing treatment based on individual
tumor biology. Am J Health Syst Pharm. 2010 Jan 1;67(1 Suppl 1):S3-9,
quiz S15-6. PubMed PMID: 20044377.
63: Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C,
Regan E, Kulke MH. Phase II study of pemetrexed in patients with
advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2010 Feb 4.
[Epub ahead of print] PubMed PMID: 20130879.
64: Subramanian J, Govindan R. Chemotherapy: continued lack of progress
in SCLC. Nat Rev Clin Oncol. 2010 Feb;7(2):77-8. PubMed PMID: 20118977.
65: Zhu ZX, Zhang WM, Jia G, Zhou J. [Effects of gemcitabine and
pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3
and PANC-1 in vitro]. Nan Fang Yi Ke Da Xue Xue Bao. 2010
Jan;30(1):149-52. Chinese. PubMed PMID: 20118008.
66: Simon S, Lumley PJ, Cooper PR, Berdal A, Machtou P, Smith AJ. Trauma
and dentinogenesis: a case report. J Endod. 2010 Feb;36(2):342-4. Epub
2009 Nov 5. PubMed PMID: 20113805.
67: Asukai Y, Valladares A, Camps C, Wood E, Taipale K, Arellano J,
Cassinello A, Sacristán JA, Dilla T. Cost-effectiveness analysis of
pemetrexed versus docetaxel in the second-line treatment of non-small
cell lung cancer in Spain: results for the non-squamous histology
population. BMC Cancer. 2010 Jan 29;10:26. PubMed PMID: 20113499; PubMed
Central PMCID: PMC2841662.
68: Belani CP, Liao J. Maintenance therapy for non-small-cell lung
cancer. Lancet. 2010 Jan 23;375(9711):281-2. PubMed PMID: 20109952.
69: Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki
K, Ohtani J, Sakai T, Yoshizumi T, Mizuarai S, Iwasawa Y, Kotani H.
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy
of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol
Ther. 2010 Apr 4;9(7). [Epub ahead of print] PubMed PMID: 20107315.
70: Hofer S, Sasse B, Scheffel H. Chemotherapy maintenance: an option
for prolonged survival in malignant peritoneal mesothelioma? Acta Oncol.
2010;49(1):122-4. PubMed PMID: 20104656.
71: Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK; Lung Cancer
Disease Site Group of Cancer Care Ontario's Program in Evidence-Based
Care. First-line systemic chemotherapy in the treatment of advanced
non-small cell lung cancer: a systematic review. J Thorac Oncol. 2010
Feb;5(2):260-74. Review. PubMed PMID: 20101151.
72: Araujo AM. Pemetrexed plus bevacizumab for second-line therapy of
non-small-cell lung cancer: the importance of patient selection. J Clin
Oncol. 2010 Mar 10;28(8):e131; author reply e132. Epub 2010 Jan 25.
PubMed PMID: 20100954.
73: Surmont V, Smit EF, de Jonge M, Aerts JG, Nackaerts K, Vernhout R,
Gras J, Van Wijk A, Phernambucq EC, van Meerbeeck JP, Senan S, Kraaij
CJ, Chouaki N, Praag J, van Klaveren RJ. Pemetrexed and cisplatin with
concurrent radiotherapy for locally advanced non-small cell and limited
disease small cell lung cancer: Results from 2 phase I studies. Lung
Cancer. 2010 Jan 21. [Epub ahead of print] PubMed PMID: 20096951.
74: Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, Kim HJ, Jung JY,
Jang G, Choi DR, Park SM, Shin TR, Lee HS, Zang DY. A phase II study of
pemetrexed and carboplatin as a salvage therapy for platinum-pretreated
patients with non-small cell lung cancer. Lung Cancer. 2010 Jan 20. [Epub
ahead of print] PubMed PMID: 20096475.
75: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2009 Nov;31(9):597-633. PubMed PMID: 20094643.
76: Abdel-Karim I, Plunkett WK Jr, O'Brien S, Giles F, Thomas D, Faderl
S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ,
Kantarjian HM. A phase I study of pemetrexed in patients with relapsed
or refractory acute leukemia. Invest New Drugs. 2010 Jan 21. [Epub ahead
of print] PubMed PMID: 20091088.
77: Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata
F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N,
von Pawel J. Phase II, double-blinded, randomized study of enzastaurin
plus pemetrexed as second-line therapy in patients with advanced
non-small cell lung cancer. J Thorac Oncol. 2010 Mar;5(3):369-75. PubMed
PMID: 20090562.
78: Neal JW. Histology matters: individualizing treatment in non-small
cell lung cancer. Oncologist. 2010;15(1):3-5. Epub 2010 Jan 19. PubMed
PMID: 20086166.
79: Manson GV, Ma PC. Response to pemetrexed chemotherapy in lung
adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Clin Lung Cancer. 2010 Jan;11(1):57-60. PubMed PMID: 20085869.
80: Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A,
Stratakos G, Fountzilas G, Syrigos KN. Carboplatin plus pemetrexed as
first-line treatment of patients with malignant pleural mesothelioma: a
phase II study. Clin Lung Cancer. 2010 Jan;11(1):30-5. PubMed PMID:
20085865.
81: Raez LE, Kobina S, Santos ES. Oxaliplatin in first-line therapy for
advanced non-small-cell lung cancer. Clin Lung Cancer. 2010
Jan;11(1):18-24. Review. PubMed PMID: 20085863.
82: Zhang YF, Chen ZW, Lu S. Pemetrexed monotherapy versus pemetrexed
plus platinum combination as second-line treatment for advanced
non-small cell lung cancer. Chin Med J (Engl). 2009 Oct
20;122(20):2472-6. PubMed PMID: 20079162.
83: Freidlin B, McShane LM, Korn EL. Randomized clinical trials with
biomarkers: design issues. J Natl Cancer Inst. 2010 Feb 3;102(3):152-60.
Epub 2010 Jan 14. PubMed PMID: 20075367.
84: Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K. The
efficacy of pemetrexed as a third- or fourth-line therapy and the
significance of thymidylate synthase expression in patients with
advanced non-small cell lung cancer. Lung Cancer. 2010 Jan 8. [Epub
ahead of print] PubMed PMID: 20061047.
85: Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W,
Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G. A phase-I trial of
pemetrexed plus carboplatin in recurrent ovarian cancer. Cancer
Chemother Pharmacol. 2010 Jan 7. [Epub ahead of print] PubMed PMID:
20054549.
86: Gridelli C, Di Maio M. The role of pemetrexed as maintenance
treatment in advanced NSCLC: a Phase III randomized trial. Expert Opin
Pharmacother. 2010 Feb;11(2):321-4. PubMed PMID: 20053140.
87: Nutt JE, Razak AR, O'Toole K, Black F, Quinn AE, Calvert AH, Plummer
ER, Lunec J. The role of folate receptor alpha (FRalpha) in the response
of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.
Br J Cancer. 2010 Feb 2;102(3):553-60. Epub 2010 Jan 5. PubMed PMID:
20051956; PubMed Central PMCID: PMC2822938.
88: Arrieta O, Villarreal-Garza C, Pachuca D, Michel Ortega RM,
Martinez-Barrera L, Flores-Estrada D, Astorga A. High response of
second-line chemotherapy with pemetrexed or gemcitabine combined with
carboplatin in patients with non-small-cell lung cancer experiencing
progression following 6 months after concluding platinum-based
chemotherapy. Med Oncol. 2010 Jan 5. [Epub ahead of print] PubMed PMID:
20049560.
89: Rudd RM. Malignant mesothelioma. Br Med Bull. 2010;93:105-23. Epub
2010 Jan 4. PubMed PMID: 20047972.
90: Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it
matter? Oncology (Williston Park). 2009 Nov 30;23(13):1133-40. Review.
PubMed PMID: 20043461.
91: Favaretto AG, Pasello G, Magro C. Second and third line treatment in
advanced non-small cell lung cancer. Discov Med. 2009 Dec;8(43):204-9.
PubMed PMID: 20040271.
92: Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone
F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis
F. Recent issues in first-line treatment of advanced non-small-cell lung
cancer: Results of an International Expert Panel Meeting of the Italian
Association of Thoracic Oncology. Lung Cancer. 2010 Jun;68(3):319-31.
Epub 2009 Dec 24. PubMed PMID: 20036027.
93: Kosuri KV, Wu X, Wang L, Villalona-Calero MA, Otterson GA. An
epigenetic mechanism for capecitabine resistance in mesothelioma.
Biochem Biophys Res Commun. 2010 Jan 15;391(3):1465-70. Epub 2009 Dec
24. PubMed PMID: 20035722; PubMed Central PMCID: PMC2860267.
94: Fournel P. [First-line chemotherapy for metastatic non-small cell
carcinoma: what are the options]. Rev Mal Respir. 2009
Dec;26(10):1091-6. Review. French. PubMed PMID: 20032844.
95: Quinn AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J. A
monoclonal antibody for detection of folylpolyglutamate synthetase in
paraffin embedded tissues. Hybridoma (Larchmt). 2009 Dec;28(6):415-21.
PubMed PMID: 20025500.
96: Nannizzi S, Veal GJ, Giovannetti E, Mey V, Ricciardi S, Ottley CJ,
Del Tacca M, Danesi R. Cellular and molecular mechanisms for the
synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon
cancer cell lines. Cancer Chemother Pharmacol. 2010 Aug;66(3):547-58.
Epub 2009 Dec 18. PubMed PMID: 20020129.
97: Wang D, He J. The role of pemetrexed in lung cancer. Curr Drug
Targets. 2010 Jan;11(1):1. PubMed PMID: 20017724.
98: Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its
use in advanced non-small cell lung cancer. Pharmacoeconomics.
2010;28(1):75-92. doi: 10.2165/10482880-000000000-00000. PubMed PMID:
20014878.
99: Scagliotti GV, De Marinis F, Rinaldi M, Crinň L, Gridelli C, Ricci
S, Zhao YD, Liepa AM, Peterson P, Tonato M. The role of histology with
common first-line regimens for advanced non-small cell lung cancer: a
brief report of the retrospective analysis of a three-arm randomized
trial. J Thorac Oncol. 2009 Dec;4(12):1568-71. PubMed PMID: 20009911.
100: Aulmann S, Waldburger N, Penzel R, Andrulis M, Schirmacher P, Sinn
HP. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional
cytotoxic chemotherapy. Hum Pathol. 2010 Apr;41(4):574-81. Epub 2009 Dec
11. PubMed PMID: 20004947.
101: Marrannes J, Delvaux S, Verheezen J. Malignant peritoneal
mesothelioma: contribution and limitation of imaging for its diagnosis.
JBR-BTR. 2009 Sep-Oct;92(5):248-50. PubMed PMID: 19999328.
102: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2009 Oct;31(8):541-57. PubMed PMID: 19967103.
103: Adema AD, Laan AC, Myhren F, Fichtner I, Verheul HM, Sandvold ML,
Peters GJ. Cell cycle effects of fatty acid derivatives of cytarabine,
CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with
oxaliplatin and docetaxel. Int J Oncol. 2010 Jan;36(1):285-94. PubMed
PMID: 19956857.
104: Pirker R, Minar W. Chemotherapy of advanced non-small cell lung
cancer. Front Radiat Ther Oncol. 2010;42:157-63. Epub 2009 Nov 24.
Review. PubMed PMID: 19955802.
105: Fisseler-Eckhoff A. Prognostic factors in histopathology of lung
cancer. Front Radiat Ther Oncol. 2010;42:1-14. Epub 2009 Nov 24. Review.
PubMed PMID: 19955788.
106: Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed
in ovarian cancer. Expert Rev Anticancer Ther. 2009 Dec;9(12):1727-35.
Review. PubMed PMID: 19954283.
107: Spirig C, Omlin A, D'Addario G, Loske KD, Esenwein P, Geismar JH,
Ruhstaller T. Radiation recall dermatitis with soft tissue necrosis
following pemetrexed therapy: a case report. J Med Case Reports. 2009
Nov 2;3:93. PubMed PMID: 19946510; PubMed Central PMCID: PMC2783093.
108: Porta JM, Vicente de Vera Floristán C, Inglán PB, Jericó JF. [Acute
renal failure associated with Pemetrexed (Alimta)]. Nefrologia.
2009;29(6):610-1. doi: 10.3265/Nefrologia.2009.29.6.5492.en.full.
Spanish. PubMed PMID: 19936010.
109: Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson
DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi
S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G;
American Society of Clinical Oncology. American Society of Clinical
Oncology Clinical Practice Guideline update on chemotherapy for stage IV
non-small-cell lung cancer. J Clin Oncol. 2009 Dec 20;27(36):6251-66.
Epub 2009 Nov 16. PubMed PMID: 19917871; PubMed Central PMCID:
PMC2793036.
110: Elbahaie AM, Kamel DE, Lawrence J, Davidson NG. Late cutaneous
metastases to the face from malignant pleural mesothelioma: a case
report and review of the literature. World J Surg Oncol. 2009 Nov
9;7:84. Review. PubMed PMID: 19900274; PubMed Central PMCID: PMC2777157.
111: Vrouchou P, Kandaswamy P, George E, Barnett D. Pemetrexed approved
for the first-line treatment of non-small-cell lung cancer: summary of
the NICE appraisal. Lancet Oncol. 2009 Nov;10(11):1031-2. PubMed PMID:
19891055.
112: Girard N, Jacoulet P, Gainet M, Elleuch R, Pernet D, Depierre A,
Dalphin JC, Westeel V. Third-line chemotherapy in advanced non-small
cell lung cancer: identifying the candidates for routine practice. J
Thorac Oncol. 2009 Dec;4(12):1544-9. PubMed PMID: 19884862.
113: Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A.
Second-line treatment for malignant pleural mesothelioma. Cancer Treat
Rev. 2010 Feb;36(1):24-32. Epub 2009 Oct 29. Review. PubMed PMID:
19879055.
114: Baldwin CM, Perry CM. Pemetrexed: a review of its use in the
management of advanced non-squamous non-small cell lung cancer. Drugs.
2009 Nov 12;69(16):2279-302. doi: 10.2165/11202640-000000000-00000.
Review. PubMed PMID: 19852529.
115: Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line
therapy for non-squamous non-small cell lung cancer. Ther Clin Risk
Manag. 2009;5:781-7. Epub 2009 Oct 12. PubMed PMID: 19851525; PubMed
Central PMCID: PMC2762436.
116: Karapanagiotou EM, Boura PG, Papamichalis G, Konstantinou M, Sepsas
E, Chamalakis G, Simsiris P, Gkiozos I, Syrigos KN.
Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell
lung cancer (NSCLC): a phase II study. Anticancer Res. 2009
Oct;29(10):4297-301. PubMed PMID: 19846990.
117: Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR,
Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II
trial of pemetrexed plus bevacizumab for second-line therapy of patients
with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J
Clin Oncol. 2010 Feb 1;28(4):614-9. Epub 2009 Oct 19. PubMed PMID:
19841321; PubMed Central PMCID: PMC2815996.
118: Konopa K, Jassem J. The role of pemetrexed combined with targeted
agents for non-small cell lung cancer. Curr Drug Targets. 2010
Jan;11(1):2-11. Review. PubMed PMID: 19839932.
119: Giovannetti E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond
J, Giaccone G, Peters GJ. Pharmacological aspects of the
enzastaurin-pemetrexed combination in non-small cell lung cancer
(NSCLC). Curr Drug Targets. 2010 Jan;11(1):12-28. Review. PubMed PMID:
19839931.
120: Chen M, Shao W, He J, Wang D. Role of pemetrexed and platinums
combination in patients with non-small cell lung cancer. Curr Drug
Targets. 2010 Jan;11(1):29-36. Review. PubMed PMID: 19839930.
121: Joerger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in
advanced non small-cell lung cancer: special focus on pharmacology and
mechanism of action. Curr Drug Targets. 2010 Jan;11(1):37-47. Review.
PubMed PMID: 19839929.
122: Kao SC, Phan VH, Clarke SJ. Predictive markers for haematological
toxicity of pemetrexed. Curr Drug Targets. 2010 Jan;11(1):48-57. Review.
PubMed PMID: 19839928.
123: Tucker S. The role of pemetrexed in second-line chemotherapy for
advanced non-small cell lung cancer. Curr Drug Targets. 2010
Jan;11(1):58-60. Review. PubMed PMID: 19839927.
124: Ngeow J, Toh CK. The role of pemetrexed combined with gemcitabine
for non-small-cell lung cancer. Curr Drug Targets. 2010 Jan;11(1):61-6.
Review. PubMed PMID: 19839926.
125: Wagner TD, Yang GY. The role of chemotherapy and radiation in the
treatment of locally advanced non-small cell lung cancer (NSCLC). Curr
Drug Targets. 2010 Jan;11(1):67-73. Review. PubMed PMID: 19839925.
126: Duruisseaux M, Cadranel J, Pérol M, Arpin D. The role of pemetrexed
in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma
features. Curr Drug Targets. 2010 Jan;11(1):74-7. Review. PubMed PMID:
19839924.
127: Vincent M. Pemetrexed: potential role in the adjuvant chemotherapy
of non-small cell lung cancer. Curr Drug Targets. 2010 Jan;11(1):78-84.
Review. PubMed PMID: 19839923.
128: Li T, Lara PN Jr, Mack PC, Perez-Soler R, Gandara DR. Intercalation
of erlotinib and pemetrexed in the treatment of non-small cell lung
cancer. Curr Drug Targets. 2010 Jan;11(1):85-94. Review. PubMed PMID:
19839922.
129: Sanoff HK, Davies J, Walko C, Buie L, Chiu WK, Ivanova A, O'Neil B,
Stinchcombe TE, Keller K, Dees EC. Phase I trial of vinflunine and
pemetrexed in refractory solid tumors. Invest New Drugs. 2009 Oct 15. [Epub
ahead of print] PubMed PMID: 19830387.
130: Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C,
Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV.
Prognostic and predictive factors in a randomized phase III trial
comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced
non-small-cell lung cancer. Ann Oncol. 2010 Mar;21(3):556-61. Epub 2009
Oct 14. PubMed PMID: 19828561.
131: Petrelli F, Ghilardi M, Cremonesi M, Cabiddu M, Barni S. Is there a
role for maintenance therapy in non-small-cell lung cancer? An emerging
issue. Expert Rev Anticancer Ther. 2009 Oct;9(10):1455-65. Review.
PubMed PMID: 19828007.
132: Jackman DM. Current options for systemic therapy in mesothelioma.
Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):154-8. Review. PubMed
PMID: 19822287.
133: Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M,
Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C. Pemetrexed
in the treatment of malignant mesothelioma: results from an expanded
access program in Germany. Respir Med. 2010 Jan;104(1):142-8. Epub 2009
Oct 8. PubMed PMID: 19818589.
134: Bosch-Barrera J, Gaztańaga M, Ceballos J, Pérez-Gracia JL,
López-Picazo JM, García-Foncillas J, Ferrer M, Sanz ML, Pretel M, Idoate
MA, Gil-Bazo I. Toxic epidermal necrolysis related to pemetrexed and
carboplatin with vitamin B12 and folic acid supplementation for advanced
non-small cell lung cancer. Onkologie. 2009 Oct;32(10):580-4. Epub 2009
Sep 14. PubMed PMID: 19816075.
135: Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R.
Significance of thymidylate synthase for resistance to pemetrexed in
lung cancer. Cancer Sci. 2010 Jan;101(1):161-6. Epub 2009 Sep 10. PubMed
PMID: 19811498.
136: Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M,
Cadranel J, Soria JC. Pemetrexed-induced pneumonitis: a case report.
Clin Lung Cancer. 2009 Sep;10(5):364-6. PubMed PMID: 19808196.
137: Ambika S, Melton A, Lee D, Hesketh PJ. Massive retroperitoneal
adrenal hemorrhage secondary to lung cancer metastasis treated by
adrenal artery embolization. Clin Lung Cancer. 2009 Sep;10(5):E1-4.
PubMed PMID: 19808165.
138: Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky
LV, Krasner CN. A phase II evaluation of pemetrexed (Alimta, LY231514,
IND #40061) in the treatment of recurrent or persistent endometrial
carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol.
2009 Dec;115(3):443-6. Epub 2009 Oct 4. PubMed PMID: 19804902.
139: Nguyen MT, Virk IY, Chew L, Villano JL. Extended use dexamethasone-associated
posterior reversible encephalopathy syndrome with cisplatin-based
chemotherapy. J Clin Neurosci. 2009 Dec;16(12):1688-90. Epub 2009 Oct 2.
PubMed PMID: 19800799.
140: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2009 Jul-Aug;31(6):397-417. PubMed PMID: 19798455.
141: Kim HR, Kang MS, Na II, Yang SH, Choi YH, Kang HJ, Kim CH, Lee JC.
The similar survival benefits of stable disease and partial response to
pemetrexed in previously treated non-small cell carcinoma patients. J
Cancer Res Clin Oncol. 2010 Apr;136(4):547-52. Epub 2009 Sep 30. PubMed
PMID: 19789893.
142: Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R,
Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as
first-line therapy for advanced nonsquamous non-small cell lung cancer.
J Thorac Oncol. 2009 Nov;4(11):1404-14. PubMed PMID: 19786904.
143: Martínez I, Robledo D, Bollinger E, Maristany M, Sanders CV,
Shellito J, Lopez FA. Clinical case of the month. A 64-year-old woman
with shortness of breath. Diagnosis: Mesothelioma. J La State Med Soc.
2009 Jul-Aug;161(4):188-9, 191-3. PubMed PMID: 19785308.
144: Norris RE, Adamson PC. Clinical potency of methotrexate,
aminopterin, talotrexin and pemetrexed in childhood leukemias. Cancer
Chemother Pharmacol. 2010 May;65(6):1125-30. Epub 2009 Sep 27. PubMed
PMID: 19784838.
145: Dogan M, Yalcin B, Utkan G, Urun Y, Ozal G. Activity of pemetrexed
on brain metastases from non-small cell lung cancer: what is the
mechanism? Lung Cancer. 2009 Dec;66(3):399. Epub 2009 Sep 24. PubMed
PMID: 19783320.
146: Stinchcombe TE, West HL. Maintenance therapy in non-small-cell lung
cancer. Lancet. 2009 Oct 24;374(9699):1398-400. Epub 2009 Sep 18. PubMed
PMID: 19767096.
147: Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack
E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH,
Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP.
Maintenance pemetrexed plus best supportive care versus placebo plus
best supportive care for non-small-cell lung cancer: a randomised,
double-blind, phase 3 study. Lancet. 2009 Oct 24;374(9699):1432-40. Epub
2009 Sep 18. PubMed PMID: 19767093.
148: Manegold C, Schmid-Bindert G, Pilz LR. Pemetrexed for the treatment
of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009
Sep;9(9):1195-209. Review. PubMed PMID: 19761423.
149: Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka
M. Efficacy differences of pemetrexed by histology in pretreated
patients with stage IIIB/IV non-small cell lung cancer: review of
results from an open-label randomized phase II study. J Thorac Oncol.
2009 Dec;4(12):1530-6. PubMed PMID: 19755925.
150: Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L,
Akerley W. Safety of bevacizumab in patients with non-small-cell lung
cancer and brain metastases. J Clin Oncol. 2009 Nov 1;27(31):5255-61.
Epub 2009 Sep 8. PubMed PMID: 19738122.
151: Cohen MH, Justice R, Pazdur R. Approval summary: pemetrexed in the
initial treatment of advanced/metastatic non-small cell lung cancer.
Oncologist. 2009 Sep;14(9):930-5. Epub 2009 Sep 8. PubMed PMID:
19737998.
152: Ray M, Kindler HL. Malignant pleural mesothelioma: an update on
biomarkers and treatment. Chest. 2009 Sep;136(3):888-96. Review. PubMed
PMID: 19736192.
153: Saxena A, Chua TC. Results of systemic pemetrexed-based combination
chemotherapy versus cytoreductive surgery and hyperthermic
intraperitoneal cisplatin and doxorubicin on survival in malignant
peritoneal mesothelioma. Lung Cancer. 2009 Nov;66(2):269-70. Epub 2009
Sep 4. PubMed PMID: 19733416.
154: Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A,
Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M,
Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.
Phase III study of pemetrexed plus carboplatin compared with etoposide
plus carboplatin in chemotherapy-naive patients with extensive-stage
small-cell lung cancer. J Clin Oncol. 2009 Oct 1;27(28):4787-92. Epub
2009 Aug 31. PubMed PMID: 19720897.
155: Sequist LV, Fidias P, Heist RS, Ostler P, Muzikansky A, Lynch TJ.
Brief report of biweekly pemetrexed and gemcitabine in elderly patients
with non-small cell lung cancer. J Thorac Oncol. 2009 Sep;4(9):1170-3.
PubMed PMID: 19704338.
156: Bräutigam K, Bauerschlag DO, Weigel MT, Biernath-Wüpping J,
Bauknecht T, Arnold N, Maass N, Meinhold-Heerlein I. Combination of
enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of
chemoresistant ovarian cancer cells regulating extracellular
signal-regulated kinase 1/2 phosphorylation. Transl Oncol. 2009 Aug
18;2(3):164-73. PubMed PMID: 19701501; PubMed Central PMCID: PMC2730140.
157: Jalal S, Waterhouse D, Edelman MJ, Nattam S, Ansari R, Koneru K,
Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N. Pemetrexed
plus cetuximab in patients with recurrent non-small cell lung cancer
(NSCLC): a phase I/II study from the Hoosier Oncology Group. J Thorac
Oncol. 2009 Nov;4(11):1420-4. PubMed PMID: 19701110.
158: Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J, Bannon PG,
McCaughan BC. Extrapleural pneumonectomy for malignant pleural
mesothelioma: outcomes of treatment and prognostic factors. J Thorac
Cardiovasc Surg. 2009 Sep;138(3):619-24. Epub 2009 Mar 9. PubMed PMID:
19698846.
159: Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R,
Planchard D, Reck M, De Marinis F, Lee JS, Park K, Biesma B, Gans S,
Ramlau R, Szczesna A, Makhson A, Manikhas G, Morgan B, Zhu Y, Chan KC,
von Pawel J. A randomized phase II study of bortezomib and pemetrexed,
in combination or alone, in patients with previously treated advanced
non-small-cell lung cancer. Lung Cancer. 2010 Jun;68(3):420-6. Epub 2009
Aug 18. PubMed PMID: 19692142.
160: De Pas TM, Toffalorio F, Catania C, Noberasco C, Spitaleri G,
Spaggiari L, De Braud F. Gemcitabine and pemetrexed combination: the key
role of the sequence of drugs administration. Ann Oncol. 2009
Oct;20(10):1747-8. Epub 2009 Aug 18. PubMed PMID: 19690055.
161: Rivera E. Management of metastatic breast cancer: monotherapy
options for patients resistant to anthracyclines and taxanes. Am J Clin
Oncol. 2010 Apr;33(2):176-85. Review. PubMed PMID: 19675449.
162: Sun JM, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Lee JS, Kim YW, Heo
DS, Bang YJ. The relationship between response to previous systemic
treatment and the efficacy of subsequent pemetrexed therapy in advanced
non-small cell lung cancer. Lung Cancer. 2010 Jun;68(3):427-32. Epub
2009 Aug 11. PubMed PMID: 19674811.
163: Hampton T. Lung cancer trials probe effects of maintenance therapy,
targeted agents. JAMA. 2009 Aug 12;302(6):616, 618. PubMed PMID:
19671897.
164: Rře OD, Anderssen E, Helge E, Pettersen CH, Olsen KS, Sandeck H,
Haaverstad R, Lundgren S, Larsson E. Genome-wide profile of pleural
mesothelioma versus parietal and visceral pleura: the emerging gene
portrait of the mesothelioma phenotype. PLoS One. 2009 Aug 7;4(8):e6554.
PubMed PMID: 19662092; PubMed Central PMCID: PMC2717215.
165: Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I,
Katirtzoglou N, Syrigos K. Docetaxel plus gemcitabine as first-line
treatment in malignant pleural mesothelioma: a single institution phase
II study. Anticancer Res. 2009 Aug;29(8):3441-4. PubMed PMID: 19661370.
166: Martin M, Blasinska-Morawiec M, Salas JF, Falcon S, Rolski J,
Ferrari BL, Gulyas S, Liu Y, Benhadji KA. A multicenter, single-arm
phase II study of pemetrexed plus doxorubicin administered every 21 days
in patients with advanced breast cancer. Clin Breast Cancer. 2009
Aug;9(3):155-60. PubMed PMID: 19661038.
167: Mendiola C, Vaz MA. Is capecitabine a new choice of treatment for
lung adenocarcinoma? A case report involving partial response in second
line of treatment and hypothesis of the biological basis. Clin Transl
Oncol. 2009 Aug;11(8):554-7. PubMed PMID: 19661033.
168: Mok TS, Ramalingam SS. Maintenance therapy in nonsmall-cell lung
cancer: a new treatment paradigm. Cancer. 2009 Nov 15;115(22):5143-54.
Review. PubMed PMID: 19658185.
169: Qin H, Cai J, Fang J, Xu H, Gong Y. Could MTA be a novel medicine
on the recurrence therapy for GCTB? Med Hypotheses. 2010
Feb;74(2):368-9. Epub 2009 Aug 4. PubMed PMID: 19656634.
170: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2009 Jun;31(5):341-56. PubMed PMID: 19649342.
171: Pemetrexed: new indication. Untreated non-small cell lung cancer:
just another cytotoxic drug. No better than the gemcitabine-cisplatin
combination with a different safety profile, as is the case for other
cytotoxic drugs. Prescrire Int. 2009 Jun;18(101):114. PubMed PMID:
19637425.
172: Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C,
Pennella EJ, Girvan AC, Guba SC. Treatment rationale and study design
for the pointbreak study: a randomized, open-label phase III study of
pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab
versus paclitaxel/carboplatin/bevacizumab followed by maintenance
bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell
lung cancer. Clin Lung Cancer. 2009 Jul;10(4):252-6. PubMed PMID:
19632943.
173: Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M,
Talamini R, Santoro A, Bartolotti M, Murgia V, Berretta M, Tirelli U.
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung
Cancer. Lung Cancer. 2010 May;68(2):264-8. Epub 2009 Jul 25. PubMed
PMID: 19632738.
174: Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganň R, Scalone
S, Scollo P, Breda E, Pietragalla A, Scambia G. Evaluation of pemetrexed
(Alimta, LY231514) as second-line chemotherapy in persistent or
recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO
(Multicentre Italian Trials in Ovarian Cancer and Gynecologic
Malignancies) Group. Ann Oncol. 2010 Jan;21(1):61-6. Epub 2009 Jul 15.
PubMed PMID: 19605508.
175: Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C,
Shanmugam R, Skaar T, Sweeney CJ. A phase II study of pemetrexed as
second-line chemotherapy for the treatment of metastatic
castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group
GU03-67. Ann Oncol. 2009 Dec;20(12):1971-6. Epub 2009 Jul 15. PubMed
PMID: 19605506.
176: Murphy CG, Seidman AD. Evolving approaches to metastatic breast
cancer previously treated with anthracyclines and taxanes. Clin Breast
Cancer. 2009 Jun;9 Suppl 2:S58-65. Review. PubMed PMID: 19596644.
177: Dent SF, Gertler S, Verma S, Segal R, Young V, Goel R, Keller O,
Canil C, Iscoe N. A phase II study of biweekly pemetrexed and
gemcitabine in patients with metastatic breast cancer. Cancer Chemother
Pharmacol. 2010 Feb;65(3):557-61. Epub 2009 Jul 11. PubMed PMID:
19593565.
178: Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C.
Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung
Cancer. 2009 Nov;66(2):141-9. Epub 2009 Jul 4. Review. PubMed PMID:
19577816.
179: Bobin-Dubigeon C, Amiand MB, Herrenknecht C, Bard JM. Development
and validation of an improved liquid chromatography-mass spectrometry
method for the determination of pemetrexed in human plasma. J Chromatogr
B Analyt Technol Biomed Life Sci. 2009 Aug 15;877(24):2451-6. Epub 2009
Jun 21. PubMed PMID: 19560408.
180: Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L. Malignant
pleural mesothelioma: current treatments and emerging drugs. Expert Opin
Emerg Drugs. 2009 Sep;14(3):423-37. Review. PubMed PMID: 19552609.
181: Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by
cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation,
AMPK activation, and mammalian target of rapamycin inhibition. Cancer
Res. 2009 Jul 1;69(13):5467-74. Epub 2009 Jun 23. PubMed PMID: 19549896;
PubMed Central PMCID: PMC2706929.
182: Vlastos F, Hillas G, Vidal P, Lacomme S, Galateau-Sallé F, Vollmer
E, Guzman-Costabel J, Vignaud JM, Martinet N. Survey and biological
insights of pemetrexed-related therapeutic improvement in mesothelioma:
The Nancy Centre of Biological Resources' Mesothelioma Cohort. J Thorac
Oncol. 2009 Oct;4(10):1259-63. PubMed PMID: 19546821.
183: Comella P, Chiuri VE, De Cataldis G, Filippelli G, Maiorino L,
Vessia G, Cioffi R, Mancarella S, Putzu C, Greco E, Palmeri L, Costanzo
R, Avallone A, Franco L. Gemcitabine combined with either pemetrexed or
paclitaxel in the treatment of advanced non-small cell lung cancer: a
randomized phase II SICOG trial. Lung Cancer. 2010 Apr;68(1):94-8. Epub
2009 Jul 9. PubMed PMID: 19545929.
184: Valentini V, Massaccesi M, Balducci M, Mantini G, Micciché F,
Mattiucci GC, Dinapoli N, Meduri B, D'Agostino GR, Salvi G, Nardone L.
Low-dose hyperradiosensitivity: is there a place for future
investigation in clinical settings? Int J Radiat Oncol Biol Phys. 2010
Feb 1;76(2):535-9. Epub 2009 Jun 18. PubMed PMID: 19540061.
185: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PubMed PMID: 19536362.
186: Stahel RA, Weder W. Improving the outcome in malignant pleural
mesothelioma: nonaggressive or aggressive approach? Curr Opin Oncol.
2009 Mar;21(2):124-30. Review. PubMed PMID: 19532013.
187: Bartminski W. Araújo A, et al. An economic analysis of erlotinib,
docetaxel, pemetrexed and best supportive care as second or third line
treatment of non-small cell lung cancer. Rev Port Pneumol 2008;
14(6):803-827. Rev Port Pneumol. 2009 May-Jun;15(3):555-9; author reply
560-6. English, Portuguese. PubMed PMID: 19526635.
188: van Meerbeeck JP, Baas P. Palliative chemotherapy: do we need yet
another end-point? Eur J Cancer. 2009 Sep;45(13):2234-5. Epub 2009 Jun
11. PubMed PMID: 19524432.
189: Trousse DS, Avaro JP, D'Journo XB, Doddoli C, Astoul P, Giudicelli
R, Fuentes PA, Thomas PA. Is malignant pleural mesothelioma a surgical
disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J
Cardiothorac Surg. 2009 Oct;36(4):759-63. Epub 2009 Jun 11. PubMed PMID:
19523843.
190: Sakamoto S, Kaburaki K, Sakaguchi S, Sano G, Sugino K, Isobe K,
Shibuya K, Kurosaki A, Uekusa T, Homma S. [Case of pemetrexed-induced
acute lung injury]. Nihon Kokyuki Gakkai Zasshi. 2009 May;47(5):415-20.
Japanese. PubMed PMID: 19514505.
191: Tanaka A, Takahashi T. [Case of malignant pleural mesothelioma with
long-term disease control after 4 different lines of systemic
chemotherapy and pleurodesis]. Nihon Kokyuki Gakkai Zasshi. 2009
May;47(5):383-7. Japanese. PubMed PMID: 19514499.
192: Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H,
Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ. Preclinical
evaluation of a novel pyrimidopyrimidine for the prevention of
nucleoside and nucleobase reversal of antifolate cytotoxicity. Mol
Cancer Ther. 2009 Jul;8(7):1828-37. Epub 2009 Jun 9. PubMed PMID:
19509274.
193: Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N,
Gandara DR. Intermittent erlotinib in combination with pemetrexed: phase
I schedules designed to achieve pharmacodynamic separation. J Thorac
Oncol. 2009 Jul;4(7):862-8. PubMed PMID: 19494788.
194: Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe
T, Kuenen B, Thornton D, McNealy P, Giaccone G. Phase Ib safety and
pharmacokinetic evaluation of daily and twice daily oral enzastaurin in
combination with pemetrexed in advanced/metastatic cancer. Ann Oncol.
2009 Sep;20(9):1565-75. Epub 2009 Jun 1. PubMed PMID: 19487488.
195: Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B,
Stahel RA. Combined FDG-PET/CT in response evaluation of malignant
pleural mesothelioma. Lung Cancer. 2010 Mar;67(3):311-7. Epub 2009 May
30. PubMed PMID: 19482372.
196: Gridelli C, Rossi A, de Marinis F. Pattern of care for advanced
non-small cell lung cancer in the era of histology-based treatment: a
survey of the Italian Association of Thoracic Oncology (AIOT). Lung
Cancer. 2010 Mar;67(3):339-42. Epub 2009 May 29. PubMed PMID: 19481831.
197: Pío-Asín M, Segrelles-Bellmunt G, Arrondo-Velasco A,
Sarobe-Carricas M. [Acute myocardial infarction and pemetrexed]. Farm
Hosp. 2009 Mar-Apr;33(2):114-5. Spanish. PubMed PMID: 19480802.
198: Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans
SJ, Visseren-Grul C, Peterson P. Survival without toxicity for cisplatin
plus pemetrexed versus cisplatin plus gemcitabine in chemonaďve patients
with advanced non-small cell lung cancer: a risk-benefit analysis of a
large phase III study. Eur J Cancer. 2009 Sep;45(13):2298-303. Epub 2009
May 25. PubMed PMID: 19473833.
199: Hata A, Nanjo S, Otsuka K, Kida Y, Higashi Y, Kaji R, Fujita S,
Katakami N. [Two cases of effective S-1 monotherapy for patients with
metastatic adenocarcinoma of the lung after multiple previous
chemotherapies]. Gan To Kagaku Ryoho. 2009 May;36(5):807-10. Japanese.
PubMed PMID: 19461182.
200: Nakamura Y, Yamamoto N. [Second-line treatment and targeted therapy
of advanced lung cancer]. Gan To Kagaku Ryoho. 2009 May;36(5):710-6.
Japanese. PubMed PMID: 19461168.
201: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2009 Mar;31(2):107-46. PubMed PMID: 19455266.
202: O'Kane SL, Eagle GL, Greenman J, Lind MJ, Cawkwell L. COX-2
specific inhibitors enhance the cytotoxic effects of pemetrexed in
mesothelioma cell lines. Lung Cancer. 2010 Feb;67(2):160-5. Epub 2009
May 17. PubMed PMID: 19450893.
203: Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: A phase III study
of pemetrexed, cisplatin, and radiation therapy followed by
consolidation pemetrexed versus etoposide, cisplatin, and radiation
therapy followed by consolidation cytotoxic chemotherapy of choice in
locally advanced stage III non-small-cell lung cancer of other than
predominantly squamous cell histology. Clin Lung Cancer. 2009
May;10(3):193-8. PubMed PMID: 19443340.
204: Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT,
Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab
with maintenance pemetrexed and bevacizumab as first-line therapy for
nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul
10;27(20):3284-9. Epub 2009 May 11. PubMed PMID: 19433684.
205: Grřnberg BH, Bremnes RM, Flřtten O, Amundsen T, Brunsvig PF, Hjelde
HH, Kaasa S, von Plessen C, Stornes F, Tollĺli T, Wammer F, Aasebř U,
Sundstrřm S. Phase III study by the Norwegian lung cancer study group:
pemetrexed plus carboplatin compared with gemcitabine plus carboplatin
as first-line chemotherapy in advanced non-small-cell lung cancer. J
Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11. PubMed PMID:
19433683.
206: Yan TD, Boyer M, Tin MM, Sim J, Kennedy C, McLean J, Bannon PG,
McCaughan BC. Prognostic features of long-term survivors after surgical
management of malignant pleural mesothelioma. Ann Thorac Surg. 2009
May;87(5):1552-6. PubMed PMID: 19379903.
207: Omlin A, D'Addario G, Gillessen S, Cerny T, von Hessling A, Früh M.
Activity of pemetrexed against brain metastases in a patient with
adenocarcinoma of the lung. Lung Cancer. 2009 Sep;65(3):383-4. Epub 2009
Apr 17. PubMed PMID: 19375814.
208: Burgin M, Gairard-Dory AC, Mennecier B, Molard A, Beretz L, Quoix
AE. [First-line treatment with pemetrexed in association with cisplatin
in patients with non-operable malignant pleural mesothelioma]. Rev
Pneumol Clin. 2009 Apr;65(2):75-83. Epub 2009 Apr 1. French. PubMed
PMID: 19375046.
209: Zucali PA, De Vincenzo F, Simonelli M, Santoro A. Future
developments in the management of malignant pleural mesothelioma. Expert
Rev Anticancer Ther. 2009 Apr;9(4):453-67. Review. PubMed PMID:
19374599.
210: Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A. First-line
treatment in advanced non-small-cell lung cancer: the emerging role of
the histologic subtype. Expert Rev Anticancer Ther. 2009
Apr;9(4):425-35. Review. PubMed PMID: 19374597.
211: Stahel RA, Felley-Bosco E, Opitz I, Weder W. Malignant pleural
mesothelioma. Future Oncol. 2009 Apr;5(3):391-402. Review. PubMed PMID:
19374545.
212: Khadse P, Prabhash K, Pramesh CS, Chaturvedi P, Shet T. Fine-needle
aspiration biopsy of pleural metastases from a carcinosarcoma or true
malignant mixed tumor of the parotid gland mimicking a mesothelioma.
Diagn Cytopathol. 2009 Sep;37(9):680-5. PubMed PMID: 19373913.
213: Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig
KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang
NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin
followed by extrapleural pneumonectomy and radiation for malignant
pleural mesothelioma. J Clin Oncol. 2009 Jun 20;27(18):3007-13. Epub
2009 Apr 13. PubMed PMID: 19364962.
214: Vorobiof DA, Mafafo K. Malignant pleural mesothelioma: medical
treatment update. Clin Lung Cancer. 2009 Mar;10(2):112-7. Review. PubMed
PMID: 19362954.
215: Scagliotti GV, Ceppi P, Capelletto E, Novello S. Updated clinical
information on multitargeted antifolates in lung cancer. Clin Lung
Cancer. 2009 Mar;10 Suppl 1:S35-40. Review. PubMed PMID: 19362945.
216: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. PubMed PMID: 19357798.
217: Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny
A, Scherpereel A, Willems L. Valproate, in combination with pemetrexed
and cisplatin, provides additional efficacy to the treatment of
malignant mesothelioma. Clin Cancer Res. 2009 Apr 15;15(8):2818-28. Epub
2009 Apr 7. PubMed PMID: 19351772.
218: Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A,
Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. Vandetanib
(ZD6474), a dual inhibitor of vascular endothelial growth factor
receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine
kinases: current status and future directions. Oncologist. 2009
Apr;14(4):378-90. Epub 2009 Apr 6. Review. PubMed PMID: 19349511.
219: Stinchcombe TE, Socinski MA. Current treatments for advanced stage
non-small cell lung cancer. Proc Am Thorac Soc. 2009 Apr 15;6(2):233-41.
Review. PubMed PMID: 19349493.
220: Duruisseaux M, Cadranel J, Biron E, Pérol M, Guérin JC, Arpin D.
Major and prolonged response to pemetrexed in two cases of lung
adenocarcinoma with bronchioloalveolar carcinoma features. Lung Cancer.
2009 Sep;65(3):385-7. Epub 2009 Apr 5. PubMed PMID: 19346028.
221: Tiseo M, Gelsomino F, Bartolotti M, Barili MP, Ardizzoni A.
Typhlitis during second-line chemotherapy with pemetrexed in non-small
cell lung cancer (NSCLC): A case report. Lung Cancer. 2009
Aug;65(2):251-3. Epub 2009 Apr 5. PubMed PMID: 19346026.
222: Sculier JP, Moro-Sibilot D. First- and second-line therapy for
advanced nonsmall cell lung cancer. Eur Respir J. 2009 Apr;33(4):915-30.
Review. PubMed PMID: 19336594.
223: Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML,
Waggoner SE, Boardman CH. Phase II evaluation of pemetrexed in the
treatment of recurrent or persistent platinum-resistant ovarian or
primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
J Clin Oncol. 2009 Jun 1;27(16):2686-91. Epub 2009 Mar 30. PubMed PMID:
19332726; PubMed Central PMCID: PMC2690393.
224: Yamamoto N, Nambu Y, Fujimoto T, Koshiji M. A landmark point
analysis with cytotoxic agents for advanced NSCLC. J Thorac Oncol. 2009
Jun;4(6):697-701. PubMed PMID: 19318995.
225: Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM,
Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ. Randomized
phase II and pharmacogenetic study of pemetrexed compared with
pemetrexed plus carboplatin in pretreated patients with advanced
non-small-cell lung cancer. J Clin Oncol. 2009 Apr 20;27(12):2038-45.
Epub 2009 Mar 23. PubMed PMID: 19307503.
226: Kano Y, Tanaka M, Akutsu M, Mori K, Yazawa Y, Mano H, Furukawa Y.
Schedule-dependent synergism and antagonism between pemetrexed and
docetaxel in human lung cancer cell lines in vitro. Cancer Chemother
Pharmacol. 2009 Nov;64(6):1129-37. Epub 2009 Mar 22. PubMed PMID:
19306094.
227: Lee HY, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, Kim HT, Ryoo HM,
Bae SH, Lee SS, Choi K, Hong DS, Lee KH, Kwon JH, Choi IS, Kim BS, Lee
NS, Gong SJ, Park K. Adenocarcinoma has an excellent outcome with
pemetrexed treatment in Korean patients: a prospective, multicenter
trial. Lung Cancer. 2009 Dec;66(3):338-43. Epub 2009 Mar 18. PubMed
PMID: 19299031.
228: Tomillero A, Moral MA. Gateways to clinical trials. December 2008.
Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82. PubMed PMID:
19271026.
229: Esteban E, Casillas M, Cassinello A. Pemetrexed in first-line
treatment of non-small cell lung cancer. Cancer Treat Rev. 2009
Jun;35(4):364-73. Epub 2009 Mar 6. Review. PubMed PMID: 19269106.
230: Ledermann JA, Stebbing J. Positioning pemetrexed in the treatment
of ovarian cancer. Eur J Cancer. 2009 May;45(8):1330-2. Epub 2009 Mar 4.
PubMed PMID: 19264477.
231: Chouaid C, Atsou K, Hejblum G, Vergnenegre A. Economics of
treatments for non-small cell lung cancer. Pharmacoeconomics.
2009;27(2):113-25. doi: 10.2165/00019053-200927020-00003. Review. PubMed
PMID: 19254045.
232: Favaretto A, Pasello G, Magro C, Schettino C, Gridelli C. Second
and third line treatment in non-small cell lung cancer. Crit Rev Oncol
Hematol. 2009 Aug;71(2):117-26. Epub 2009 Feb 26. Review. PubMed PMID:
19249227.
233: Miliauskas S, Zemaitis M, Pranys D. Malignant pleural and
peritoneal mesothelioma: incidental diagnosis and excellent treatment
results. J Thorac Oncol. 2009 Mar;4(3):435-6. PubMed PMID: 19247093.
234: Greillier L, Monjanel-Mouterde S, Fraticelli A, Devictor-Pierre B,
Bouvenot J, Coltel N, Lamarche G, Astoul P. Intrapleural administration
of pemetrexed: a pharmacokinetic study in an animal model. J Thorac
Oncol. 2009 Mar;4(3):404-8. PubMed PMID: 19247087.
235: Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee
S, Ahn MJ. Comparison of survival in advanced non-small cell lung cancer
patients in the pre- and post-gefitinib eras. Oncology.
2009;76(4):239-46. Epub 2009 Feb 25. PubMed PMID: 19246948.
236: de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts
H, Tsao MS, Leighl N, Keshavjee S, Johnston MR. Trimodality therapy with
induction chemotherapy followed by extrapleural pneumonectomy and
adjuvant high-dose hemithoracic radiation for malignant pleural
mesothelioma. J Clin Oncol. 2009 Mar 20;27(9):1413-8. Epub 2009 Feb 17.
PubMed PMID: 19224855.
237: Mizutani H, Gemma A. [Lung cancer]. Gan To Kagaku Ryoho. 2009
Feb;36(2):171-5. Japanese. PubMed PMID: 19223731.
238: Izbicka E, Diaz A, Streeper R, Wick M, Campos D, Steffen R,
Saunders M. Distinct mechanistic activity profile of pralatrexate in
comparison to other antifolates in in vitro and in vivo models of human
cancers. Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9. Epub 2009 Feb
17. PubMed PMID: 19221750; PubMed Central PMCID: PMC2728224.
239: Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson
P, Simms L, Shepherd FA. The differential efficacy of pemetrexed
according to NSCLC histology: a review of two Phase III studies.
Oncologist. 2009 Mar;14(3):253-63. Epub 2009 Feb 16. PubMed PMID:
19221167.
240: Celio L, Sternberg CN, Labianca R, La Torre I, Amoroso V, Barone C,
Pinotti G, Cascinu S, Di Costanzo F, Cetto GL, Bajetta E. Pemetrexed in
combination with oxaliplatin as a first-line therapy for advanced
gastric cancer: a multi-institutional phase II study. Ann Oncol. 2009
Jun;20(6):1062-7. Epub 2009 Feb 13. PubMed PMID: 19218305.
241: Leone JP, Dudek AZ. Enzyme replacement therapy for Gaucher's
disease in patient treated for non-small cell lung cancer. Anticancer
Res. 2008 Nov-Dec;28(6B):3937-9. PubMed PMID: 19192653.
242: Müller C, Mindt TL, de Jong M, Schibli R. Evaluation of a novel
radiofolate in tumour-bearing mice: promising prospects for folate-based
radionuclide therapy. Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):938-46.
Epub 2009 Jan 30. PubMed PMID: 19183997.
243: Deng QF, Su B, Zhao YM, Zhou CC. [Sensitivity of two cell lines
with acquired resistance to gefitinib to several chemotherapeutic
drugs]. Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):813-6. Chinese.
PubMed PMID: 19173824.
244: Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J.
A randomised, double-blind, phase II study of two doses of pemetrexed in
the treatment of platinum-resistant, epithelial ovarian or primary
peritoneal cancer. Eur J Cancer. 2009 May;45(8):1415-23. Epub 2009 Jan
23. PubMed PMID: 19168349.
245: Blakely LJ, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson
A, Walker MS. A phase II trial of pemetrexed and gemcitabine as first
line therapy for poor performance status and/or elderly patients with
stage IIIB/IV non-small cell lung cancer. Lung Cancer. 2009
Oct;66(1):97-102. Epub 2009 Jan 22. PubMed PMID: 19167130.
246: Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, Esteban
González E, Martín Algarra S. Management of platinum-resistant ovarian
cancer with the combination of pemetrexed and gemcitabine. Clin Transl
Oncol. 2009 Jan;11(1):35-40. PubMed PMID: 19155202.
247: West HL, Wakelee HA, Perry MC, Belt RJ, Chen R, Obasaju C.
Gemcitabine and pemetrexed administered in rapid sequence as front-line
chemotherapy for advanced non-small-cell lung cancer: a phase II
clinical trial. Ann Oncol. 2009 May;20(5):850-6. Epub 2009 Jan 15.
PubMed PMID: 19150937.
248: Tassinari D, Carloni F, Santelmo C, Tamburini E, Lazzari Agli L,
Tombesi P, Sartori S. Second line treatments in advanced
platinum-resistant non small cell lung cancer. A critical review of
literature. Rev Recent Clin Trials. 2009 Jan;4(1):27-33. Review. PubMed
PMID: 19149760.
249: Hsu JY, Wakelee H. Pemetrexed disodium for the treatment of NSCLC:
an update. Drugs Today (Barc). 2008 Sep;44(9):669-78. Review. PubMed
PMID: 19137122.
250: Yamanaka T, Tanaka F, Hasegawa S, Okada M, Soejima T, Kamikonya N,
Fukuoka K, Nakano T. A feasibility study of induction pemetrexed plus
cisplatin followed by extrapleural pneumonectomy and postoperative
hemithoracic radiation for malignant pleural mesothelioma. Jpn J Clin
Oncol. 2009 Mar;39(3):186-8. Epub 2009 Jan 8. PubMed PMID: 19131427.
251: Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in
chemonaive patients with locally advanced or metastatic malignant
pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res.
2009 Jan 1;15(1):382-9. PubMed PMID: 19118069.
252: Latz JE, Schneck KL, Nakagawa K, Miller MA, Takimoto CH. Population
pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia:
effect of vitamin supplementation and differences between Japanese and
Western patients. Clin Cancer Res. 2009 Jan 1;15(1):346-54. PubMed PMID:
19118064.
253: Galetta D, Rossi A, Colucci G, Gebbia V. Third-line therapy for
advanced non-small-cell lung cancer patients: a feasible therapeutic
option? Oncology. 2009;77 Suppl 1:113-21. Epub 2010 Feb 2. Review.
PubMed PMID: 20130439.
254: Rossi A, Galetta D, Gridelli C. Biological prognostic and
predictive factors in lung cancer. Oncology. 2009;77 Suppl 1:90-6. Epub
2010 Feb 2. Review. PubMed PMID: 20130436.
255: de Marinis F, Ricciardi S. [Role of pemetrexed in the treatment of
advanced non-small-cell lung cancer: news from ASCO, 2008]. Tumori. 2008
Sep-Oct;94(5):suppl 3-13. Review. Italian. PubMed PMID: 19112963.
256: Gridelli C, Maione P, Rossi A, Falanga M, Bareschino M, Schettino
C, Colantuoni G, Guerriero C, Nicolella D, Rossi E, Ferrara ML,
Palazzolo G. New avenues for second-line treatment of metastatic
non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009
Jan;9(1):115-24. Review. PubMed PMID: 19105711.
257: Jalal S, Ansari R, Govindan R, Bhatia S, Bruetman D, Fisher W,
Masters G, White A, Stover D, Yu M, Hanna N; Hoosier Oncology Group.
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier
Oncology Group phase II study. J Thorac Oncol. 2009 Jan;4(1):93-6.
PubMed PMID: 19096313.
258: Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke
M. Gemcitabine combined with oxaliplatin in pretreated patients with
malignant pleural mesothelioma: an observational study. J Occup Med
Toxicol. 2008 Dec 18;3:34. PubMed PMID: 19091133; PubMed Central PMCID:
PMC2621228.
259: de Boer R, Humblet Y, Wolf J, Nogová L, Ruffert K, Milenkova T,
Smith R, Godwood A, Vansteenkiste J. An open-label study of vandetanib
with pemetrexed in patients with previously treated non-small-cell lung
cancer. Ann Oncol. 2009 Mar;20(3):486-91. Epub 2008 Dec 16. PubMed PMID:
19088171.
260: Tieu BH, Sanborn RE, Thomas CR Jr. Neoadjuvant therapy for
resectable non-small cell lung cancer with mediastinal lymph node
involvement. Thorac Surg Clin. 2008 Nov;18(4):403-15. Review. PubMed
PMID: 19086609.
261: Melosky B, Agulnik J, Assi H. Retrospective practice review of
treatment of metastatic non-small-cell lung cancer with second-line
erlotinib. Curr Oncol. 2008 Dec;15(6):279-85. PubMed PMID: 19079629;
PubMed Central PMCID: PMC2601023.
262: Demolin G, Focan C, Plomteux O, Kreutz F, Moeneclaey N,
Focan-Henrard D. [Chemotherapy for human gastric cancer: a review]. Rev
Med Liege. 2008 Sep;63(9):532-41. Review. French. PubMed PMID: 19051508.
263: Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D,
Liu Y, Blatter J, Visseren-Grul C, Stahel R. Malignant peritoneal
mesothelioma-Results from the International Expanded Access Program
using pemetrexed alone or in combination with a platinum agent. Lung
Cancer. 2009 May;64(2):211-8. Epub 2008 Nov 29. PubMed PMID: 19042053.
264: Fathi AT, Brahmer JR. Chemotherapy for advanced stage non-small
cell lung cancer. Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):210-6.
Review. PubMed PMID: 19038730.
265: Saito Y, Furukawa T, Arano Y, Fujibayashi Y, Saga T. Comparison of
semiquantitative fluorescence imaging and PET tracer uptake in
mesothelioma models as a monitoring system for growth and therapeutic
effects. Nucl Med Biol. 2008 Nov;35(8):851-60. PubMed PMID: 19026946.
266: Berghmans T. [Other thoracic cancers. Mesothelioma: treatment]. Rev
Mal Respir. 2008 Oct;25(8 Pt 2):3S191-5. French. PubMed PMID: 18971845.
267: Quoix E. [Stage IV NSCLC. Second-line therapy for metastatic
non-small cell lung cancer]. Rev Mal Respir. 2008 Oct;25(8 Pt
2):3S113-8. French. PubMed PMID: 18971835.
268: Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler
JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract
and gallbladder carcinomas: a North Central Cancer Treatment Group
(NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer.
2007;38(2-4):87-94. Epub 2008 Nov 21. PubMed PMID: 19023677.
269: Araújo A, Parente B, Sotto-Mayor R, Teixeira E, Almodôvar T, Barata
F, Queiroga H, Pereira C, Pereira H, Negreiro F, Silva C. An economic
analysis of erlotinib, docetaxel, pemetrexed and best supportive care as
second or third line treatment of non-small cell lung cancer. Rev Port
Pneumol. 2008 Nov-Dec;14(6):803-27. English, Portuguese. PubMed PMID:
19023496.
270: Field MS, Anguera MC, Page R, Stover PJ.
5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors
and modifies the efficacy of antipurine LY309887. Arch Biochem Biophys.
2009 Jan 15;481(2):145-50. Epub 2008 Nov 8. PubMed PMID: 19022216.
271: Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken
JB. Pharmacokinetic evaluation of platinum derived from cisplatin
administered alone and with pemetrexed in head and neck cancer patients.
Cancer Chemother Pharmacol. 2009 Jul;64(2):233-41. Epub 2008 Nov 15.
PubMed PMID: 19011858.
272: Bosch-Barrera J, Montero A, López-Picazo JM, García-Foncillas J,
Ferrer M, Yuste JR, Gil-Bazo I. Adult onset Still's disease after first
cycle of pemetrexed and gemcitabine for non-small cell lung cancer. Lung
Cancer. 2009 Apr;64(1):124-6. Epub 2008 Nov 13. PubMed PMID: 19008012.
273: Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with
first-line platinum-based combination chemotherapy for malignant pleural
mesothelioma: a review of practice in British Columbia. Lung Cancer.
2009 Jun;64(3):308-13. Epub 2008 Nov 11. PubMed PMID: 19004520.
274: Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN,
Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II
study of carboplatin and pemetrexed for the treatment of
platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec
10;26(35):5761-6. Epub 2008 Nov 10. PubMed PMID: 19001330.
275: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PubMed PMID: 18985183.
276: Socinski MA, Raju RN, Neubauer M, Smith DA, Richards DA, Savin M,
Ruxer RL, Reynolds CH, Zhan F, Bromund JL, Chen R, Obasaju C. Pemetrexed
in relapsed small-cell lung cancer and the impact of shortened vitamin
supplementation lead-in time: results of a phase II trial. J Thorac
Oncol. 2008 Nov;3(11):1308-16. PubMed PMID: 18978567.
277: Berhoune M, Banu E, Scotte F, Prognon P, Oudard S, Bonan B.
Therapeutic strategy for treatment of metastatic non-small cell lung
cancer. Ann Pharmacother. 2008 Nov;42(11):1640-52. Epub 2008 Oct 28.
Review. PubMed PMID: 18957625.
278: Hanauske AR, Dumez H, Piccart M, Yilmaz E, Graefe T, Gil T, Simms
L, Musib L, Awada A. Pemetrexed combined with paclitaxel: a dose-finding
study evaluating three schedules in solid tumors. Invest New Drugs. 2009
Aug;27(4):356-65. Epub 2008 Oct 28. PubMed PMID: 18956139.
279: Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS.
Efficacy and toxicity of pemetrexed as a third-line treatment for
non-small cell lung cancer. Jpn J Clin Oncol. 2009 Jan;39(1):27-32. Epub
2008 Oct 24. PubMed PMID: 18952704.
280: Janku F, Bird B. Personalized medicine in advanced non-small-cell
lung cancer: reality or wishful thinking? J Clin Oncol. 2008 Dec
1;26(34):5651; author reply 5651-2. Epub 2008 Oct 20. PubMed PMID:
18936465.
281: Li L, Razak AR, Hughes A. Carboplatin and pemetrexed in the
management of malignant pleural mesothelioma: a realistic treatment
option? Lung Cancer. 2009 May;64(2):207-10. Epub 2008 Oct 15. PubMed
PMID: 18926592.
282: Hesdorffer ME, Chabot J, DeRosa C, Taub R. Peritoneal mesothelioma.
Curr Treat Options Oncol. 2008 Jun;9(2-3):180-90. Epub 2008 Oct 8.
Review. PubMed PMID: 18841478.
283: Zafar SY, Currow D, Abernethy AP. Defining best supportive care. J
Clin Oncol. 2008 Nov 1;26(31):5139-40. Epub 2008 Oct 6. PubMed PMID:
18838696.
284: Castagnari A. Conclusions of the expert panel: importance of
erlotinib as a second-line therapeutic option. BMC Proc. 2008 Sep 24;2
Suppl 2:S4. PubMed PMID: 18831720; PubMed Central PMCID: PMC2559800.
285: Hensley ML, Larkin J, Fury M, Gerst S, Tai DF, Sabbatini P, Konner
J, Orlando M, Goss TL, Aghajanian CA. A phase I trial of pemetrexed plus
gemcitabine given biweekly with B-vitamin support in solid tumor
malignancies or advanced epithelial ovarian cancer. Clin Cancer Res.
2008 Oct 1;14(19):6310-6. PubMed PMID: 18829514.
286: Felip E, Rosell R. Pemetrexed as second-line therapy for advanced
non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag. 2008
Jun;4(3):579-85. PubMed PMID: 18827853; PubMed Central PMCID:
PMC2500250.
287: Shvartsbeyn M, Edelman MJ. Pemetrexed-induced typhlitis in
non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1188-90.
PubMed PMID: 18827618.
288: Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS,
Lynch TJ. A phase II study of oxaliplatin, pemetrexed, and bevacizumab
in previously treated advanced non-small cell lung cancer. J Thorac
Oncol. 2008 Oct;3(10):1153-8. PubMed PMID: 18827612.
289: Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C,
Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C,
Robinson LA. Clinical efficacy and predictive molecular markers of
neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung
cancer. J Thorac Oncol. 2008 Oct;3(10):1112-8. PubMed PMID: 18827606;
PubMed Central PMCID: PMC2639211.
290: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find
Exp Clin Pharmacol. 2008 Jun;30(5):383-408. PubMed PMID: 18806898.
291: Hanauske AR, Endler C, Graefe T, Fleeth J, von Scheel J, Lüdtke FE,
Müller-Hagen S, Depenbrock H, Ohnmacht U, Bolling C. Phase-I-study of
four different schedules of pemetrexed, gemcitabine and cisplatin in
patients with locally advanced or metastatic solid tumours. Eur J
Cancer. 2008 Nov;44(16):2444-52. Epub 2008 Sep 18. PubMed PMID:
18804996.
292: Ono A, Yamamoto N. [Advances in chemotherapy for lung cancer]. Gan
To Kagaku Ryoho. 2008 Sep;35(9):1475-81. Japanese. PubMed PMID:
18799900.
293: Kindler HL. Systemic treatments for mesothelioma: standard and
novel. Curr Treat Options Oncol. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3.
Review. PubMed PMID: 18770046; PubMed Central PMCID: PMC2782121.
294: Ramalingam SS, Belani CP. Recent advances in the treatment of
malignant pleural mesothelioma. J Thorac Oncol. 2008 Sep;3(9):1056-64.
Review. PubMed PMID: 18758312.
295: Goudar RK. Review of pemetrexed in combination with cisplatin for
the treatment of malignant pleural mesothelioma. Ther Clin Risk Manag.
2008 Feb;4(1):205-11. PubMed PMID: 18728709; PubMed Central PMCID:
PMC2503655.
296: Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ.
Molecular pathways involved in the synergistic interaction of the PKC
beta inhibitor enzastaurin with the antifolate pemetrexed in non-small
cell lung cancer cells. Br J Cancer. 2008 Sep 2;99(5):750-9. Epub 2008
Aug 19. PubMed PMID: 18728666; PubMed Central PMCID: PMC2528136.
297: Bracke A, Van Marck E, Lambert J. Acute generalized exanthematous
pustulosis after pemetrexed, and recurrence after re-introduction. Clin
Exp Dermatol. 2009 Apr;34(3):337-9. Epub 2008 Aug 9. PubMed PMID:
18699838.
298: Calabrň F, Sternberg CN. The evolving role of chemotherapy in
advanced urothelial cancer. Curr Opin Support Palliat Care. 2007
Oct;1(3):180-6. Review. PubMed PMID: 18685360.
299: Smetak M, Weigang-Koehler K, Hanauske A, Ohnmacht U, Lahn M,
Wilhelm M, Birkmann J. Reduction of HLA-DR+ lymphocytes after treatment
with enzastaurin in patients with metastatic thyroid cancer.
Chemotherapy. 2008;54(4):268-73. Epub 2008 Jul 31. PubMed PMID:
18667816.
300: Russo F, Bearz A, Pampaloni G; Investigators of Italian Pemetrexed
Monotherapy of NSCLC Group. Pemetrexed single agent chemotherapy in
previously treated patients with locally advanced or metastatic
non-small cell lung cancer. BMC Cancer. 2008 Jul 31;8:216. PubMed PMID:
18667090; PubMed Central PMCID: PMC2529337.
301: Sharma S, Freeman B, Turner J, Symanowski J, Manno P, Berg W,
Vogelzang N. A phase I trial of PTK787/ZK222584 in combination with
pemetrexed and cisplatin in patients with advanced solid tumors. Invest
New Drugs. 2009 Feb;27(1):63-5. Epub 2008 Jul 19. PubMed PMID: 18641920.
302: Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel
SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK,
Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for
patients with peritoneal mesothelioma: final report of a phase II trial.
J Clin Oncol. 2008 Jul 20;26(21):3567-72. PubMed PMID: 18640937.
303: Sudoh J, Gemma A. [Pemetrexed]. Gan To Kagaku Ryoho. 2008
Jun;35(6):1033-8. Japanese. PubMed PMID: 18633241.
304: Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer:
status of first-line chemotherapy and the search for active agents in
the second-line setting. Cancer. 2008 Sep 15;113(6):1284-93. Review.
PubMed PMID: 18629841.
305: Khanfir K, Anchisi S. Pemetrexed-associated radiation recall
dermatitis. Acta Oncol. 2008;47(8):1607-8. PubMed PMID: 18607836.
306: Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van
Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener
D, Liu Y, Adachi S, Blatter J, von Pawel J. Single-agent pemetrexed for
chemonaďve and pretreated patients with malignant pleural mesothelioma:
results of an International Expanded Access Program. J Thorac Oncol.
2008 Jul;3(7):764-71. PubMed PMID: 18594323.
307: Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M,
Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J,
Visseren-Grul CM, Manegold C. Pemetrexed plus cisplatin or pemetrexed
plus carboplatin for chemonaďve patients with malignant pleural
mesothelioma: results of the International Expanded Access Program. J
Thorac Oncol. 2008 Jul;3(7):756-63. PubMed PMID: 18594322.
308: Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N,
Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Efficacy
and safety of two doses of pemetrexed supplemented with folic acid and
vitamin B12 in previously treated patients with non-small cell lung
cancer. Clin Cancer Res. 2008 Jul 1;14(13):4206-12. PubMed PMID:
18594001.
309: Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, Gridelli C,
Ciardiello F. Sequence-dependent, synergistic antiproliferative and
proapoptotic effects of the combination of cytotoxic drugs and
enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung
cancer cells. Mol Cancer Ther. 2008 Jun;7(6):1698-707. PubMed PMID:
18566241.
310: Reck M, Heigener DF, Gatzemeier U. [Chemotherapy of malignant
pleural mesothelioma: have we made any progress?]. Zentralbl Chir. 2008
Jun;133(3):238-42. Review. German. PubMed PMID: 18563688.
311: Sienel W, Kirschbaum A, Passlick B. [Multimodal therapy for
malignant pleural mesothelioma including extrapleural pneumonectomy].
Zentralbl Chir. 2008 Jun;133(3):231-7. German. PubMed PMID: 18563687.
312: Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F. Schedule-dependent
synergistic effect of pemetrexed combined with gemcitabine against
malignant pleural mesothelioma and non-small cell lung cancer cell
lines. Chemotherapy. 2008;54(3):166-75. Epub 2008 Jun 18. PubMed PMID:
18560222.
313: Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G. Predictive
factors for chemotherapy-related toxic effects in patients with
colorectal cancer. Nat Clin Pract Oncol. 2008 Aug;5(8):455-65. Epub 2008
Jun 10. Review. PubMed PMID: 18542119.
314: Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M,
Grossi F, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, Salamina S,
De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A. Pemetrexed
plus carboplatin in elderly patients with malignant pleural mesothelioma:
combined analysis of two phase II trials. Br J Cancer. 2008 Jul
8;99(1):51-6. Epub 2008 Jun 10. PubMed PMID: 18542071; PubMed Central
PMCID: PMC2453025.
315: Grřnberg BH, Bremnes RM, Aasebř U, Brunsvig P, Flřtten O, Amundsen
T, von Plessen C, Wang M, Sundstrřm S; Norwegian Lung Cancer Study
Group. A prospective phase II study: high-dose pemetrexed as second-line
chemotherapy in small-cell lung cancer. Lung Cancer. 2009
Jan;63(1):88-93. Epub 2008 Jun 6. PubMed PMID: 18538889.
316: Dietz A, Boehm A, Mozet C, Wichmann G, Giannis A. Current aspects
of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol.
2008 Jul;265 Suppl 1:S3-12. Review. PubMed PMID: 18535834.
317: Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID. The
proton-coupled folate transporter: impact on pemetrexed transport and on
antifolates activities compared with the reduced folate carrier. Mol
Pharmacol. 2008 Sep;74(3):854-62. Epub 2008 Jun 4. PubMed PMID:
18524888; PubMed Central PMCID: PMC2716086.
318: Declercq I, Lievens Y, Verbeken E, Vansteenkiste J. Image of the
month. Rash in a patient treated with pemetrexed for relapsed non-small
cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):662-3. PubMed PMID:
18520810.
319: Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J,
Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS,
Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms
L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus
gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive
patients with advanced-stage non-small-cell lung cancer. J Clin Oncol.
2008 Jul 20;26(21):3543-51. Epub 2008 May 27. PubMed PMID: 18506025.
320: Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE,
Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in
locally advanced non-small-cell lung cancer: are we making progress?
Clin Lung Cancer. 2008 Mar;9(2):85-91. Review. PubMed PMID: 18501094.
321: Palumbo C, Bei R, Procopio A, Modesti A. Molecular targets and
targeted therapies for malignant mesothelioma. Curr Med Chem.
2008;15(9):855-67. Review. PubMed PMID: 18473795.
322: Gebbia V. Does an optimal therapeutic sequence exist in advanced
non-small cell lung cancer? Expert Opin Pharmacother. 2008
Jun;9(8):1321-37. Review. PubMed PMID: 18473707.
323: Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA,
Middlebrook V, Nicol S, Rothenberg ML. Phase I trial of pemetrexed plus
oxaliplatin administered every other week in patients with metastatic
cancer. Invest New Drugs. 2008 Aug;26(4):339-45. Epub 2008 May 8. PubMed
PMID: 18463792.
324: Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ; Eastern Cooperative
Oncology Group. Phase 2 trial of pemetrexed disodium and gemcitabine in
advanced urothelial cancer (E4802): a trial of the Eastern Cooperative
Oncology Group. Cancer. 2008 Jun 15;112(12):2671-5. PubMed PMID:
18459175; PubMed Central PMCID: PMC2674559.
325: Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO;
Gynecologic Oncology Group. Evaluation of pemetrexed (Alimta, LY231514)
as second line chemotherapy in persistent or recurrent carcinoma of the
cervix: a phase II study of the Gynecologic Oncology Group. Gynecol
Oncol. 2008 Jul;110(1):65-70. Epub 2008 May 5. PubMed PMID: 18455781.
326: Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of
anthracycline- and taxane-refractory metastatic breast cancer. Semin
Oncol. 2008 Apr;35(2 Suppl 2):S31-8; quiz S40. Review. PubMed PMID:
18410797.
327: Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T,
Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M. Efficacy and safety
of pemetrexed in combination with cisplatin for malignant pleural
mesothelioma: a phase I/II study in Japanese patients. Jpn J Clin Oncol.
2008 May;38(5):339-46. Epub 2008 Apr 22. PubMed PMID: 18434338.
328: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PubMed PMID: 18389098.
329: Fasola G, Aita M, Marini L, Follador A, Tosolini M, Mattioni L,
Mansutti M, Piga A, Brusaferro S, Aprile G. Drug waste minimisation and
cost-containment in Medical Oncology: two-year results of a feasibility
study. BMC Health Serv Res. 2008 Apr 1;8:70. PubMed PMID: 18380901;
PubMed Central PMCID: PMC2374784.
330: Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone
F, Rosell R, Shepherd FA, Thatcher N, Vansteenkiste J, De Petris L, Di
Maio M, De Marinis F. Second-line treatment of advanced non-small cell
lung cancer. J Thorac Oncol. 2008 Apr;3(4):430-40. PubMed PMID:
18379366.
331: Cortinovis D, Bidoli P, Cullurŕ D, Lorusso V, Ardizzoia A, Amoroso
V, Bandera M, Aitini E, Fusi A, Zilembo N, Radula D, Bajetta E. Is
irinotecan plus docetaxel useful as second-line therapy in advanced
non-small cell lung cancer? J Thorac Oncol. 2008 Apr;3(4):405-11. PubMed
PMID: 18379360.
332: Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee
TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK. Phase 1/2
dose escalating study of twice-monthly pemetrexed and gemcitabine in
patients with advanced cancer and non-small cell lung cancer. J Thorac
Oncol. 2008 Apr;3(4):394-9. PubMed PMID: 18379358.
333: Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced
pancreatic cancer: targeting the epidermal growth factor and vascular
endothelial growth factor pathways. Oncologist. 2008 Mar;13(3):289-98.
Review. PubMed PMID: 18378539.
334: Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S,
Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of
pemetrexed plus best supportive care compared with best supportive care
in previously treated patients with advanced malignant pleural
mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. PubMed PMID:
18375898.
335: Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S,
Johnston MR, de Perrot M. Impact of tumor-infiltrating T cells on
survival in patients with malignant pleural mesothelioma. J Thorac
Cardiovasc Surg. 2008 Apr;135(4):823-9. PubMed PMID: 18374762.
336: Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis
of randomized trials: evaluation of benefit from gemcitabine-based
combination chemotherapy applied in advanced pancreatic cancer. BMC
Cancer. 2008 Mar 28;8:82. PubMed PMID: 18373843; PubMed Central PMCID:
PMC2292732.
337: Hillerdal G, Sorensen JB, Sundström S, Vikström A, Hjerpe A.
Treatment of malignant pleural mesothelioma with liposomized
doxorubicine: prolonged time to progression and good survival. A Nordic
study. Clin Respir J. 2008 Apr;2(2):80-5. PubMed PMID: 20298311.
338: Sřrensen JB. Current concepts in chemotherapy for malignant pleural
mesothelioma. Clin Respir J. 2008 Apr;2(2):74-9. PubMed PMID: 20298310.
339: Kulkarni PM, Chen R, Anand T, Monberg MJ, Obasaju CK. Efficacy and
safety of pemetrexed in elderly cancer patients: results of an
integrated analysis. Crit Rev Oncol Hematol. 2008 Jul;67(1):64-70. Epub
2008 Mar 20. PubMed PMID: 18358737.
340: Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P,
Monberg M, Obasaju C, Kindler H. Phase II trial of pemetrexed and
gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin
Oncol. 2008 Mar 20;26(9):1465-71. PubMed PMID: 18349397.
341: Müller C, Schibli R, Krenning EP, de Jong M. Pemetrexed improves
tumor selectivity of 111In-DTPA-folate in mice with folate
receptor-positive ovarian cancer. J Nucl Med. 2008 Apr;49(4):623-9. Epub
2008 Mar 14. PubMed PMID: 18344429.
342: Underhill C, Goldstein D, Gorbounova VA, Biakhov MY, Bazin IS,
Granov DA, Hossain AM, Blatter J, Kaiser C, Ma D. A randomized phase II
trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated
5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally
advanced or metastatic colorectal cancer. Oncology. 2007;73(1-2):9-20.
Epub 2008 Mar 11. PubMed PMID: 18334829.
343: Stinchcombe TE, Socinski MA. Considerations for second-line therapy
of non-small cell lung cancer. Oncologist. 2008;13 Suppl 1:28-36.
Review. PubMed PMID: 18263772.
344: de Marinis F, Grossi F. Clinical evidence for second- and
third-line treatment options in advanced non-small cell lung cancer.
Oncologist. 2008;13 Suppl 1:14-20. Review. PubMed PMID: 18263770.
345: Ramalingam S, Belani C. Systemic chemotherapy for advanced
non-small cell lung cancer: recent advances and future directions.
Oncologist. 2008;13 Suppl 1:5-13. Review. PubMed PMID: 18263769.
346: Bunn PA Jr, Thatcher N. Systemic treatment for advanced (stage IIIb/IV)
non-small cell lung cancer: more treatment options; more things to
consider. Introduction. Oncologist. 2008;13 Suppl 1:1-4. PubMed PMID:
18263768.
347: Nakano T. Current therapies for malignant pleural mesothelioma.
Environ Health Prev Med. 2008 Mar;13(2):75-83. Epub 2008 Feb 28. PubMed
PMID: 19568885; PubMed Central PMCID: PMC2698270.
348: Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM,
Ilegbodu D, Asmar L. A phase II study of pemetrexed in patients with
advanced hepatocellular carcinoma. Invest New Drugs. 2008
Aug;26(4):381-6. Epub 2008 Feb 28. PubMed PMID: 18305899.
349: Park GM, Han KS, Chang YH, Kim CH, Lee JC. Immune hemolytic anemia
after treatment with pemetrexed for lung cancer. J Thorac Oncol. 2008
Feb;3(2):196-7. PubMed PMID: 18303446.
350: Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra
DL. Comparative clinical and economic outcomes of treatments for
refractory non-small cell lung cancer (NSCLC). Lung Cancer. 2008
Sep;61(3):405-15. Epub 2008 Mar 4. PubMed PMID: 18295368.
351: Gangjee A, Jain HD, Kurup S. Recent advances in classical and
non-classical antifolates as antitumor and antiopportunistic infection
agents: Part II. Anticancer Agents Med Chem. 2008 Feb;8(2):205-31.
Review. PubMed PMID: 18288923.
352: Porret E, Madelaine J, Galateau-Sallé F, Bergot E, Zalcman G.
[Epidemiology, molecular biology, diagnostic and therapeutic strategy of
malignant pleural mesothelioma in 2007 - an update]. Rev Mal Respir.
2007 Oct;24(8 Pt 2):6S157-64. Review. French. PubMed PMID: 18235409.
353: Souquet PJ. [Non-small cell lung cancer - from treatment of relapse
to treatments for relapses]. Rev Mal Respir. 2007 Oct;24(8 Pt
2):6S108-13. Review. French. PubMed PMID: 18235402.
354: Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R,
Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with
malignant pleural mesothelioma. Cancer. 2008 Apr 1;112(7):1555-61.
PubMed PMID: 18286536.
355: Mauritz R, Peters GJ, Kathmann I, Teshale H, Noordhuis P, Comijn
EM, Pinedo HM, Jansen G. Dynamics of antifolate transport via the
reduced folate carrier and the membrane folate receptor in murine
leukaemia cells in vitro and in vivo. Cancer Chemother Pharmacol. 2008
Nov;62(6):937-48. Epub 2008 Feb 19. PubMed PMID: 18283461.
356: Cullen MH, Zatloukal P, Sörenson S, Novello S, Fischer JR, Joy AA,
Zereu M, Peterson P, Visseren-Grul CM, Iscoe N. A randomized phase III
trial comparing standard and high-dose pemetrexed as second-line
treatment in patients with locally advanced or metastatic non-small-cell
lung cancer. Ann Oncol. 2008 May;19(5):939-45. Epub 2008 Feb 17. PubMed
PMID: 18283036.
357: Small GR, Nicolson M, Buchan K, Broadhurst P. Pericardial malignant
mesothelioma: a latent complication of radiotherapy? Eur J Cardiothorac
Surg. 2008 Apr;33(4):745-7. Epub 2008 Feb 14. PubMed PMID: 18280176.
358: Paridaens R, Dirix L, Dumez H, Prové A, Wildiers H, Alvarez A,
Oliveira CT, Latz J, Simms L, Melemed A. Phase I/II pharmacokinetic
study of pemetrexed and epirubicin in patients with locally advanced or
metastatic breast cancer. Clin Breast Cancer. 2007 Dec;7(11):861-6.
PubMed PMID: 18269776.
359: Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J.
Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural
mesothelioma treatment in UK clinical practice. Value Health. 2008
Jan-Feb;11(1):4-12. PubMed PMID: 18237355.
360: Hutson TE, Vukelja S, Atienza D, Awasthi S, Delaune R, Deutsch M,
Dien PY, Gregory TF, Kolodziej MJ, Muscato JJ, Raju RN, Ruxer RL Jr,
Mull S, Ilegbodu D, Hood K, Nicol S, Berry W. Phase I study of a 3-drug
regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic
transitional cell carcinoma of the urothelium. Invest New Drugs. 2008
Apr;26(2):151-8. Epub 2008 Jan 31. PubMed PMID: 18236006.
361: Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, Gaudino
G. Imatinib mesylate enhances therapeutic effects of gemcitabine in
human malignant mesothelioma xenografts. Clin Cancer Res. 2008 Jan
15;14(2):541-8. PubMed PMID: 18223230.
362: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735. PubMed PMID:
18200333.
363: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55. PubMed PMID:
18193114.
364: Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA,
Ricciardi S, Danesi R, Giaccone G, Peters GJ. Molecular mechanisms
underlying the synergistic interaction of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, with the multitargeted
antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol.
2008 Apr;73(4):1290-300. Epub 2008 Jan 10. PubMed PMID: 18187583.
365: Gridelli C, Rossi A, Morgillo F, Bareschino MA, Maione P, Di Maio
M, Ciardiello F. A randomized phase II study of pemetrexed or RAD001 as
second-line treatment of advanced non-small-cell lung cancer in elderly
patients: treatment rationale and protocol dynamics. Clin Lung Cancer.
2007 Nov;8(9):568-71. PubMed PMID: 18186963.
366: de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M,
Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ. Lung Cancer Symptom
Scale outcomes in relation to standard efficacy measures: an analysis of
the phase III study of pemetrexed versus docetaxel in advanced non-small
cell lung cancer. J Thorac Oncol. 2008 Jan;3(1):30-6. PubMed PMID:
18166838.
367: Doral Stefani S, Giorgio Saggia M, Vicino dos Santos EA. Cost-minimisation
analysis of erlotinib in the second-line treatment of non-small-cell
lung cancer: a Brazilian perspective. J Med Econ. 2008;11(3):383-96.
PubMed PMID: 19450094.
368: Arellano J, Leteneux C. Comment and reply on: A comparison of the
estimated costs of erlotinib, docetaxel and pemetrexed for the
second-line treatment of non-small cell lung cancer from the German
healthcare perspective. J Med Econ. 2008;11(2):363-66; author reply
366-70. PubMed PMID: 19450092.
369: Scagliotti GV, Selvaggi G. New data integrating multitargeted
antifolates into treatment of first-line and relapsed non-small-cell
lung cancer. Clin Lung Cancer. 2008;9 Suppl 3:S122-8. Review. PubMed
PMID: 19419926.
370: Hoschek S, Hoschek-Risslegger U, Fiegl M, Zabernigg A, Pall G,
Auberger T, Gunsilius E, Schmid T, Jamnig H, Hilbe W; Tiroler
Arbeitskreis für Onkologie TAKO. [Small cell lung cancer]. Wien Klin
Wochenschr. 2007;119(23-24):697-710. Review. German. PubMed PMID:
18157602.
371: Hoschek S, Hoschek-Risslegger U, Fiegl M, Zabernigg A, Pall G,
Auberger T, Gunsilius E, Schmid T, Jamnig H, Hilbe W. [Updated
strategies in Small Cell Lung Cancer post ASCO 2007]. Wien Med
Wochenschr. 2007;157(21-22):562-8. Review. German. PubMed PMID:
18157594.
372: Ploner F. [NSCLC: update on second line therapy following ASCO
2007]. Wien Med Wochenschr. 2007;157(21-22):540-4. Review. German.
PubMed PMID: 18157591.
373: Zabernigg A. [Upcoming strategies in the treatment of non-small
cell lung cancer stage IIIB/wet and IV]. Wien Med Wochenschr.
2007;157(21-22):536-9. German. PubMed PMID: 18157590.
374: Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O,
Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto
L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination
with carboplatin in patients with malignant pleural mesothelioma (MPM).
Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20. PubMed PMID:
18156144.
375: Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M,
Lara PN, Lau DH, Gandara DR. Phase I study of two different schedules of
bortezomib and pemetrexed in advanced solid tumors with emphasis on
non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1112-6.
PubMed PMID: 18090584.
376: Gangjee A, Li W, Yang J, Kisliuk RL. Design, synthesis, and
biological evaluation of classical and nonclassical
2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual
thymidylate synthase and dihydrofolate reductase inhibitors. J Med Chem.
2008 Jan 10;51(1):68-76. Epub 2007 Dec 12. PubMed PMID: 18072727.
377: Meriggi F, Di Biasi B, Caliolo C, Zaniboni A. The potential role of
pemetrexed in gastrointestinal cancer. Chemotherapy. 2008;54(1):1-8.
Epub 2007 Dec 7. Review. PubMed PMID: 18063861.
378: Burkitt V. In Australia, patients and government at odds over
mesothelioma treatment costs. J Natl Cancer Inst. 2007 Dec
5;99(23):1750-2. Epub 2007 Nov 27. PubMed PMID: 18042927.
379: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PubMed PMID:
18040531.
380: Cho RC, Cole PD, Sohn KJ, Gaisano G, Croxford R, Kamen BA, Kim YI.
Effects of folate and folylpolyglutamyl synthase modulation on
chemosensitivity of breast cancer cells. Mol Cancer Ther. 2007
Nov;6(11):2909-20. PubMed PMID: 18025275.
381: Bearz A, Garassino I, Cavina R, Favaretto A, Boccalon M, Talamini
R, Berretta M, Spazzapan S, Simonelli C, Santoro A, Tirelli U.
Pemetrexed single agent in previously treated non-small cell lung
cancer: a multi-institutional observational study. Lung Cancer. 2008
May;60(2):240-5. Epub 2007 Nov 26. PubMed PMID: 18022729.
382: Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J. A
novel monoclonal antibody for detection of folate receptor alpha in
paraffin-embedded tissues. Hybridoma (Larchmt). 2007 Oct;26(5):281-8.
PubMed PMID: 17979543.
383: Kim YH, Chung HC, Kang WK, Park SR, Kim CS, Kim TY, Shin SW, Park
BJ, Cha SJ, Bang YJ. Pemetrexed and cisplatin in patients with advanced
gastric cancer: a Korean cancer study group multicenter phase II study.
Cancer Chemother Pharmacol. 2008 Jul;62(2):263-70. Epub 2007 Oct 25.
PubMed PMID: 17960386.
384: Santos C, Montesinos J, Castańer E, Sole JM, Baga R. Primary
pericardial mesothelioma. Lung Cancer. 2008 May;60(2):291-3. Epub 2007
Oct 23. PubMed PMID: 17936406.
385: Apostolidou E, Swords R, Alvarado Y, Giles FJ. Treatment of acute
lymphoblastic leukaemia : a new era. Drugs. 2007;67(15):2153-71. Review.
PubMed PMID: 17927282.
386: El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to
improve survival in small cell lung cancer? Lung Cancer. 2007 Aug;57
Suppl 2:S30-4. Review. PubMed PMID: 17686444.
387: Manegold C, Thatcher N. Survival improvement in thoracic cancer:
progress from the last decade and beyond. Lung Cancer. 2007 Aug;57 Suppl
2:S3-5. PubMed PMID: 17686443.
388: Baas P. Optimising survival in malignant mesothelioma. Lung Cancer.
2007 Aug;57 Suppl 2:S24-9. Review. PubMed PMID: 17686442.
389: Vansteenkiste J. Improving patient management in metastatic
non-small cell lung cancer. Lung Cancer. 2007 Aug;57 Suppl 2:S12-7.
Review. PubMed PMID: 17686440.
390: Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R,
Modesti A. Recombinant erythropoietin differently affects proliferation
of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.
Cancer Chemother Pharmacol. 2008 Apr;61(5):893-901. Epub 2007 Oct 6.
PubMed PMID: 17922127.
391: Razak AR, Chatten KJ, Hughes AN. Retreatment with pemetrexed-based
chemotherapy in malignant pleural mesothelioma (MPM): a second line
treatment option. Lung Cancer. 2008 May;60(2):294-7. Epub 2007 Oct 4.
PubMed PMID: 17919769.
392: Li KM, Rivory LP, Clarke SJ. Pemetrexed pharmacokinetics and
pharmacodynamics in a phase I/II study of doublet chemotherapy with
vinorelbine: implications for further optimisation of pemetrexed
schedules. Br J Cancer. 2007 Oct 22;97(8):1071-6. Epub 2007 Oct 2.
PubMed PMID: 17912246; PubMed Central PMCID: PMC2360430.
393: Hillerdal G, Elmberger G. Malignant mediastinal tumor with bone
formation--mesothelioma or sarcoma? J Thorac Oncol. 2007
Oct;2(10):983-4. PubMed PMID: 17909365.
394: Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart
L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and
safety of bevacizumab in combination with chemotherapy or erlotinib
compared with chemotherapy alone for treatment of recurrent or
refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct
20;25(30):4743-50. Epub 2007 Oct 1. PubMed PMID: 17909199.
395: Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S. The
therapeutic efficacy of anti vascular endothelial growth factor
antibody, bevacizumab, and pemetrexed against orthotopically implanted
human pleural mesothelioma cells in severe combined immunodeficient
mice. Clin Cancer Res. 2007 Oct 1;13(19):5918-25. PubMed PMID: 17908988.
396: Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman
K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR,
Febbo PG, Potti A. Pharmacogenomic strategies provide a rational
approach to the treatment of cisplatin-resistant patients with advanced
cancer. J Clin Oncol. 2007 Oct 1;25(28):4350-7. Erratum in: J Clin Oncol.
2010 Jun 1;28(16):2805. PubMed PMID: 17906199.
397: Gangjee A, Jain HD, Kurup S. Recent advances in classical and
non-classical antifolates as antitumor and antiopportunistic infection
agents: part I. Anticancer Agents Med Chem. 2007 Sep;7(5):524-42.
Review. PubMed PMID: 17896913.
398: Iaffaioli RV, Milano A, Caponigro F. Therapy of metastatic bladder
carcinoma. Ann Oncol. 2007 Jun;18 Suppl 6:vi153-6. Review. PubMed PMID:
17591811.
399: Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, Ames
MM, Adjei AA. Identification and characterization of genetic variation
in the folylpolyglutamate synthase gene. Cancer Res. 2007 Sep
15;67(18):8772-82. PubMed PMID: 17875718.
400: Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K,
Karaseva V, Tjulandin S. A phase II study of pemetrexed and carboplatin
in patients with locally advanced or metastatic breast cancer. Breast
Cancer Res Treat. 2008 Jul;110(2):309-15. Epub 2007 Sep 13. PubMed PMID:
17851759.
401: Sablin MP, Le Tourneau C, El Maalouf G, Raymond E, Faivre S. [Gemcitabine
and pemetrexed: novel associations and mechanisms of resistance]. Bull
Cancer. 2007;94 Spec No Actualites:S149-54. Review. French. PubMed PMID:
17845986.
402: Chaigneau L, Villanueva C, Thierry-Vuillemin A, Legat-Fagnoni C,
N'Guyen T, Maurina T, Lorgis V, Pivot X. [Pemetrexed development in
oncology]. Bull Cancer. 2007;94 Spec No Actualites:S142-8. Review.
French. PubMed PMID: 17845985.
403: Brechot JM, Morčre JF. [Update of pemetrexed in thoracic oncology].
Bull Cancer. 2007;94 Spec No Actualites:S139-41. Review. French. PubMed
PMID: 17845984.
404: Lansiaux A, Lokiec F. [Pemetrexed: from preclinic to clinic]. Bull
Cancer. 2007;94 Spec No Actualites:S134-8. Review. French. PubMed PMID:
17845983.
405: Fléchon A. [Gemcitabine and pemetrexed in genito-urinary tumors
treatment]. Bull Cancer. 2007;94 Spec No Actualites:S116-21. Review.
French. PubMed PMID: 17845980.
406: Spano JP, Bay JO. [Gemcitabine and pemetrexed update]. Bull Cancer.
2007;94 Spec No Actualites:S83. French. PubMed PMID: 17845975.
407: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PubMed PMID:
17805439.
408: De Santis M, Bachner M. New developments in first- and second-line
chemotherapy for transitional cell, squamous cell and adenocarcinoma of
the bladder. Curr Opin Urol. 2007 Sep;17(5):363-8. Review. PubMed PMID:
17762632.
409: Doval DC, Pande SB, Sharma JB, Rao SA, Prakash N, Vaid AK. Report
of a case of pericardial mesothelioma with liver metastases responding
well to pemetrexed and platinum-based chemotherapy. J Thorac Oncol. 2007
Aug;2(8):780-1. PubMed PMID: 17762349.
410: Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce
JL, Arrieta O, González-Fierro A, Chávez-Blanco A, de la Cruz-Hernández
E, Camargo MF, Trejo-Becerril C, Pérez-Cárdenas E, Pérez-Plasencia C,
Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, Dueńas-González A.
A phase II study of epigenetic therapy with hydralazine and magnesium
valproate to overcome chemotherapy resistance in refractory solid
tumors. Ann Oncol. 2007 Sep;18(9):1529-38. PubMed PMID: 17761710.
411: Müller C, Schibli R, Forrer F, Krenning EP, de Jong M.
Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate
uptake in tumors and kidneys. Nucl Med Biol. 2007 Aug;34(6):603-8.
PubMed PMID: 17707799.
412: Müller C, Schubiger PA, Schibli R. Isostructural folate conjugates
radiolabeled with the matched pair 99mTc/188Re: a potential strategy for
diagnosis and therapy of folate receptor-positive tumors. Nucl Med Biol.
2007 Aug;34(6):595-601. PubMed PMID: 17707798.
413: Gkiozos I, Charpidou A, Syrigos K. Developments in the treatment of
non-small cell lung cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2823-7.
Review. PubMed PMID: 17695454.
414: Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, Goetz
MP, Weinshilboum RM, Nicol SJ, Goldberg RM. Pemetrexed and oxaliplatin
for metastatic colorectal cancer: results of a phase I Mayo Cancer
Center Research Consortium trial, MC0248. Clin Colorectal Cancer. 2007
Jul;6(8):572-7. PubMed PMID: 17681103.
415: Ceresoli GL, Gridelli C, Santoro A. Multidisciplinary treatment of
malignant pleural mesothelioma. Oncologist. 2007 Jul;12(7):850-63.
Review. PubMed PMID: 17673616.
416: Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID.
Commentary: a case for minimizing folate supplementation in clinical
regimens with pemetrexed based on the marked sensitivity of the drug to
folate availability. Oncologist. 2007 Jul;12(7):808-15. PubMed PMID:
17673612.
417: Socinski MA. Antibodies to the epidermal growth factor receptor in
non small cell lung cancer: current status of matuzumab and panitumumab.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4597-601. Review. PubMed PMID:
17671148.
418: Kalykaki A, Vamvakas L, Agelaki S, Kalbakis K, Vardakis N,
Sfakiotaki G, Ignatiadis M, Saridaki Z, Karampeazis A, Mavroudis D,
Georgoulias V. A dose escalation study of gemcitabine plus pemetrexed
administered biweekly in patients with solid tumors. Oncology.
2006;71(3-4):197-203. Epub 2007 Jul 19. Erratum in: Oncology.
2007;73(5-6):406. Karabeazis, A [corrected to Karampeazis, A]. PubMed
PMID: 17641541.
419: Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in
advanced non-small cell lung cancer. Curr Treat Options Oncol. 2007
Feb;8(1):38-46. Review. PubMed PMID: 17634834.
420: Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating
NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr
Treat Options Oncol. 2007 Feb;8(1):15-27. Review. PubMed PMID: 17634832.
421: Min SH, Goldman ID, Zhao R. Caffeine markedly sensitizes human
mesothelioma cell lines to pemetrexed. Cancer Chemother Pharmacol. 2008
Apr;61(5):819-27. Epub 2007 Jun 27. PubMed PMID: 17594092.
422: Ponce Lorenzo J, Giménez Ortiz A, Aparisi Aparisi F, Fleitas
Kanonnikoff T, Montalar Salcedo J. [Peritoneal mesothelioma: an inusual
clinical presentation in a patient without exposure to asbestos]. An Med
Interna. 2007 Feb;24(2):81-3. Spanish. PubMed PMID: 17590095.
423: Zalcman G, Lechapt E, Bergot E. [Management of malignant pleural
effusion]. Rev Prat. 2007 Mar 15;57(5):513-23. Review. French. PubMed
PMID: 17583136.
424: Llombart-Cussac A, Martin M, Harbeck N, Anghel RM, Eniu AE, Verrill
MW, Neven P, De Grčve J, Melemed AS, Clark R, Simms L, Kaiser CJ, Ma D.
A randomized, double-blind, phase II study of two doses of pemetrexed as
first-line chemotherapy for advanced breast cancer. Clin Cancer Res.
2007 Jun 15;13(12):3652-9. PubMed PMID: 17575230.
425: Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA Jr. Single-institution
experience with pemetrexed and bevacizumab as salvage therapy in
advanced non-small-cell lung cancer. Clin Lung Cancer. 2007
Mar;8(5):335-8. PubMed PMID: 17562234.
426: Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ.
Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate
synthase inhibition. Oncol Rep. 2007 Jul;18(1):287-91. PubMed PMID:
17549381.
427: Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent
cytotoxic synergism of pemetrexed and erlotinib in human non-small cell
lung cancer cells. Clin Cancer Res. 2007 Jun 1;13(11):3413-22. PubMed
PMID: 17545550.
428: Rodrigues GB, Roa WH. In regard to Allen et al.: Fatal pneumonitis
associated with intensity-modulated radiation therapy for mesothelioma (Int
J Radiat Oncol Biol Phys 2006;65:640-645). Int J Radiat Oncol Biol Phys.
2007 Jul 1;68(3):959. PubMed PMID: 17544006.
429: Amoroso V, Pittiani F, Grisanti S, Valcamonico F, Simoncini E,
Ferrari VD, Marini G. Osteoblastic flare in a patient with advanced
gastric cancer after treatment with pemetrexed and oxaliplatin:
implications for response assessment with RECIST criteria. BMC Cancer.
2007 Jun 1;7:94. PubMed PMID: 17540044; PubMed Central PMCID:
PMC1896169.
430: Bodmer N, Walters DK, Fuchs B. Pemetrexed, a multitargeted
antifolate drug, demonstrates lower efficacy in comparison to
methotrexate against osteosarcoma cell lines. Pediatr Blood Cancer. 2008
Apr;50(4):905-8. PubMed PMID: 17534933.
431: Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S,
Hanauske-Abel H, Ma D, Chen V, Paoletti P, Niyikiza C. In vitro
chemosensitivity of freshly explanted tumor cells to pemetrexed is
correlated with target gene expression. Invest New Drugs. 2007
Oct;25(5):417-23. Epub 2007 May 30. PubMed PMID: 17534577.
432: Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current
concepts in treatment. Nat Clin Pract Oncol. 2007 Jun;4(6):344-52.
Review. PubMed PMID: 17534390.
433: Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL,
Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome
inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother
Pharmacol. 2008 Apr;61(4):549-58. Epub 2007 May 24. PubMed PMID:
17522864.
434: Goudar RK. Management options for malignant pleural mesothelioma:
clinical and cost considerations. Drugs. 2007;67(8):1149-65. Review.
PubMed PMID: 17521217.
435: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45. PubMed PMID:
17520107.
436: Tummino C, Barlesi F, Tchouhadjian C, Tasei AM, Gaudy-Marqueste C,
Richard MA, Astoul P. [Severe cutaneous toxicity after Pemetrexed as
second line treatment for a refractory non small cell lung cancer]. Rev
Mal Respir. 2007 May;24(5):635-8. French. PubMed PMID: 17519817.
437: Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P,
Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P,
Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M. Doxorubicin/pemetrexed
followed by docetaxel versus doxorubicin/ cyclophosphamide followed by
docetaxel as neoadjuvant treatment for early-stage breast cancer: a
randomized phase II trial. Clin Breast Cancer. 2007 Apr;7(7):555-8.
PubMed PMID: 17509164.
438: Ferraldeschi R, Thatcher N, Lorigan P. Pemetrexed in small-cell
lung cancer: background and review of the ongoing GALES pivotal trial.
Expert Rev Anticancer Ther. 2007 May;7(5):635-40. Review. PubMed PMID:
17492928.
439: Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H,
De Leyn P, Thomas M. Trial on refinement of early stage non-small cell
lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus
vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007 May
8;7:77. PubMed PMID: 17488518; PubMed Central PMCID: PMC1878496.
440: Pujol JL, Paul S, Chouaki N, Peterson P, Moore P, Berry DA,
Salzberg M. Survival without common toxicity criteria grade 3/4 toxicity
for pemetrexed compared with docetaxel in previously treated patients
with advanced non-small cell lung cancer (NSCLC): a risk-benefit
analysis. J Thorac Oncol. 2007 May;2(5):397-401. PubMed PMID: 17473654.
441: Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M,
Forouzesh B, de Bono J, Tolcher AW, Patnaik A, Monroe P, Wood L, Schneck
KB, Clark R, Rowinsky EK. Phase I and pharmacokinetic study of
pemetrexed with high-dose folic acid supplementation or multivitamin
supplementation in patients with locally advanced or metastatic cancer.
Clin Cancer Res. 2007 May 1;13(9):2675-83. PubMed PMID: 17473199.
442: Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D.
Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed
protects against pemetrexed cytotoxicity in human bone marrow.
Anticancer Res. 2007 Mar-Apr;27(2):825-33. PubMed PMID: 17465208.
443: Simon M, Blatter J, Granzow C. Antifolate pseudo-resistance due to
elevated levels of thymidine and hypoxanthine in a commercial serum
preparation. Anticancer Res. 2007 Mar-Apr;27(2):769-73. PubMed PMID:
17465201.
444: Crinň L, Foglietta J, Hamzaj A. Lung cancer. J Thorac Oncol. 2007
May;2(5 Suppl):S24-6. Review. PubMed PMID: 17457226.
445: Lievens Y, Nafteux P, Vanstraelen B, Nackaerts K. In regards to
Allen et al. (Int J Radiat Oncol Biol Phys 2006;65:640-645). Int J
Radiat Oncol Biol Phys. 2007 May 1;68(1):315-6; author reply 316. PubMed
PMID: 17448889.
446: Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M,
Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC;
Children's Oncology Group. Phase I trial and pharmacokinetic study of
pemetrexed in children with refractory solid tumors: the Children's
Oncology Group. J Clin Oncol. 2007 Apr 20;25(12):1505-11. Erratum in: J
Clin Oncol. 2008 Jan 1;26(1):165. PubMed PMID: 17442992.
447: Yusa T. [Treatment of malignant pleural mesothelioma]. Gan To
Kagaku Ryoho. 2007 Apr;34(4):520-6. Review. Japanese. PubMed PMID:
17431335.
448: Mercalli A, Sordi V, Formicola R, Dandrea M, Beghelli S, Scarpa A,
Di Carlo V, Reni M, Piemonti L. A preclinical evaluation of pemetrexed
and irinotecan combination as second-line chemotherapy in pancreatic
cancer. Br J Cancer. 2007 May 7;96(9):1358-67. Epub 2007 Apr 10. PubMed
PMID: 17426706; PubMed Central PMCID: PMC2360188.
449: Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold
C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F,
Peterson P, Muńoz M, Reck M. Single-agent pemetrexed or sequential
pemetrexed/gemcitabine as front-line treatment of advanced non-small
cell lung cancer in elderly patients or patients ineligible for
platinum-based chemotherapy: a multicenter, randomized, phase II trial.
J Thorac Oncol. 2007 Mar;2(3):221-9. PubMed PMID: 17410045.
450: Sřrensen JB, Sundstrřm S, Perell K, Thielsen AK. Pemetrexed as
second-line treatment in malignant pleural mesothelioma after
platinum-based first-line treatment. J Thorac Oncol. 2007
Feb;2(2):147-52. PubMed PMID: 17410031.
451: Noble J, Ellis PM, Mackay JA, Evans WK; Lung Cancer Disease Site
Group of Cancer Care Ontario's Program in Evidence-based Care.
Second-line or subsequent systemic therapy for recurrent or progressive
non-small cell lung cancer: a systematic review and practice guideline.
J Thorac Oncol. 2006 Nov;1(9):1042-58. Review. PubMed PMID: 17409993.
452: Hanna N. Second-line treatment of non-small cell lung cancer: big
targets, small progress; small targets, big progress? J Thorac Oncol.
2006 Nov;1(9):927-8. PubMed PMID: 17409973.
453: Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS; Lung Cancer
Disease Site Group of Cancer Care Ontario's Program in Evidence-based
Care. The use of chemotherapy in patients with advanced malignant
pleural mesothelioma: a systematic review and practice guideline. J
Thorac Oncol. 2006 Jul;1(6):591-601. Review. PubMed PMID: 17409924.
454: Bedano PM, Hanna NH. Salvage therapy in patients with advanced
non-small cell lung cancer. J Thorac Oncol. 2006 Jul;1(6):582-7. Review.
PubMed PMID: 17409922.
455: Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA,
Mintzer DM, Ye Z, Monberg MJ, Obasaju CK; Pemetrexed expanded access
program investigators. Pemetrexed alone or in combination with cisplatin
in previously treated malignant pleural mesothelioma: outcomes from a
phase IIIB expanded access program. J Thorac Oncol. 2006
Jul;1(6):506-12. Erratum in: J Thorac Oncol. 2006 Sep;1(7):621. PubMed
PMID: 17409909.
456: van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF,
Hoogsteden HC, van Klaveren RJ. Pemetrexed maintenance therapy in
patients with malignant pleural mesothelioma. J Thorac Oncol. 2006
Jan;1(1):25-30. PubMed PMID: 17409823.
457: Velcheti V, Govindan R. Pneumocystis pneumonia in a patient with
non-small cell lung cancer (NSCLC) treated with pemetrexed containing
regimen. Lung Cancer. 2007 Aug;57(2):240-2. Epub 2007 Apr 2. PubMed
PMID: 17400329.
458: Beekman KW, Bradley D, Hussain M. New molecular targets and novel
agents in the treatment of advanced urothelial cancer. Semin Oncol. 2007
Apr;34(2):154-64. Review. PubMed PMID: 17382799.
459: Bellmunt J, Albiol S. Chemotherapy for metastatic or unresectable
bladder cancer. Semin Oncol. 2007 Apr;34(2):135-44. Review. PubMed PMID:
17382797.
460: Stathopoulos GP, Dimitroulis J, Toubis M, Katis C, Karaindros D,
Stathopoulos J, Koutandos J. Pemetrexed combined with paclitaxel in
patients with advanced or metastatic non-small-cell lung cancer: a phase
I-II trial. Lung Cancer. 2007 Jul;57(1):66-71. Epub 2007 Mar 26. PubMed
PMID: 17382431.
461: Dasanu CA, Wiernik PH, Vaillant J, Alexandrescu DT. A complex
pattern of melanonychia and onycholysis after treatment with pemetrexed
for lung cancer. Skinmed. 2007 Mar-Apr;6(2):95-6. PubMed PMID: 17366681.
462: Longo-Sorbello GS, Chen B, Budak-Alpdogan T, Bertino JR. Role of
pemetrexed in non-small cell lung cancer. Cancer Invest. 2007
Feb;25(1):59-66. Review. PubMed PMID: 17364559.
463: Alvarado Y, Apostolidou E, Swords R, Giles FJ. Emerging therapeutic
options for Philadelphia-positive acute lymphocytic leukemia. Expert
Opin Emerg Drugs. 2007 Mar;12(1):165-79. Review. PubMed PMID: 17355221.
464: Scagliotti GV, Selvaggi G. Emerging drugs for mesothelioma. Expert
Opin Emerg Drugs. 2007 Mar;12(1):127-37. Review. PubMed PMID: 17355218.
465: Wan L. Pemetrexed improves survival in pancreatic cancer. Lancet
Oncol. 2007 Mar;8(3):197. PubMed PMID: 17354298.
466: Babiak A, Hetzel J, Godde F, König HH, Pietsch M, Hetzel M.
Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a
phase II trial. Br J Cancer. 2007 Apr 10;96(7):1052-6. Epub 2007 Mar 13.
PubMed PMID: 17353918; PubMed Central PMCID: PMC2360135.
467: Ono A, Yamamoto N. [Lung cancer]. Gan To Kagaku Ryoho. 2007
Mar;34(3):367-73. Review. Japanese. PubMed PMID: 17353626.
468: Zhao R, Goldman ID. The molecular identity and characterization of
a Proton-coupled Folate Transporter--PCFT; biological ramifications and
impact on the activity of pemetrexed. Cancer Metastasis Rev. 2007
Mar;26(1):129-39. Review. PubMed PMID: 17340171.
469: Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM,
Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters GJ. Changes in
the status of p53 affect drug sensitivity to thymidylate synthase (TS)
inhibitors by altering TS levels. Br J Cancer. 2007 Mar 12;96(5):769-75.
PubMed PMID: 17339891; PubMed Central PMCID: PMC2360080.
470: Matherly LH, Hou Z, Deng Y. Human reduced folate carrier:
translation of basic biology to cancer etiology and therapy. Cancer
Metastasis Rev. 2007 Mar;26(1):111-28. Review. PubMed PMID: 17334909.
471: Assaraf YG. Molecular basis of antifolate resistance. Cancer
Metastasis Rev. 2007 Mar;26(1):153-81. Review. PubMed PMID: 17333344.
472: Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based
combination chemotherapy in A375 human melanoma and RPMI 8226 human
myeloma cell lines. Cancer Chemother Pharmacol. 2007 May;59(6):749-57.
Epub 2007 Feb 28. PubMed PMID: 17333195.
473: Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen
B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA Jr. The impact of
induction chemotherapy on the outcome of second-line therapy with
pemetrexed or docetaxel in patients with advanced non-small-cell lung
cancer. Ann Oncol. 2007 Mar;18(3):453-60. PubMed PMID: 17322539.
474: Ramirez JM, Ocio EM, San Miguel JF, Pandiella A. Pemetrexed acts as
an antimyeloma agent by provoking cell cycle blockade and apoptosis.
Leukemia. 2007 Apr;21(4):797-804. Epub 2007 Feb 22. PubMed PMID:
17315026.
475: Touraine F, Sainte Laudy J, Boumediene A, Ndikumwenayo F,
Decroisette C, Melloni B, Vergnenegre A, Bonnaud F. [Investigation of
allergic reactions to platinum salts]. Rev Mal Respir. 2006 Nov;23(5 Pt
1):458-62. French. PubMed PMID: 17314746.
476: Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S,
Tassi G, Favoni R, Gaudino G, Mutti L. Preliminary data suggestive of a
novel translational approach to mesothelioma treatment: imatinib
mesylate with gemcitabine or pemetrexed. Thorax. 2007 Aug;62(8):690-5.
Epub 2007 Feb 20. PubMed PMID: 17311837.
477: Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and
cellular pharmacology, mechanisms, and clinical applications. Mol Cancer
Ther. 2007 Feb;6(2):404-17. Review. PubMed PMID: 17308042.
478: Nambu Y. [Expanded access program in the United States and Alimta
program for malignant mesothelioma patients]. Gan To Kagaku Ryoho. 2007
Feb;34(2):284-6. Japanese. PubMed PMID: 17301544.
479: Rowinsky EK, Beeram M, Hammond LA, Schwartz G, De Bono J, Forouzesh
B, Chu Q, Latz JE, Hong S, John W, Nguyen B. A phase I and
pharmacokinetic study of pemetrexed plus irinotecan in patients with
advanced solid malignancies. Clin Cancer Res. 2007 Jan 15;13(2 Pt
1):532-9. PubMed PMID: 17255275.
480: Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L,
Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of
pemetrexed, carboplatin, and concurrent radiotherapy in patients with
locally advanced or metastatic non-small cell lung or esophageal cancer.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22. PubMed PMID: 17255273.
481: Hann CL, Brahmer JR. Second-line Therapy for advanced
non-small-cell lung cancer. Curr Oncol Rep. 2006 Jul;8(4):243-7. Review.
PubMed PMID: 17254522.
482: Green J, Dundar Y, Dodd S, Dickson R, Walley T. Pemetrexed disodium
in combination with cisplatin versus other cytotoxic agents or
supportive care for the treatment of malignant pleural mesothelioma.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005574. Review. PubMed
PMID: 17253564.
483: Ho C, Ross H, Davies A. Phase II trial of premetrexed in patients
with selected stage IIIB/IV bronchioloalveolar carcinoma. Clin Lung
Cancer. 2006 Nov;8(3):220-2. PubMed PMID: 17239300.
484: Llombart-Cussac A, Theodoulou M, Rowland K, Clark RS, Nakamura T,
Carrasco E, Cruciani G. Pemetrexed in patients with locally advanced or
metastatic breast cancer who had received previous anthracycline and
taxane treatment: phase II study. Clin Breast Cancer. 2006
Dec;7(5):380-5. PubMed PMID: 17239262.
485: Neukirchen J, Meier A, Rohrbeck A, Garcia-Pardillos G, Steidl U,
Fenk R, Haas R, Kronenwett R, Rohr UP. The proteasome inhibitor
bortezomib acts differently in combination with p53 gene transfer or
cytotoxic chemotherapy on NSCLC cells. Cancer Gene Ther. 2007
Apr;14(4):431-9. Epub 2007 Jan 19. PubMed PMID: 17235352.
486: Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan
J, Stötzer O, Zeuzem S, Lordick F, Köhne CH, Kröning H, Steinmetz T,
Depenbrock H, Heinemann V. Second-line chemotherapy with pemetrexed
after gemcitabine failure in patients with advanced pancreatic cancer: a
multicenter phase II trial. Ann Oncol. 2007 Apr;18(4):745-51. Epub 2007
Jan 17. PubMed PMID: 17229775.
487: Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R,
McLeod C, Walley T. Pemetrexed disodium for the treatment of malignant
pleural mesothelioma: a systematic review and economic evaluation.
Health Technol Assess. 2007 Jan;11(1):1-90. Review. PubMed PMID:
17181984.
488: Fasola G, Puglisi F, Follador A, Aita M, Di Terlizzi S, Belvedere
O. Dramatic tumour response to pemetrexed single-agent in an elderly
patient with malignant peritoneal mesothelioma: a case report. BMC
Cancer. 2006 Dec 18;6:289. PubMed PMID: 17176466; PubMed Central PMCID:
PMC1764904.
489: Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin
DF. Phase II trial of pemetrexed as second-line therapy in patients with
metastatic urothelial carcinoma. Invest New Drugs. 2007
Jun;25(3):265-70. Epub 2006 Dec 5. PubMed PMID: 17146733.
490: Dittrich C, Petruzelka L, Vodvarka P, Gneist M, Janku F, Kysela T,
Melemed A, Latz J, Simms L, Krejcy K. A phase I study of pemetrexed
(ALIMTA) and cyclophosphamide in patients with locally advanced or
metastatic breast cancer. Clin Cancer Res. 2006 Dec 1;12(23):7071-8.
PubMed PMID: 17145830.
491: Müller C, Brühlmeier M, Schubiger PA, Schibli R. Effects of
antifolate drugs on the cellular uptake of radiofolates in vitro and in
vivo. J Nucl Med. 2006 Dec;47(12):2057-64. PubMed PMID: 17138750.
492: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):533-91. PubMed PMID:
17136234.
493: Giudicelli R, Regnard JF, Astoul P, Ruffie P. [Malignant
mesothelioma of the pleura: place of surgery]. Rev Mal Respir. 2006
Sep;23(4 Pt 2):10S106-10S109. French. PubMed PMID: 17127980.
494: Paesmans M, Berghmans T, Sculier JP. Second-line treatment for
advanced non-small cell lung cancer: how to design a clinical trial for
a new agent? Lung Cancer. 2007 Feb;55(2):135-6. Epub 2006 Nov 21. PubMed
PMID: 17118490.
495: Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA,
Bonomi P. Phase II trial of cetuximab in patients with previously
treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov
20;24(33):5253-8. PubMed PMID: 17114658.
496: Tweats DJ, Blakey D, Heflich RH, Jacobs A, Jacobsen SD, Morita T,
Nohmi T, O'Donovan MR, Sasaki YF, Sofuni T, Tice R; IWGT Working Group.
Report of the IWGT working group on strategy/interpretation for
regulatory in vivo tests II. Identification of in vivo-only positive
compounds in the bone marrow micronucleus test. Mutat Res. 2007 Feb
3;627(1):92-105. Epub 2006 Nov 20. Review. PubMed PMID: 17113817; PubMed
Central PMCID: PMC2790421.
497: Assaraf YG. The role of multidrug resistance efflux transporters in
antifolate resistance and folate homeostasis. Drug Resist Updat. 2006
Aug-Oct;9(4-5):227-46. Epub 2006 Nov 7. Review. PubMed PMID: 17092765.
498: Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ,
Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA; Pemetrexed Expanded
Access Program Investigators. Single-arm, open label study of pemetrexed
plus cisplatin in chemotherapy naďve patients with malignant pleural
mesothelioma: outcomes of an expanded access program. Lung Cancer. 2007
Feb;55(2):187-94. Epub 2006 Nov 7. PubMed PMID: 17092602.
499: Milano E, Pourroy B, Rome A, Delarue A, Coze C, Gorincour G,
Bouvier C, Braguer D, André N. Efficacy of a combination of pemetrexed
and multiple redo-surgery in an 11-year-old girl with a recurrent
multifocal abdominal mesothelioma. Anticancer Drugs. 2006
Nov;17(10):1231-4. PubMed PMID: 17075325.
500: Can pemetrexed help in malignant mesothelioma? Drug Ther Bull. 2006
Oct;44(10):77-80. Review. PubMed PMID: 17067119.
501: Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, van den
Ijssel P, Ylstra B, Peters GJ. Micro-array analysis of resistance for
gemcitabine results in increased expression of ribonucleotide reductase
subunits. Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1001-7.
PubMed PMID: 17065054.
502: Vansteenkiste J. Second-line therapeutic options in non-small-cell
lung cancer. Lung Cancer. 2006 Dec;54 Suppl 2:S15-8. Epub 2006 Oct 24.
Review. PubMed PMID: 17064813.
503: Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP,
Prager D, Monberg MJ, Ye Z, Obasaju CK. Randomized phase II trial of
pemetrexed combined with either cisplatin or carboplatin in untreated
extensive-stage small-cell lung cancer. J Clin Oncol. 2006 Oct
20;24(30):4840-7. Erratum in: J Clin Oncol. 2007 Jan 1;25(1):167. PubMed
PMID: 17050869.
504: Barlési F, Tummino C, Tasei AM, Astoul P. Unsuccessful rechallenge
with pemetrexed after a previous radiation recall dermatitis. Lung
Cancer. 2006 Dec;54(3):423-5. Epub 2006 Oct 17. PubMed PMID: 17049669.
505: Chattopadhyay S, Zhao R, Tsai E, Schramm VL, Goldman ID. The effect
of a novel transition state inhibitor of methylthioadenosine
phosphorylase on pemetrexed activity. Mol Cancer Ther. 2006
Oct;5(10):2549-55. PubMed PMID: 17041099.
506: Wilson RH. Novel therapeutic developments other than EGFR and VEGF
inhibition in colorectal cancer. Oncologist. 2006 Oct;11(9):1018-24.
Review. PubMed PMID: 17030644.
507: Vootukuru V, Liew YP, Nally JV Jr. Pemetrexed-induced acute renal
failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a
patient with non-small cell lung cancer. Med Oncol. 2006;23(3):419-22.
PubMed PMID: 17018900.
508: Perabo FG, Müller SC. New agents for treatment of advanced
transitional cell carcinoma. Ann Oncol. 2007 May;18(5):835-43. Epub 2006
Oct 3. Review. PubMed PMID: 17018703.
509: Aelony Y. Raltitrexed and pemetrexed studies in mesothelioma have
not shown improved quality of life nor prolonged survival compared with
effective pleurodesis with thoracoscopic talc poudrage. J Clin Oncol.
2006 Oct 1;24(28):4667; author reply 4667-8. PubMed PMID: 17008709.
510: Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S,
Incarbone M, Alloisio M, Santoro A. Early response evaluation in
malignant pleural mesothelioma by positron emission tomography with
[18F]fluorodeoxyglucose. J Clin Oncol. 2006 Oct 1;24(28):4587-93. PubMed
PMID: 17008700.
511: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed
PMID: 17003851.
512: Kurata T, Tamura K, Okamoto I, Satoh T, Nakagawa K, Fukuoka M.
Pemetrexed-induced edema of the eyelid. Lung Cancer. 2006
Nov;54(2):241-2. Epub 2006 Sep 22. PubMed PMID: 16996165.
513: Zucali PA, Giaccone G. Biology and management of malignant pleural
mesothelioma. Eur J Cancer. 2006 Nov;42(16):2706-14. Epub 2006 Sep 20.
Review. PubMed PMID: 16989994.
514: Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH,
Nguyen B, Paul S, McAndrews P, Bunn PA Jr, Kelly K. Elderly patients
benefit from second-line cytotoxic chemotherapy: a subset analysis of a
randomized phase III trial of pemetrexed compared with docetaxel in
patients with previously treated advanced non-small-cell lung cancer. J
Clin Oncol. 2006 Sep 20;24(27):4405-11. Erratum in: J Clin Oncol. 2006
Dec 1;24(34):5477. PubMed PMID: 16983108.
515: Nakagawa K, Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz JE,
Adachi S, Fukuoka M. A phase I study of pemetrexed (LY231514)
supplemented with folate and vitamin B12 in Japanese patients with solid
tumours. Br J Cancer. 2006 Sep 18;95(6):677-82. Epub 2006 Aug 29. PubMed
PMID: 16940981; PubMed Central PMCID: PMC2360511.
516: Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Inoue K, Mori K,
Fujii H, Mano H, Odgerel T, Furukawa Y. Schedule-dependent interactions
between pemetrexed and cisplatin in human carcinoma cell lines in vitro.
Oncol Res. 2006;16(2):85-95. PubMed PMID: 16898269.
517: Atagi S. [Combination therapy with S-1 plus docetaxel (DOC) for
previously treated patients with non-small cell lung cancer]. Gan To
Kagaku Ryoho. 2006 Jun;33 Suppl 1:197-201. Review. Japanese. PubMed
PMID: 16898002.
518: Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M,
Muramatsu H, Maeda H, Niimi T, Ueda R. The determinants of sensitivity
and acquired resistance to gemcitabine differ in non-small cell lung
cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther.
2006 Jul;5(7):1800-6. PubMed PMID: 16891466.
519: Gemma A, Seike M, Kosaihira S, Minegishi Y, Noro R, Nara M, Hosomi
Y, Okano T, Kokubo Y, Yoshimura A, Shibuya M, Kudoh S. Phase I/II study
of paclitaxel + carboplatin for refractory or recurrent non-small cell
lung cancer. Anticancer Res. 2006 Jul-Aug;26(4B):3083-7. PubMed PMID:
16886638.
520: von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough
J, Chen G, Kania M. A phase II trial of pemetrexed plus gemcitabine in
locally advanced and/or metastatic transitional cell carcinoma of the
urothelium. Ann Oncol. 2006 Oct;17(10):1533-8. Epub 2006 Jul 27. PubMed
PMID: 16873433.
521: Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij
F, De Cobelli O, Pece S, Del Tacca M, Danesi R. In vitro synergistic
cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic
evaluation of response to gemcitabine in bladder cancer patients. Br J
Cancer. 2006 Aug 7;95(3):289-97. Epub 2006 Jul 25. PubMed PMID:
16868547; PubMed Central PMCID: PMC2360654.
522: Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey
L, Nuchtern J, Dauser R, Blaney SM. Plasma and cerebrospinal fluid
pharmacokinetics of pemetrexed after intravenous administration in
non-human primates. Cancer Chemother Pharmacol. 2007 Mar;59(4):461-6.
Epub 2006 Jul 20. PubMed PMID: 16855840.
523: Brody JR, Gallmeier E, Yoshimura K, Hucl T, Kulesza P, Canto MI,
Hruban RH, Schulick RD, Kern SE. A proposed clinical test for monitoring
fluoropyrimidine therapy: detection and stability of thymidylate
synthase ternary complexes. Cancer Biol Ther. 2006 Aug;5(8):923-7. Epub
2006 Aug 2. PubMed PMID: 16855390.
524: Takimoto CH, Mita AC. Design, conduct, and interpretation of organ
impairment studies in oncology patients. J Clin Oncol. 2006 Jul
20;24(21):3509-10; author reply 3510-1. PubMed PMID: 16849773.
525: Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE,
Obasaju CK, Wang Y, Nicol SJ, Kaufman DS. Phase II study of pemetrexed
for second-line treatment of transitional cell cancer of the urothelium.
J Clin Oncol. 2006 Jul 20;24(21):3451-7. PubMed PMID: 16849761.
526: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43. PubMed PMID:
16845450.
527: Zhang Y, Trissel LA. Physical instability of frozen pemetrexed
solutions in PVC bags. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1289-92.
Epub 2006 Jul 5. PubMed PMID: 16822897.
528: Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R.
Chemotherapy and chemosensitization of non-small cell lung cancer with a
novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.
Mol Cancer Ther. 2006 Jun;5(6):1585-92. PubMed PMID: 16818518.
529: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2006 Apr;28(3):185-206. PubMed PMID:
16810345.
530: Brandes JC, Grossman SA, Ahmad H. Alteration of pemetrexed
excretion in the presence of acute renal failure and effusions:
presentation of a case and review of the literature. Cancer Invest. 2006
Apr-May;24(3):283-7. PubMed PMID: 16809156.
531: Rosti G, Carminati O, Monti M, Tamberi S, Marangolo M. Chemotherapy
advances in small cell lung cancer. Ann Oncol. 2006 May;17 Suppl
5:v99-102. Review. PubMed PMID: 16807475.
532: Monnerat C, Le Chevalier T. Review of the pemetrexed and
gemcitabine combination in patients with advanced-stage non-small cell
lung cancer. Ann Oncol. 2006 May;17 Suppl 5:v86-90. Review. PubMed PMID:
16807472.
533: De Marinis F, De Santis S, De Petris L. Second-line chemotherapy
for non-small cell lung cancer. Ann Oncol. 2006 May;17 Suppl 5:v68-71.
Review. PubMed PMID: 16807467.
534: Adjei AA. Clinical studies of pemetrexed and gemcitabine
combinations. Ann Oncol. 2006 May;17 Suppl 5:v29-32. Review. PubMed
PMID: 16807459.
535: Giovannetti E, Danesi R, Mey V, Nannizzi S, Pasqualetti G, Del
Tacca M. In vitro studies on gemcitabine combinations with other
antiblastics. Ann Oncol. 2006 May;17 Suppl 5:v17-19. Review. PubMed
PMID: 16807450.
536: Marangolo M, Vertogen B. Pemetrexed and malignant pleural
mesothelioma. Ann Oncol. 2006 May;17 Suppl 5:v103-5. Review. PubMed
PMID: 16807435.
537: Goedhals L, van Wiyk AL, Smith BL, Fourie SJ. Pemetrexed (Alimta,
LY231514) demonstrates clinical activity in chemonaive patients with
cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer.
2006 May-Jun;16(3):1172-8. PubMed PMID: 16803502.
538: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2006 May;28(4):233-77. PubMed PMID:
16801985.
539: Dittrich C. Use of pemetrexed in breast cancer. Semin Oncol. 2006
Jun;33(3 Suppl 9):S24-8. Review. PubMed PMID: 16797379.
540: Ramalingam S, Sandler AB. Salvage therapy for advanced non-small
cell lung cancer: factors influencing treatment selection. Oncologist.
2006 Jun;11(6):655-65. Review. PubMed PMID: 16794244.
541: Ho C, Davies AM, Lara PN Jr, Gandara DR. Second-line treatment for
advanced-stage non-small-cell lung cancer: current and future options.
Clin Lung Cancer. 2006 May;7 Suppl 4:S118-25. Review. PubMed PMID:
16764752.
542: Pagliaro LC, Sharma P. Review of metastatic bladder cancer. Minerva
Urol Nefrol. 2006 Mar;58(1):53-71. Review. PubMed PMID: 16760884.
543: Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris
JR, Court L, Baldini EH. Fatal pneumonitis associated with
intensity-modulated radiation therapy for mesothelioma. Int J Radiat
Oncol Biol Phys. 2006 Jul 1;65(3):640-5. PubMed PMID: 16751058.
544: Treat J, Bonomi P, McCleod M, Christiansen NP, Mintzer DM, Monberg
MJ, Ye Z, Chen R, Obasaju CK. Administration of pemetrexed immediately
following gemcitabine as front-line therapy in advanced non-small cell
lung cancer: a phase II trial. Lung Cancer. 2006 Jul;53(1):77-83. Epub
2006 May 30. PubMed PMID: 16730854.
545: Zhang Y, Trissel LA. Physical and chemical stability of pemetrexed
in infusion solutions. Ann Pharmacother. 2006 Jun;40(6):1082-5. Epub
2006 May 23. PubMed PMID: 16720706.
546: Hendricksen K, Moonen PM, van der Heijden AG, Molkenboer-Kuenen J,
Hulsbergen-van de Kaa CA, Witjes JA. Potential and toxicity of
intravesical pemetrexed: a preclinical study in pigs. Clin Cancer Res.
2006 Apr 15;12(8):2597-601. PubMed PMID: 16638871.
547: Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate
therapeutic alternative for cancer chemotherapy. Pharmacotherapy. 2006
May;26(5):641-54. Review. PubMed PMID: 16637794.
548: Goeminne H, van Meerbeeck JP. Pemetrexed in thoracic cancer. Expert
Opin Pharmacother. 2006 May;7(7):917-28. Review. PubMed PMID: 16634714.
549: Chow WA, Bedell V, Gaytan P, Borden E, Goldblum J, Hicks D, Slovak
ML. Methylthioadenosine phosphorylase gene deletions are frequently
detected by fluorescence in situ hybridization in conventional
chondrosarcomas. Cancer Genet Cytogenet. 2006 Apr 15;166(2):95-100.
PubMed PMID: 16631464.
550: Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the
management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006
Aug;32(6):676-81. Epub 2006 Apr 17. Review. PubMed PMID: 16616827.
551: Ceribelli A, Cecere FL, Milella M, Facciolo F, Gelibter A, Cognetti
F. Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.
Lancet Oncol. 2006 Apr;7(4):353. PubMed PMID: 16574552.
552: Solomon B, Bunn PA Jr. Clinical activity of pemetrexed: a
multitargeted antifolate anticancer agent. Future Oncol. 2005
Dec;1(6):733-46. Review. PubMed PMID: 16556051.
553: Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte
G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ,
Santoro A. Phase II study of pemetrexed plus carboplatin in malignant
pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8. PubMed
PMID: 16549838.
554: Chua YJ, Cunningham D. Chemotherapy for advanced pancreatic cancer.
Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):327-48. Review. PubMed
PMID: 16549331.
555: Uramoto H, Kagami S, Iwashige A, Tsukada J. [Chemotherapy for lung
cancer patients]. J UOEH. 2006 Mar 1;28(1):75-84. Review. Japanese.
PubMed PMID: 16541742.
556: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2006 Jan-Feb;28(1):31-63. PubMed PMID:
16541195.
557: Bogart JA, Govindan R. A randomized phase II study of radiation
therapy, pemetrexed, and carboplatin with or without cetuximab in stage
III non-small-cell lung cancer. Clin Lung Cancer. 2006 Jan;7(4):285-7.
PubMed PMID: 16512986.
558: Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J,
Kelly WK. Potential role of histone deacetylase inhibitors in
mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
Clin Lung Cancer. 2006 Jan;7(4):257-61. PubMed PMID: 16512979.
559: Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, Goldman ID. The
inverse relationship between reduced folate carrier function and
pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther.
2006 Feb;5(2):438-49. PubMed PMID: 16505119.
560: Opitz I, Kestenholz P, Lardinois D, Müller M, Rousson V, Schneiter
D, Stahel R, Weder W. Incidence and management of complications after
neoadjuvant chemotherapy followed by extrapleural pneumonectomy for
malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2006
Apr;29(4):579-84. Epub 2006 Feb 21. PubMed PMID: 16495068.
561: Martin M. Clinical experience with pemetrexed in breast cancer.
Semin Oncol. 2006 Feb;33(1 Suppl 2):S15-8. Review. PubMed PMID:
16472713.
562: Miller VA. Optimizing therapy in previously treated non-small cell
lung cancer. Semin Oncol. 2006 Feb;33(1 Suppl 1):S25-31. Review. PubMed
PMID: 16472706.
563: de Marinis F, De Santis S, De Petris L. Second-line treatment
options in non-small cell lung cancer: a comparison of cytotoxic agents
and targeted therapies. Semin Oncol. 2006 Feb;33(1 Suppl 1):S17-24.
Review. PubMed PMID: 16472705.
564: Cullen M. Second-line treatment options in advanced non-small cell
lung cancer: current status. Semin Oncol. 2006 Feb;33(1 Suppl 1):S3-8.
Review. PubMed PMID: 16472703.
565: Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X,
Bauer NL, Hockett RD, Chen VJ, Niyikiza C, Hanauske AR. A phase II trial
of pemetrexed in advanced breast cancer: clinical response and
association with molecular target expression. Clin Cancer Res. 2006 Feb
1;12(3 Pt 1):832-8. PubMed PMID: 16467096.
566: Raez LE, Lilenbaum R. New developments in chemotherapy for advanced
non-small cell lung cancer. Curr Opin Oncol. 2006 Mar;18(2):156-61.
Review. PubMed PMID: 16462185.
567: Scagliotti GV, Selvaggi G. Antimetabolites and cancer: emerging
data with a focus on antifolates. Expert Opin Ther Pat. 2006
Feb;16(2):189-200. PubMed PMID: 20144046.
568: Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH,
Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A,
Mita AC, Rowinsky EK. Two drug interaction studies evaluating the
pharmacokinetics and toxicity of pemetrexed when coadministered with
aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res.
2006 Jan 15;12(2):536-42. PubMed PMID: 16428497.
569: Muńoz A, Barceló R, López-Vivanco G. Malignant mesothelioma. N Engl
J Med. 2006 Jan 19;354(3):305-7; author reply 305-7. PubMed PMID:
16422026.
570: Pemetrexed: new drug. Pleural mesothelioma: a first encouraging
trial. Prescrire Int. 2005 Dec;14(80):212-4. PubMed PMID: 16400741.
571: Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A,
Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz
JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I
and pharmacokinetic study of pemetrexed administered every 3 weeks to
advanced cancer patients with normal and impaired renal function. J Clin
Oncol. 2006 Feb 1;24(4):552-62. Epub 2006 Jan 3. PubMed PMID: 16391300.
572: Rahman A, White RM. Cytotoxic anticancer agents and renal
impairment study: the challenge remains. J Clin Oncol. 2006 Feb
1;24(4):533-6. Epub 2006 Jan 3. Review. PubMed PMID: 16391294.
573: Walling J. From methotrexate to pemetrexed and beyond. A review of
the pharmacodynamic and clinical properties of antifolates. Invest New
Drugs. 2006 Jan;24(1):37-77. Review. PubMed PMID: 16380836.
574: van Hezik EJ. [Malignant pleural mesothelioma: further options].
Arch Bronconeumol. 2005 Dec;41(12):703. Spanish. PubMed PMID: 16373048.
575: Oberschmidt O, Eismann U, Schulz L, Struck S, Blatter J, Lahn MM,
Ma D, Hanauske AR. Enzastaurin and pemetrexed exert synergistic
antitumor activity in thyroid cancer cell lines in vitro. Int J Clin
Pharmacol Ther. 2005 Dec;43(12):603-4. PubMed PMID: 16372535.
576: Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Lüdtke FE, Struck S,
Schulz L, Blatter J, Lahn MM, Ma D, Niyikiza C, Paoletti P, Hanauske AR.
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR
correlates with the in vitro chemosensitivity of human solid tumors. Int
J Clin Pharmacol Ther. 2005 Dec;43(12):567-9. PubMed PMID: 16372519.
577: Hooijberg JH, de Vries NA, Kaspers GJ, Pieters R, Jansen G, Peters
GJ. Multidrug resistance proteins and folate supplementation:
therapeutic implications for antifolates and other classes of drugs in
cancer treatment. Cancer Chemother Pharmacol. 2006 Jul;58(1):1-12. Epub
2005 Dec 15. Review. PubMed PMID: 16362298.
578: Barlési F, Jacot W, Astoul P, Pujol JL. Second-line treatment for
advanced non-small cell lung cancer: a systematic review. Lung Cancer.
2006 Feb;51(2):159-72. Epub 2005 Dec 19. Review. PubMed PMID: 16360238.
579: Lopes G, Vincek V, Raez LE. Pemetrexed-associated urticarial
vasculitis. Lung Cancer. 2006 Feb;51(2):247-9. Epub 2005 Dec 19. PubMed
PMID: 16360237.
580: Hochster H, Kettner E, Kroning H, Becker K, Lordick F, Ramanathan
RK, Macdonald J, Hong S, John W, Schmoll HJ. Phase I/II dose-escalation
study of pemetrexed plus irinotecan in patients with advanced colorectal
cancer. Clin Colorectal Cancer. 2005 Nov;5(4):257-62. PubMed PMID:
16356302.
581: Assaraf YG, Ifergan I, Kadry WN, Pinter RY. Computer modelling of
antifolate inhibition of folate metabolism using hybrid functional petri
nets. J Theor Biol. 2006 Jun 21;240(4):637-47. Epub 2005 Dec 13. PubMed
PMID: 16352313.
582: Neragi-Miandoab S. Multimodality approach in management of
malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2006
Jan;29(1):14-9. Epub 2005 Dec 15. Review. PubMed PMID: 16343925.
583: Kumar A, Wakelee H. Second- and third-line treatments in non-small
cell lung cancer. Curr Treat Options Oncol. 2006 Jan;7(1):37-49. Review.
PubMed PMID: 16343367.
584: Jacoulet P. [Mesothelioma: advances in chemotherapy]. Rev Mal
Respir. 2005 Dec;22(6 Pt 2):8S49-54. Review. French. PubMed PMID:
16340836.
585: Pratt S, Chen V, Perry WI 3rd, Starling JJ, Dantzig AH. Kinetic
validation of the use of carboxydichlorofluorescein as a drug surrogate
for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
Epub 2005 Dec 5. PubMed PMID: 16337112.
586: Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical
application of a semimechanistic-physiologic population PK/PD model for
neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol.
2006 Apr;57(4):427-35. Epub 2005 Dec 2. PubMed PMID: 16322992.
587: Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population
pharmacokinetic analysis of ten phase II clinical trials of pemetrexed
in cancer patients. Cancer Chemother Pharmacol. 2006 Apr;57(4):401-11.
Epub 2005 Dec 2. PubMed PMID: 16322991.
588: Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. A
semimechanistic-physiologic population pharmacokinetic/pharmacodynamic
model for neutropenia following pemetrexed therapy. Cancer Chemother
Pharmacol. 2006 Apr;57(4):412-26. Epub 2005 Dec 2. PubMed PMID:
16322990.
589: Scagliotti G. An evaluation of pemetrexed in second-line treatment
of non-small cell lung cancer. Expert Opin Pharmacother. 2005
Dec;6(16):2855-66. Review. PubMed PMID: 16318436.
590: Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW,
Hillman DW, Perez EA, Ingle JN, Adjei AA. A phase II trial of a
combination of pemetrexed and gemcitabine in patients with metastatic
breast cancer: an NCCTG study. Ann Oncol. 2006 Feb;17(2):226-31. Epub
2005 Nov 22. PubMed PMID: 16303865.
591: Einhorn L. Perspective on the development of new agents in thoracic
cancers. Lung Cancer. 2005 Oct;50 Suppl 1:S27-8. PubMed PMID: 16291431.
592: Socinski MA. Seeking new options for the treatment of small-cell
lung cancer. Lung Cancer. 2005 Oct;50 Suppl 1:S25-6. PubMed PMID:
16291430.
593: Vogelzang NJ. Standard therapy for the treatment of malignant
pleural mesothelioma. Lung Cancer. 2005 Oct;50 Suppl 1:S23-4. PubMed
PMID: 16291429.
594: Scagliotti GV. Pemetrexed: a new cytotoxic agent in the development
for first-line non-small-cell lung cancer. Lung Cancer. 2005 Oct;50
Suppl 1:S18-9. PubMed PMID: 16291426.
595: Hanna N. Advances in the treatment of second-line non-small-cell
lung cancer. Lung Cancer. 2005 Oct;50 Suppl 1:S15-7. PubMed PMID:
16291425.
596: Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin
Ther. 2005 Sep;27(9):1343-82. Review. PubMed PMID: 16291410.
597: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2005 Oct;27(8):569-612. PubMed PMID:
16273137.
598: Mornex F. [Role of pemetrexed given with radiotherapy]. Rev Pneumol
Clin. 2005 Sep;61(4 Pt 2):4S18-9. French. PubMed PMID: 16273005.
599: Pérol M. [Second-line treatment of advanced non-small-cell lung
cancer: role of pemetrexed]. Rev Pneumol Clin. 2005 Sep;61(4 Pt
2):4S14-7. French. PubMed PMID: 16273004.
600: Margery J. [Medical treatment of malignant pleural mesothelioma.
Role of pemetrexed in current treatment]. Rev Pneumol Clin. 2005
Sep;61(4 Pt 2):4S10-3. French. PubMed PMID: 16273003.
601: Lokiec F. [Pemetrexed: new multitargeted antimetabolite]. Rev
Pneumol Clin. 2005 Sep;61(4 Pt 2):4S5-7. French. PubMed PMID: 16273001.
602: Kris MG. How today's developments in the treatment of non-small
cell lung cancer will change tomorrow's standards of care. Oncologist.
2005 Oct;10 Suppl 2:23-9. PubMed PMID: 16272456.
603: Schultz RM. Preclinical development of Alimta (Pemetrexed,
LY231514), a multitargeted antifolate. Prog Drug Res. 2005;63:275-300.
Review. PubMed PMID: 16265884.
604: Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR Jr,
Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z,
Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed
in combination with carboplatin in the first-line treatment of advanced
nonsmall cell lung cancer. Cancer. 2005 Dec 1;104(11):2449-56. PubMed
PMID: 16258975.
605: Zhang Y, Trissel LA. Physical and chemical stability of pemetrexed
solutions in plastic syringes. Ann Pharmacother. 2005 Dec;39(12):2026-8.
Epub 2005 Oct 14. PubMed PMID: 16227449.
606: Mahé MA, Cellerin L, Michaud JL, Sagan C, Supiot S, Le Péchoux C.
[Recent progress in treatment of malignant pleural mesothelioma]. Cancer
Radiother. 2005 Nov;9(6-7):362-5. Epub 2005 Oct 10. Review. French.
PubMed PMID: 16219479.
607: Atkins JN, Jacobs SA, Wieand HS, Smith RE, John WJ, Colangelo LH,
Vogel VG, Kuebler JP, Cescon TP, Miller BJ, Geyer CE Jr, Wolmark N.
Pemetrexed/oxaliplatin for first-line treatment of patients with
advanced colorectal cancer: a phase II trial of the National Surgical
Adjuvant Breast and Bowel Project Foundation Research Program. Clin
Colorectal Cancer. 2005 Sep;5(3):181-7. PubMed PMID: 16197621.
608: Spásová I. [Treatment of the unresectable non small cell lung
carcinoma]. Cas Lek Cesk. 2005;144(9):602-12; discussion 612-3. Review.
Czech. PubMed PMID: 16193938.
609: Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin
Radiat Oncol. 2005 Oct;15(4):245-53. Review. PubMed PMID: 16183478.
610: Edelman MJ. Second-line chemotherapy and beyond for non-small-cell
lung cancer. Clin Adv Hematol Oncol. 2004 Jun;2(6):373-8. Review. PubMed
PMID: 16163207.
611: Pearce HL, Alice Miller M. The evolution of cancer research and
drug discovery at Lilly Research Laboratories. Adv Enzyme Regul.
2005;45:229-55. Epub 2005 Sep 6. PubMed PMID: 16143373.
612: Richards DA. Chemotherapeutic gemcitabine doublets in pancreatic
carcinoma. Semin Oncol. 2005 Aug;32(4 Suppl 6):S9-13. Review. PubMed
PMID: 16143162.
613: Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM,
Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C,
Adjei AA; North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly &
Company. Randomized phase II trial of three schedules of pemetrexed and
gemcitabine as front-line therapy for advanced non-small-cell lung
cancer. J Clin Oncol. 2005 Sep 1;23(25):5929-37. PubMed PMID: 16135464.
614: Cappuzzo F, Finocchiaro G, Trisolini R, Toschi L, Bartolini S,
Metro G, Crinň L. Perspectives on salvage therapy for non-small-cell
lung cancer. Oncology (Williston Park). 2005 Jul;19(8):989-95;
discussion 995-6, 999, 1003-4, passim. Review. PubMed PMID: 16131043.
615: Hureaux J, Le Guen Y, Tuchais C, Savary L, Urban T. Radiation
recall dermatitis with pemetrexed. Lung Cancer. 2005 Nov;50(2):255-8.
Epub 2005 Aug 18. PubMed PMID: 16111784.
616: Zhao R, Hanscom M, Goldman ID. The relationship between folate
transport activity at low pH and reduced folate carrier function in
human Huh7 hepatoma cells. Biochim Biophys Acta. 2005 Aug
30;1715(1):57-64. PubMed PMID: 16109384.
617: Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA,
Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK.
Open-label study of pemetrexed alone or in combination with cisplatin
for the treatment of patients with peritoneal mesothelioma: outcomes of
an expanded access program. Clin Lung Cancer. 2005 Jul;7(1):40-6. PubMed
PMID: 16098243.
618: Kerr C. Pemetrexed combination improves mesothelioma survival.
Lancet Oncol. 2005 Aug;6(8):548. PubMed PMID: 16094758.
619: Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M,
Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase
III trial of pemetrexed plus gemcitabine versus gemcitabine in patients
with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005
Oct;16(10):1639-45. Epub 2005 Aug 8. Erratum in: Ann Oncol. 2006
Mar;17(3):535. PubMed PMID: 16087696.
620: Perry WL 3rd, Shepard RL, Sampath J, Yaden B, Chin WW, Iversen PW,
Jin S, Lesoon A, O'Brien KA, Peek VL, Rolfe M, Shyjan A, Tighe M,
Williamson M, Krishnan V, Moore RE, Dantzig AH. Human splicing factor
SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs
when overexpressed--a phenotype partially reversed by selective estrogen
receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. PubMed
PMID: 16061639.
621: Reck M. Current approaches in chemotherapy of advanced and
metastatic non-small cell lung cancer (NSCLC). Anticancer Res. 2005
May-Jun;25(3A):1501-6. Review. PubMed PMID: 16033051.
622: Lopes G, Rocha Lima CM. Docetaxel in the management of advanced
pancreatic cancer. Semin Oncol. 2005 Apr;32(2 Suppl 4):S10-23. Review.
PubMed PMID: 16015551.
623: Socinski MA. Combined modality trials in unresectable stage III
non-small cell lung cancer: the Cancer and Leukemia Group B experience.
Semin Oncol. 2005 Apr;32(2 Suppl 3):S114-8. Review. PubMed PMID:
16015547.
624: Coudray AM, Louvet C, Kornprobst M, Raymond E, André T, Tournigand
C, Faivre S, De Gramont A, Larsen AK, Gespach C. Increased anticancer
activity of the thymidylate synthase inhibitor BGC9331 combined with the
topoisomerase I inhibitor SN-38 in human colorectal and breast cancer
cells: induction of apoptosis and ROCK cleavage through
caspase-3-dependent and -independent mechanisms. Int J Oncol. 2005
Aug;27(2):553-61. PubMed PMID: 16010439.
625: O'Shaughnessy JA, Clark RS, Blum JL, Mennel RG, Snyder D, Ye Z,
Liepa AM, Melemed AS, Yardley DA. Phase II study of pemetrexed in
patients pretreated with an anthracycline, a taxane, and capecitabine
for advanced breast cancer. Clin Breast Cancer. 2005 Jun;6(2):143-9.
PubMed PMID: 16001992.
626: Nowak AK, Byrne MJ. Cisplatin and gemcitabine in malignant
mesothelioma. Ann Oncol. 2005 Oct;16(10):1711. Epub 2005 Jul 6. PubMed
PMID: 16000339.
627: Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ.
Measuring quality of life in patients with pleural mesothelioma using a
modified version of the Lung Cancer Symptom Scale (LCSS): psychometric
properties of the LCSS-Meso. Support Care Cancer. 2006 Jan;14(1):11-21.
Epub 2005 Jul 6. PubMed PMID: 15999264.
628: Vogelzang NJ, Porta C, Mutti L. New agents in the management of
advanced mesothelioma. Semin Oncol. 2005 Jun;32(3):336-50. Review.
PubMed PMID: 15988688.
629: Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate
pemetrexed to the brain. J Pharmacol Exp Ther. 2005 Oct;315(1):222-9.
Epub 2005 Jun 29. PubMed PMID: 15987831.
630: Yokoba M, Yanase N, Masuda N. [New anti-cancer agents--from
cytotoxic systemic chemotherapy to target-based agents]. Gan To Kagaku
Ryoho. 2005 Jun;32(6):783-8. Review. Japanese. PubMed PMID: 15984516.
631: Ueoka H. [Chemotherapy for advanced non-small cell lung cancer].
Gan To Kagaku Ryoho. 2005 Jun;32(6):770-6. Review. Japanese. PubMed
PMID: 15984514.
632: Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug
approval summary: pemetrexed for injection (Alimta) for the treatment of
non-small cell lung cancer. Oncologist. 2005 Jun-Jul;10(6):363-8. PubMed
PMID: 15967829.
633: Gibbs D, Jackman A. Pemetrexed disodium. Nat Rev Drug Discov. 2005
May;Suppl:S16-7. Review. PubMed PMID: 15962527.
634: Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, Jung KH, Im SA,
Kim TY, Kim NK, Bang YJ. Cytotoxic effects of pemetrexed in gastric
cancer cells. Cancer Sci. 2005 Jun;96(6):365-71. PubMed PMID: 15958060.
635: Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and
management of malignant pleural mesothelioma. Respirology. 2005
Jun;10(3):266-83. Review. PubMed PMID: 15955137.
636: Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and
radiotherapy in the treatment of malignant pleural mesothelioma: the
Memorial Sloan-Kettering experience. Lung Cancer. 2005 Jul;49 Suppl
1:S71-4. Epub 2005 Apr 7. PubMed PMID: 15950805.
637: Favaretto A. Overview on ongoing or planned clinical trials in
Europe. Lung Cancer. 2005 Jul;49 Suppl 1:S117-21. Epub 2005 Apr 9.
Review. PubMed PMID: 15950791.
638: Besse B, Soria JC, Le Chevalier T. Front-line doublets in advanced
non-small cell lung cancer: The golden age for second line chemotherapy.
Ann Oncol. 2005 Jul;16(7):997-8. Epub 2005 Jun 9. PubMed PMID: 15946975.
639: Goudar RK. New therapeutic options for mesothelioma. Curr Oncol
Rep. 2005 Jul;7(4):260-5. Review. PubMed PMID: 15946584.
640: Bennett R, Maskell N. Management of malignant pleural effusions.
Curr Opin Pulm Med. 2005 Jul;11(4):296-300. Review. PubMed PMID:
15928495.
641: Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D,
White S, Childs A, Beale P, Latz J, Suri A, Iglesias JL. A phase I/II
study of pemetrexed and vinorelbine in patients with non-small cell lung
cancer. Lung Cancer. 2005 Sep;49(3):401-12. PubMed PMID: 15923057.
642: Ris HB. Photodynamic therapy as an adjunct to surgery for malignant
pleural mesothelioma. Lung Cancer. 2005 Jul;49 Suppl 1:S65-8. Review.
PubMed PMID: 15916831.
643: [Multi-target tumor therapy]. Krankenpfl J. 2005;43(1-3):38-9.
German. PubMed PMID: 15912831.
644: Serke M, Loddenkemper R. [Therapeutic options in malignant pleural
mesothelioma]. Pneumologie. 2005 May;59(5):337-48. Review. German.
PubMed PMID: 15902599.
645: Reck M, Gatzemeier U. Pemetrexed-cisplatin combination in
mesothelioma. Expert Rev Anticancer Ther. 2005 Apr;5(2):231-7. Review.
PubMed PMID: 15877521.
646: Bergqvist M, Henriksson R, Brattström D. Novel agents in the
treatment of non-small cell lung cancer: implications for neoadjuvant
chemotherapy? In Vivo. 2005 May-Jun;19(3):523-33. Review. PubMed PMID:
15875771.
647: Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R,
Gröne HJ, Debus J, Lipson KE, Abdollahi A. Trimodal cancer treatment:
beneficial effects of combined antiangiogenesis, radiation, and
chemotherapy. Cancer Res. 2005 May 1;65(9):3643-55. PubMed PMID:
15867359.
648: Friberg G, Kindler HL. Chemotherapy for advanced pancreatic cancer:
past, present, and future. Curr Oncol Rep. 2005 May;7(3):186-95. Review.
PubMed PMID: 15847709.
649: Bass P, Burgers JA. [Development in the treatment of malignant
mesothelioma]. Ned Tijdschr Geneeskd. 2005 Apr 2;149(14):747-53. Review.
Dutch. PubMed PMID: 15835625.
650: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2005 Mar;27(2):145-59. PubMed PMID:
15834466.
651: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):193-219. PubMed PMID:
15834452.
652: Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J,
Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study)
chemotherapy received by patients treated in the phase III trial of
pemetrexed plus cisplatin versus cisplatin alone in malignant pleural
mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. PubMed
PMID: 15824080.
653: Dubey S, Schiller JH. Three emerging new drugs for NSCLC:
pemetrexed, bortezomib, and cetuximab. Oncologist. 2005
Apr;10(4):282-91. Review. PubMed PMID: 15821248.
654: Scagliotti GV. Pemetrexed plus carboplatin or oxaliplatin in
advanced non-small cell lung cancer. Semin Oncol. 2005 Apr;32(2 Suppl
2):S5-8. Review. PubMed PMID: 15818537.
655: Socinski MA, Stinchcombe TE, Hayes DN. The evolving role of
pemetrexed (Alimta) in lung cancer. Semin Oncol. 2005 Apr;32(2 Suppl
2):S16-22. Review. PubMed PMID: 15818533.
656: Socinski MA. Pemetrexed (Alimta) in small cell lung cancer. Semin
Oncol. 2005 Apr;32(2 Suppl 2):S1-4. Review. PubMed PMID: 15818532.
657: Blackhall FH, Shepherd FA, Albain KS. Improving survival and
reducing toxicity with chemotherapy in advanced non-small cell lung
cancer : a realistic goal? Treat Respir Med. 2005;4(2):71-84. Review.
PubMed PMID: 15813659.
658: Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del
Tacca M, Danesi R. Cellular and pharmacogenetics foundation of
synergistic interaction of pemetrexed and gemcitabine in human
non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8.
Epub 2005 Mar 28. PubMed PMID: 15795320.
659: Puto K, Garey JS. Pemetrexed therapy for malignant pleural
mesothelioma. Ann Pharmacother. 2005 Apr;39(4):678-83. Epub 2005 Mar 8.
Review. PubMed PMID: 15755794.
660: Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg
RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA. A
phase IB study of the pharmacokinetics of gemcitabine and pemetrexed,
when administered in rapid sequence to patients with advanced solid
tumors. Cancer Chemother Pharmacol. 2005 Jun;55(6):522-30. Epub 2005 Mar
8. PubMed PMID: 15754203.
661: O'Neil BH, Goldberg RM. Chemotherapy for advanced colorectal
cancer: let's not forget how we got here (until we really can). Semin
Oncol. 2005 Feb;32(1):35-42. Review. PubMed PMID: 15726504.
662: Nagel S, Hobrack E, Jehle P, Schütte W. [Second-line treatment of
malignant pleural mesothelioma with Pemetrexed (Alimta) -- a case
report]. Pneumologie. 2005 Feb;59(2):108-11. German. PubMed PMID:
15724224.
663: Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID. Loss of
reduced folate carrier function and folate depletion result in enhanced
pemetrexed inhibition of purine synthesis. Clin Cancer Res. 2005 Feb
1;11(3):1294-301. PubMed PMID: 15709201.
664: Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY,
Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P,
Johnson JR, Pazdur R. Pemetrexed in malignant pleural mesothelioma. Clin
Cancer Res. 2005 Feb 1;11(3):982-92. PubMed PMID: 15709163.
665: Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R,
O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J,
Kayitalire L, Crino L, Paz-Ares L. Pemetrexed combined with oxaliplatin
or carboplatin as first-line treatment in advanced non-small cell lung
cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005
Jan 15;11(2 Pt 1):690-6. PubMed PMID: 15701857.
666: Ardizzoni A, Tiseo M. Second-line chemotherapy in the treatment of
advanced non-small cell lung cancer (NSCLC). J Chemother. 2004 Nov;16
Suppl 4:104-7. Review. PubMed PMID: 15688623.
667: Morčre JF. [New approaches for mesothelioma.]. Rev Pneumol Clin.
2004 Nov;60(5 Pt 3):4S57-4S60. Review. French. PubMed PMID: 15687997.
668: Steele JP, Klabatsa A. Chemotherapy options and new advances in
malignant pleural mesothelioma. Ann Oncol. 2005 Mar;16(3):345-51. Epub
2005 Jan 27. Review. PubMed PMID: 15677623.
669: Akita H. [Second-line treatment for advanced non-small-cell lung
cancers]. Gan To Kagaku Ryoho. 2005 Jan;32(1):15-8. Review. Japanese.
PubMed PMID: 15675575.
670: Gemcitabine, pemetrexed, and novel agents in the treatment of
thoracic cancer. Selected presentations from the 10th World Congress on
Lung Cancer. Vancouver, Canada. Oncology (Williston Park). 2004 Jul;18(8
Suppl 5):5-71. PubMed PMID: 15675032.
671: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):801-27. PubMed PMID:
15672123.
672: Rodenbach M, Eyol E, Seelig MH, Berger MR. Combination treatment of
CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed
disodium and gemcitabine. J Cancer Res Clin Oncol. 2005
May;131(5):289-99. Epub 2005 Jan 19. PubMed PMID: 15657768.
673: Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D,
Massuti B, Alberola V, Sanchez JJ. The promise of pharmacogenomics:
gemcitabine and pemetrexed. Oncology (Williston Park). 2004 Nov;18(13
Suppl 8):70-6. Review. PubMed PMID: 15655942.
674: Hanauske AR. Translational research with pemetrexed in breast
cancer. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):66-9. Review.
PubMed PMID: 15655941.
675: Smith I. Phase II studies of pemetrexed in metastatic breast and
gynecologic cancers. Oncology (Williston Park). 2004 Nov;18(13 Suppl
8):63-5. Review. PubMed PMID: 15655940.
676: Louvet C, de Gramont A. Pemetrexed in advanced colorectal cancer.
Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):56-62. Review. PubMed
PMID: 15655939.
677: Sobrero A, Caprioni F, Fornarini G, Mammoliti S, Comandini D, Baldo
S, Decian F. Pemetrexed in gastric cancer. Oncology (Williston Park).
2004 Nov;18(13 Suppl 8):51-5. Review. PubMed PMID: 15655938.
678: von der Maase H. Pemetrexed in transitional cell carcinoma of the
urothelium. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):48-50.
Review. PubMed PMID: 15655937.
679: Seitz JF, Dahan L, Ries P. Pemetrexed in pancreatic cancer.
Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):43-7. Review. PubMed
PMID: 15655936.
680: De Marinis F, De Petris L. Pemetrexed in second-line treatment of
non-small-cell lung cancer. Oncology (Williston Park). 2004 Nov;18(13
Suppl 8):38-42. Review. PubMed PMID: 15655935.
681: Scagliotti GV, Novello S, Crino L, Rosell R. Pemetrexed in
front-line chemotherapy for advanced non-small-cell lung cancer.
Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):32-7. Review. PubMed
PMID: 15655934.
682: Gatzemeier U. Pemetrexed in malignant pleural mesothelioma.
Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):26-31. Review. PubMed
PMID: 15655933.
683: Hanauske AR, Dittrich C, Otero J. Overview of phase I/II pemetrexed
studies. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):18-25.
Review. PubMed PMID: 15655932.
684: Calvert AH. Biochemical pharmacology of pemetrexed. Oncology
(Williston Park). 2004 Nov;18(13 Suppl 8):13-7. Review. PubMed PMID:
15655931.
685: Zhao R, Chattopadhyay S, Hanscom M, Goldman ID. Antifolate
resistance in a HeLa cell line associated with impaired transport
independent of the reduced folate carrier. Clin Cancer Res. 2004 Dec
15;10(24):8735-42. PubMed PMID: 15623659.
686: Budde LS, Hanna NH. Antimetabolites in the management of non-small
cell lung cancer. Curr Treat Options Oncol. 2005 Jan;6(1):83-93. Review.
PubMed PMID: 15610718.
687: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2004 Oct;26(8):639-63. PubMed PMID:
15605126.
688: Govindan R, Garfield DH. Treatment approaches in patients with
advanced non-small cell lung cancer and poor performance status. Semin
Oncol. 2004 Dec;31(6 Suppl 11):27-31. Review. PubMed PMID: 15599832.
689: Chattopadhyay S, Wang Y, Zhao R, Goldman ID. Lack of impact of the
loss of constitutive folate receptor alpha expression, achieved by RNA
Interference, on the activity of the new generation antifolate
pemetrexed in HeLa cells. Clin Cancer Res. 2004 Dec 1;10(23):7986-93.
PubMed PMID: 15585634.
690: Nowak AK, Byrne MJ, Millward MJ, Alvarez JM, Robinson BW. Current
chemotherapeutic treatment of malignant pleural mesothelioma. Expert
Opin Pharmacother. 2004 Dec;5(12):2441-9. Review. PubMed PMID: 15571462.
691: Jänne PA, Baldini EH. Patterns of failure following surgical
resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004
Nov;14(4):567-73. Review. PubMed PMID: 15559064.
692: Vogelzang NJ. Multimodality therapy in mesothelioma: role of
chemotherapy. Thorac Surg Clin. 2004 Nov;14(4):531-42. Review. PubMed
PMID: 15559060.
693: Reck M, Gatzemeier U. Chemotherapy in stage-IV NSCLC. Lung Cancer.
2004 Aug;45 Suppl 2:S217-22. Review. PubMed PMID: 15552802.
694: Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical
compatibility of pemetrexed disodium with other drugs during simulated
Y-site administration. Am J Health Syst Pharm. 2004 Nov
1;61(21):2289-93. PubMed PMID: 15552637.
695: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):587-612. Review. PubMed
PMID: 15538546.
696: Souquet PJ. [Second-line chemotherapy in non-small cell lung
cancer]. Rev Pneumol Clin. 2004 Nov;60(5 Pt 2):3S57-9. Review. French.
PubMed PMID: 15536355.
697: Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU,
Weber KJ, Huber PE. Triple combination of irradiation, chemotherapy (pemetrexed),
and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int
J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1220-32. PubMed PMID:
15519795.
698: Damaraju VL, Hamilton KF, Seth-Smith ML, Cass CE, Sawyer MB.
Characterization of binding of folates and antifolates to brush-border
membrane vesicles isolated from human kidney. Mol Pharmacol. 2005
Feb;67(2):453-9. Epub 2004 Oct 27. PubMed PMID: 15509714.
699: Moreno Alvarez PJ. [Pemetrexed (Alimta). Laboratory: Lilly]. Farm
Hosp. 2004 Sep-Oct;28(5):387-8. Spanish. PubMed PMID: 15504098.
700: Muhsin M, Gricks C, Kirkpatrick P. Pemetrexed disodium. Nat Rev
Drug Discov. 2004 Oct;3(10):825-6. PubMed PMID: 15497247.
701: Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update,
current management, and newer therapeutic strategies. Chest. 2004
Oct;126(4):1318-29. Review. PubMed PMID: 15486399.
702: Aelony Y. Need for further information on pemetrexed study. J Clin
Oncol. 2004 Oct 15;22(20):4234-5; author reply 4235-6. PubMed PMID:
15483040.
703: Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval
summaries: pemetrexed (Alimta). Oncologist. 2004;9(5):482-8. Review.
PubMed PMID: 15477632.
704: Rosell R, Felip E, Garcia-Campelo R, Balańa C. The biology of
non-small-cell lung cancer: identifying new targets for rational
therapy. Lung Cancer. 2004 Nov;46(2):135-48. Review. PubMed PMID:
15474661.
705: Wang Y, Zhao R, Goldman ID. Characterization of a folate
transporter in HeLa cells with a low pH optimum and high affinity for
pemetrexed distinct from the reduced folate carrier. Clin Cancer Res.
2004 Sep 15;10(18 Pt 1):6256-64. PubMed PMID: 15448015.
706: Hochster HS. The role of pemetrexed in the treatment of
gastrointestinal malignancy. Clin Colorectal Cancer. 2004
Sep;4(3):190-5. Review. PubMed PMID: 15377402.
707: Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N,
Banerjee D, Maley F, Bertino JR. Protection of hematopoietic stem cells
from pemetrexed toxicity by retroviral gene transfer with a mutant
dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer
Gene Ther. 2004 Dec;11(12):767-73. PubMed PMID: 15359285.
708: Kano Y, Akutsu M, Tsunoda S, Izumi T, Mori K, Fujii H, Yazawa Y,
Mano H, Furukawa Y. Schedule-dependent synergism and antagonism between
pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer
Chemother Pharmacol. 2004 Dec;54(6):505-13. Epub 2004 Aug 31. PubMed
PMID: 15340759.
709: Rosell R, Sanchez JM, Taron M, Moran T, Ciuraqui B, Canela M, Felip
E, Massuti B, Camps C. Pemetrexed in previously treated non-small-cell
lung cancer. Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):63-71.
Review. PubMed PMID: 15339062.
710: Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a
review of the clinical data. Oncology (Williston Park). 2004 Jul;18(8
Suppl 5):54-62. Review. PubMed PMID: 15339061.
711: Kindler HL. The emerging role of pemetrexed for the treatment of
malignant mesothelioma. Oncology (Williston Park). 2004 Jul;18(8 Suppl
5):49-53. Review. PubMed PMID: 15339060.
712: Manegold C. Pemetrexed: its promise in treating non-small-cell lung
cancer. Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):43-8. Review.
PubMed PMID: 15339059.
713: Bunn P Jr. New investigative regimens and cytotoxic agents in
thoracic cancers: gemcitabine and pemetrexed. Oncology (Williston Park).
2004 Jul;18(8 Suppl 5):5-11. Review. PubMed PMID: 15339053.
714: Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello
S, Nakamura T, Liepa AM, Bozec L, Bunn PA Jr, Ettinger DS. Phase II
study of pemetrexed-gemcitabine combination in patients with
advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004 Aug
15;10(16):5439-46. PubMed PMID: 15328182.
715: Heinzl S. [Folic acid antagonists pemetrexed]. Med Monatsschr
Pharm. 2004 Jul;27(7):220-2. Review. German. PubMed PMID: 15296355.
716: Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ.
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the
LCSS-Meso conceptual model for validation. Cancer. 2004 Aug
1;101(3):587-95. PubMed PMID: 15274072.
717: Kut V, Patel JD, Argiris A. Pemetrexed: a novel antifolate agent
enters clinical practice. Expert Rev Anticancer Ther. 2004
Aug;4(4):511-22. Review. PubMed PMID: 15270656.
718: Hanauske AR. The role of Alimta in the treatment of malignant
pleural mesothelioma: an overview of preclinical and clinical trials.
Lung Cancer. 2004 Aug;45 Suppl 1:S121-4. Review. PubMed PMID: 15261444.
719: Tomek S, Manegold C. Chemotherapy for malignant pleural
mesothelioma: past results and recent developments. Lung Cancer. 2004
Aug;45 Suppl 1:S103-19. Review. PubMed PMID: 15261443.
720: First drug for rare cancer. FDA Consum. 2004 May-Jun;38(3):4.
PubMed PMID: 15218827.
721: Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic
agent. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4276s-4280s. Review.
PubMed PMID: 15217974.
722: Current data and ongoing trials in patients with recurrent
non-small-cell lung cancer. Clin Lung Cancer. 2004 May;5(6):337-9.
Review. PubMed PMID: 15217532.
723: Orbaugh KK. Nursing considerations for administering pemetrexed (Alimta)
in combination with cisplatin for malignant pleural mesothelioma. Clin J
Oncol Nurs. 2004 Jun;8(3):242-7. Review. PubMed PMID: 15208818.
724: Misset JL, Gamelin E, Campone M, Delaloge S, Latz JE, Bozec L,
Fumoleau P. Phase I and pharmacokinetic study of the multitargeted
antifolate pemetrexed in combination with oxaliplatin in patients with
advanced solid tumors. Ann Oncol. 2004 Jul;15(7):1123-9. PubMed PMID:
15205208.
725: Diaz-Rubio E. New chemotherapeutic advances in pancreatic,
colorectal, and gastric cancers. Oncologist. 2004;9(3):282-94. Review.
PubMed PMID: 15169983.
726: Zhao R, Goldman ID. Enter Alimta: a new generation antifolate.
Oncologist. 2004;9(3):242-4. PubMed PMID: 15169978.
727: Budde LS, Hanna NH. Pemetrexed (Alimta): improving outcomes in
malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2004
Jun;4(3):361-8. Review. PubMed PMID: 15161435.
728: Catalano A, Gianni W, Procopio A. Experimental therapy of malignant
mesothelioma: new perspectives from anti-angiogenic treatments. Crit Rev
Oncol Hematol. 2004 May;50(2):101-9. Review. PubMed PMID: 15157659.
729: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PubMed PMID:
15148527.
730: Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic
cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed
combination in pancreatic cancer cell lines. Clin Cancer Res. 2004 May
1;10(9):2936-43. PubMed PMID: 15131028.
731: Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective
preservation of pemetrexed pharmacological activity in HeLa cells
lacking the reduced folate carrier: association with the presence of a
secondary transport pathway. Cancer Res. 2004 May 1;64(9):3313-9. PubMed
PMID: 15126375.
732: Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von
Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C,
Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn
L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel
in patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 2004 May 1;22(9):1589-97. PubMed PMID:
15117980.
733: Hanna NH. Second-line chemotherapy for non-small-cell lung cancer:
recent data with pemetrexed. Clin Lung Cancer. 2004 Apr;5 Suppl 2:S75-9.
Review. PubMed PMID: 15117429.
734: Zinner RG, Herbst RS. Pemetrexed in the treatment of advanced
non-small-cell lung cancer: a review of the clinical data. Clin Lung
Cancer. 2004 Apr;5 Suppl 2:S67-74. Review. PubMed PMID: 15117428.
735: Gadgeel SM, Pass HI. Novel combinations using pemetrexed in
malignant mesothelioma. Clin Lung Cancer. 2004 Apr;5 Suppl 2:S61-6.
Review. PubMed PMID: 15117427.
736: Suwanrusme H, Meyer ML, Green MR. Pemetrexed alone and in
combination with platinum compounds in the management of malignant
mesothelioma. Clin Lung Cancer. 2004 Apr;5 Suppl 2:S56-60. Review.
PubMed PMID: 15117426.
737: Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin
Lung Cancer. 2004 Apr;5 Suppl 2:S51-5. Review. PubMed PMID: 15117425.
738: Pemetrexed (Alimta) for mesothelioma. Med Lett Drugs Ther. 2004 Apr
12;46(1180):31-2. PubMed PMID: 15079145.
739: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PubMed PMID:
15071612.
740: Caponigro F, Ionna F, Comella G. New cytotoxic and
molecular-targeted therapies of head and neck tumors. Curr Opin Oncol.
2004 May;16(3):225-30. Review. PubMed PMID: 15069317.
741: Evans TL. Highlights from the Tenth World Conference on Lung
Cancer. Oncologist. 2004;9(2):232-8. PubMed PMID: 15047929.
742: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Review.
PubMed PMID: 14988742.
743: Fossella FV. Pemetrexed for treatment of advanced non-small cell
lung cancer. Semin Oncol. 2004 Feb;31(1 Suppl 1):100-5. Review. PubMed
PMID: 14981587.
744: Theti DS, Jackman AL. The role of alpha-folate receptor-mediated
transport in the antitumor activity of antifolate drugs. Clin Cancer
Res. 2004 Feb 1;10(3):1080-9. PubMed PMID: 14871988.
745: Green MR. The evolving role of gemcitabine and pemetrexed (Alimta)
in the management of patients with malignant mesothelioma. Clin Lung
Cancer. 2002 Mar;3 Suppl 1:S26-9. PubMed PMID: 14720352.
746: Ettinger DS. Pemetrexed (Alimta): a new antifolate for
non-small-cell lung cancer. Clin Lung Cancer. 2002 Mar;3 Suppl 1:S22-5.
PubMed PMID: 14720351.
747: Adjei AA. Current data with pemetrexed (Alimta) in non-small-cell
lung cancer. Clin Lung Cancer. 2003 Jan;4 Suppl 2:S64-7. PubMed PMID:
14720339.
748: Silvestris N, D'Aprile M, Andreola G, Locopo N, Marini L, Crucitta
E, De Lena M, Lorusso V. Rationale for the use of gemcitabine in breast
cancer (Review). Int J Oncol. 2004 Feb;24(2):389-98. Review. PubMed
PMID: 14719116.
749: van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van
Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation
in patients with malignant pleural mesothelioma. Lung Cancer. 2004
Jan;43(1):63-9. PubMed PMID: 14698538.
750: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2003 Nov;25(9):747-71. PubMed PMID:
14685303.
751: Taylor EC, Liu B. A new and efficient synthesis of pyrrolo[2,3-d]pyrimidine
anticancer agents: Alimta (LY231514, MTA), homo-Alimta, TNP-351, and
some aryl 5-substituted pyrrolo[2,3-d]pyrimidines. J Org Chem. 2003 Dec
26;68(26):9938-47. PubMed PMID: 14682686.
752: Maung K. Pemetrexed (Alimta): a novel antifolate in the treatment
of malignant pleural mesothelioma. Clin Lung Cancer. 2002
May;3(4):240-2. PubMed PMID: 14662030.
753: Kulke MH. Advanced pancreatic cancer: is there a role for
combination therapy? Expert Rev Anticancer Ther. 2003 Oct;3(5):729-39.
Review. PubMed PMID: 14599095.
754: Molina JR, Adjei AA. The role of Pemetrexed (Alimta , LY231514) in
lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. Review.
PubMed PMID: 14596699.
755: Castro M. Thymidine rescue: an antidote for pemetrexed-related
toxicity in the setting of acute renal failure. J Clin Oncol. 2003 Nov
1;21(21):4066. PubMed PMID: 14581433.
756: Thödtmann R, Sauter T, Weinknecht S, Weissbach L, Blatter J,
Ohnmacht U, Hanauske A. A phase II trial of pemetrexed in patients with
metastatic renal cancer. Invest New Drugs. 2003 Aug;21(3):353-8. PubMed
PMID: 14578684.
757: Haller DG. New perspectives in the management of pancreas cancer.
Semin Oncol. 2003 Aug;30(4 Suppl 11):3-10. Review. PubMed PMID:
14506598.
758: Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchianň A, Martinetti
A, Longarini R, Becerra C, Ilardi C, John W. Phase II study of
pemetrexed disodium (Alimta) administered with oral folic acid in
patients with advanced gastric cancer. Ann Oncol. 2003
Oct;14(10):1543-8. PubMed PMID: 14504056.
759: Patients with asbestos-related cancer report better quality of life
with pemetrexed plus cisplatin. Oncology (Williston Park). 2003
Aug;17(8):1094. PubMed PMID: 12966677.
760: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506. PubMed
PMID: 12949633.
761: Le Chevalier T. The emerging role of pemetrexed (Alimta) and
gemcitabine in non-small cell lung cancer. Semin Oncol. 2003 Aug;30(4
Suppl 10):37-44. Review. PubMed PMID: 12947960.
762: Shepherd FA. Second-line chemotherapy for non-small cell lung
cancer. Expert Rev Anticancer Ther. 2003 Aug;3(4):435-42. Review. PubMed
PMID: 12934656.
763: Manegold C. Pemetrexed (Alimta, MTA, multitargeted antifolate,
LY231514) for malignant pleural mesothelioma. Semin Oncol. 2003 Aug;30(4
Suppl 10):32-6. Review. PubMed PMID: 12917819.
764: Bischof M, Huber P, Stoffregen C, Wannenmacher M, Weber KJ.
Radiosensitization by pemetrexed of human colon carcinoma cells in
different cell cycle phases. Int J Radiat Oncol Biol Phys. 2003 Sep
1;57(1):289-92. PubMed PMID: 12909245.
765: Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ.
Induction of resistance to the multitargeted antifolate Pemetrexed
(ALIMTA) in WiDr human colon cancer cells is associated with thymidylate
synthase overexpression. Biochem Pharmacol. 2003 Aug 1;66(3):431-8.
PubMed PMID: 12907242.
766: Martin M, Spielmann M, Namer M, duBois A, Unger C, Dodwell D,
Vodvarka P, Lind M, Calvert H, Casado A, Zelek L, Lluch A, Carrasco E,
Kayitalire L, Zielinski C. Phase II study of pemetrexed in breast cancer
patients pretreated with anthracyclines. Ann Oncol. 2003
Aug;14(8):1246-52. PubMed PMID: 12881387.
767: Kosmidis PA, Manegold C. Advanced NSCLC: new cytostatic agents.
Lung Cancer. 2003 Aug;41 Suppl 1:S123-32. Review. PubMed PMID: 12867071.
768: Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E,
Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C,
Paoletti P. Phase III study of pemetrexed in combination with cisplatin
versus cisplatin alone in patients with malignant pleural mesothelioma.
J Clin Oncol. 2003 Jul 15;21(14):2636-44. PubMed PMID: 12860938.
769: Rusch VW. Pemetrexed and cisplatin for malignant pleural
mesothelioma: a new standard of care? J Clin Oncol. 2003 Jul
15;21(14):2629-30. PubMed PMID: 12860935.
770: Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and
other newer agents in urothelial and kidney cancers. Crit Rev Oncol
Hematol. 2003 Jun 27;46 Suppl:S105-15. Review. PubMed PMID: 12850531.
771: Chu E, Callender MA, Farrell MP, Schmitz JC. Thymidylate synthase
inhibitors as anticancer agents: from bench to bedside. Cancer Chemother
Pharmacol. 2003 Jul;52 Suppl 1:S80-9. Epub 2003 Jun 18. Review. PubMed
PMID: 12819937.
772: Nishiwaki Y. [Malignant pleural mesothelioma]. Gan To Kagaku Ryoho.
2003 May;30(5):589-94. Review. Japanese. PubMed PMID: 12795087.
773: Kanzawa F, Akiyama Y, Saijo N, Nishio K. In vitro effects of
combinations of cis-amminedichloro (2-methylpyridine) platinum (II)
(ZD0473) with other novel anticancer drugs on the growth of SBC-3, a
human small cell lung cancer cell line. Lung Cancer. 2003
Jun;40(3):325-32. PubMed PMID: 12781432.
774: Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V,
Oniga F, Stefani M, Rea F, Bortolotti L, Loreggian L, Monfardini S.
Gemcitabine combined with carboplatin in patients with malignant pleural
mesothelioma: a multicentric phase II study. Cancer. 2003 Jun
1;97(11):2791-7. PubMed PMID: 12767092.
775: Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate
agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. Review. PubMed
PMID: 12722874.
776: Calvert H. Pemetrexed (Alimta): a promising new agent for the
treatment of breast cancer. Semin Oncol. 2003 Apr;30(2 Suppl 3):2-5.
Review. PubMed PMID: 12722017.
777: Scagliotti GV, Novello S. Pemetrexed and its emerging role in the
treatment of thoracic malignancies. Expert Opin Investig Drugs. 2003
May;12(5):853-63. Review. PubMed PMID: 12720495.
778: Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U,
Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven
JJ. Phase II study of pemetrexed with and without folic acid and vitamin
B12 as front-line therapy in malignant pleural mesothelioma. J Clin
Oncol. 2003 Apr 15;21(8):1556-61. PubMed PMID: 12697881.
779: Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H.
Review of a promising new agent--pemetrexed disodium. Cancer. 2003 Apr
15;97(8 Suppl):2056-63. Review. PubMed PMID: 12673697.
780: Wang Y, Zhao R, Goldman ID. Decreased expression of the reduced
folate carrier and folypolyglutamate synthetase is the basis for
acquired resistance to the pemetrexed antifolate (LY231514) in an L1210
murine leukemia cell line. Biochem Pharmacol. 2003 Apr 1;65(7):1163-70.
PubMed PMID: 12663051.
781: Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant
pleural mesothelioma: past results and recent developments. Br J Cancer.
2003 Jan 27;88(2):167-74. Review. PubMed PMID: 12610498; PubMed Central
PMCID: PMC2377054.
782: Tomek S, Manegold C. Chemotherapy for malignant pleural
mesothelioma. Curr Opin Oncol. 2003 Mar;15(2):148-56. Review. PubMed
PMID: 12601280.
783: Smit EF, Mattson K, von Pawel J, Manegold C, Clarke S, Postmus PE.
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell
lung cancer: a phase II study. Ann Oncol. 2003 Mar;14(3):455-60. PubMed
PMID: 12598353.
784: Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep.
2003 Mar;5(2):114-25. Review. PubMed PMID: 12583828.
785: Haller DG. Future directions in the treatment of pancreatic cancer.
Semin Oncol. 2002 Dec;29(6 Suppl 20):31-9. Review. PubMed PMID:
12577231.
786: Heinemann V. Gemcitabine in the treatment of advanced pancreatic
cancer: a comparative analysis of randomized trials. Semin Oncol. 2002
Dec;29(6 Suppl 20):9-16. Review. PubMed PMID: 12577228.
787: Paz-Ares L, Ciruelos E, García-Carbonero R, Castellano D, Lopez-Martín
A, Cortés-Funes H. Pemetrexed in bladder, head and neck, and cervical
cancers. Semin Oncol. 2002 Dec;29(6 Suppl 18):69-75. Review. PubMed
PMID: 12571815.
788: Celio L, Buzzoni R, Longarini R, Marchianň A, Bajetta E. Pemetrexed
in gastric cancer: clinical experience and future perspectives. Semin
Oncol. 2002 Dec;29(6 Suppl 18):63-8. Review. PubMed PMID: 12571814.
789: O'Shaughnessy JA. Pemetrexed: an active new agent for breast
cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):57-62. Review. PubMed PMID:
12571813.
790: Hochster H. The role of pemetrexed in the treatment of colorectal
cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):54-6. Review. PubMed PMID:
12571812.
791: Kindler HL. Pemetrexed in pancreatic cancer. Semin Oncol. 2002
Dec;29(6 Suppl 18):49-53. Review. PubMed PMID: 12571811.
792: Shepherd FA. Pemetrexed in the treatment of non-small cell lung
cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):43-8. Review. PubMed PMID:
12571810.
793: Vogelzang NJ. Emerging insights into the biology and therapy of
malignant mesothelioma. Semin Oncol. 2002 Dec;29(6 Suppl 18):35-42.
Review. PubMed PMID: 12571809.
794: Adjei AA. Preclinical and clinical studies with combinations of
pemetrexed and gemcitabine. Semin Oncol. 2002 Dec;29(6 Suppl 18):30-4.
Review. PubMed PMID: 12571808.
795: Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R,
Paoletti P, Bunn PA Jr. Pemetrexed safety and dosing strategy. Semin
Oncol. 2002 Dec;29(6 Suppl 18):24-9. Review. PubMed PMID: 12571807.
796: Boyer MJ, Rivory LP, Clarke SJ. Pemetrexed: single-agent and
combination phase I study overview. Semin Oncol. 2002 Dec;29(6 Suppl
18):18-23. Review. PubMed PMID: 12571806.
797: Goldman ID, Zhao R. Molecular, biochemical, and cellular
pharmacology of pemetrexed. Semin Oncol. 2002 Dec;29(6 Suppl 18):3-17.
Review. PubMed PMID: 12571805.
798: Steele JP. The new front line treatment for malignant pleural
mesothelioma? Thorax. 2003 Feb;58(2):96-7. PubMed PMID: 12554885; PubMed
Central PMCID: PMC1746576.
799: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):525-51. PubMed PMID:
12500432.
800: Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ,
Stabler SP, Paoletti P, Calvert AH, Allen RH. Homocysteine and
methylmalonic acid: markers to predict and avoid toxicity from
pemetrexed therapy. Mol Cancer Ther. 2002 May;1(7):545-52. PubMed PMID:
12479273.
801: Georgoulias VA. Second-line chemotherapy in relapsing or refractory
patients with non-small cell lung cancer. Lung Cancer. 2002 Dec;38 Suppl
3:S61-6. Review. PubMed PMID: 12468149.
802: Seidman AD, O'Shaughnessy J, Misset JL. Single-agent capecitabine:
a reference treatment for taxane-pretreated metastatic breast cancer?
Oncologist. 2002;7 Suppl 6:20-8. Review. PubMed PMID: 12454316.
803: Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in
colorectal cancer. Clin Colorectal Cancer. 2001 Nov;1(3):175-8;
discussion 179-81. Review. PubMed PMID: 12450432.
804: Rose MG, Farrell MP, Schmitz JC. Thymidylate synthase: a critical
target for cancer chemotherapy. Clin Colorectal Cancer. 2002
Feb;1(4):220-9. Review. PubMed PMID: 12450420.
805: Gligorov J, André T, Epaud C, Culine S. [Updates on gemcitabine at
the American Society of Clinical Oncology congress (ASCO, 2002) ]. Bull
Cancer. 2002 Aug;89 Spec No:S134-44. French. PubMed PMID: 12449045.
806: Wang Y, Zhao R, Chattopadhyay S, Goldman ID. A novel folate
transport activity in human mesothelioma cell lines with high affinity
and specificity for the new-generation antifolate, pemetrexed. Cancer
Res. 2002 Nov 15;62(22):6434-7. Erratum in: Cancer Res. 2003 Oct
15;63(20):7004. PubMed PMID: 12438230.
807: Sarries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, Rosell
R. Pharmacogenomic strategies for developing customized chemotherapy in
non-small cell lung cancer. Pharmacogenomics. 2002 Nov;3(6):763-80.
Review. PubMed PMID: 12437479.
808: Green MR. Alimta (pemetrexed disodium): a multitargeted antifolate
for the treatment of mesothelioma. Lung Cancer. 2002 Nov;38 Suppl
2:S55-7. Review. PubMed PMID: 12431831.
809: Postmus PE. Activity of pemetrexed (alimta), a new antifolate,
against non-small cell lung cancer. Lung Cancer. 2002 Nov;38 Suppl
2:S3-7. PubMed PMID: 12431822.
810: Manegold C. Pemetrexed: current development and future directions
in thoracic cancers. Suppl Tumori. 2002 Jul-Aug;1(4):S11-2. Review.
PubMed PMID: 12415805.
811: Kindler HL. The pemetrexed/gemcitabine combination in pancreatic
cancer. Cancer. 2002 Aug 15;95(4 Suppl):928-32. Review. PubMed PMID:
12209673.
812: Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J,
Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H. Phase I clinical
and pharmacokinetic study of pemetrexed and carboplatin in patients with
malignant pleural mesothelioma. J Clin Oncol. 2002 Aug
15;20(16):3533-44. PubMed PMID: 12177114.
813: Raymond E, Louvet C, Tournigand C, Coudray AM, Faivre S, De Gramont
A, Gespach C. Pemetrexed disodium combined with oxaliplatin, SN38, or
5-fluorouracil, based on the quantitation of drug interactions in human
HT29 colon cancer cells. Int J Oncol. 2002 Aug;21(2):361-7. PubMed PMID:
12118332.
814: Jones RJ, Twelves CJ. Pemetrexed: a multitargeted antifolate
(ALIMTA, LY-231514). Expert Rev Anticancer Ther. 2002 Feb;2(1):13-22.
Review. PubMed PMID: 12113062.
815: Le Chevalier T. Gemcitabine and pemetrexed (Alimta) in thoracic
cancers: present and future perspectives. Introduction and current
controversies. Semin Oncol. 2002 Jun;29(3 Suppl 9):43-6. Review. PubMed
PMID: 12094338.
816: Hanauske AR. Pemetrexed: translational research in breast cancer.
Semin Oncol. 2002 Jun;29(3 Suppl 9):40-2. Review. PubMed PMID: 12094337.
817: Culine S. The present and future of combination chemotherapy in
bladder cancer. Semin Oncol. 2002 Jun;29(3 Suppl 9):32-9. Review. PubMed
PMID: 12094336.
818: Bunn PA Jr. Incorporation of pemetrexed (Alimta) into the treatment
of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002
Jun;29(3 Suppl 9):17-22. Review. PubMed PMID: 12094334.
819: Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP.
Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in
chemotherapy-naďve patients with advanced non-small-cell lung cancer.
Ann Oncol. 2002 May;13(5):737-41. PubMed PMID: 12075742.
820: Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M. Peritoneal
mesothelioma. Curr Treat Options Oncol. 2000 Oct;1(4):303-12. Review.
PubMed PMID: 12057156.
821: Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat
Options Oncol. 2001 Dec;2(6):459-71. Review. PubMed PMID: 12057092.
822: Tripathy D. Gemcitabine in breast cancer: future directions. Clin
Breast Cancer. 2002 May;3 Suppl 1:45-8. Review. PubMed PMID: 12057046.
823: Adjei AA. Pemetrexed (Alimta) and gemcitabine in breast cancer
patients previously treated with anthracyclines and taxanes. Clin Breast
Cancer. 2002 May;3 Suppl 1:21-3. Review. PubMed PMID: 12057041.
824: Calvert H, Bunn PA Jr. Future directions in the development of
pemetrexed. Semin Oncol. 2002 Apr;29(2 Suppl 5):54-61. Review. PubMed
PMID: 12023794.
825: Adjei AA. Pemetrexed in the treatment of selected solid tumors.
Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. Review. PubMed PMID: 12023793.
826: de Gramont A, Kindler HL. Pemetrexed in patients with
gastrointestinal carcinoma. Semin Oncol. 2002 Apr;29(2 Suppl 5):42-9.
Review. PubMed PMID: 12023792.
827: O'Shaughnessy JA, Gennari A, Conte P. Pemetrexed: a promising new
treatment for breast cancer. Semin Oncol. 2002 Apr;29(2 Suppl 5):36-41.
Review. PubMed PMID: 12023791.
828: Manegold C, Aisner J. Pemetrexed for diffuse malignant pleural
mesothelioma. Semin Oncol. 2002 Apr;29(2 Suppl 5):30-5. Review. PubMed
PMID: 12023790.
829: Rosell R, Crinó L. Pemetrexed combination therapy in the treatment
of non-small cell lung cancer. Semin Oncol. 2002 Apr;29(2 Suppl 5):23-9.
Review. PubMed PMID: 12023789.
830: Postmus PE, Bunn PA Jr. Pemetrexed as a single agent in the therapy
of advanced lung cancer. Semin Oncol. 2002 Apr;29(2 Suppl 5):17-22.
Review. PubMed PMID: 12023788.
831: Fossella FV, Gatzemeier U. Phase I trials of pemetrexed. Semin
Oncol. 2002 Apr;29(2 Suppl 5):8-16. Review. PubMed PMID: 12023787.
832: Calvert H. Folate status and the safety profile of antifolates.
Semin Oncol. 2002 Apr;29(2 Suppl 5):3-7. Review. PubMed PMID: 12023786.
833: Pemetrexed, an novel multitargeted antifolate: current development
and future directions. Proceedings of a meeting. August 17-19, 2000.
Colorado Springs, Colorado, USA. Semin Oncol. 2002 Apr;29(2 Suppl
5):1-61; quiz 62-9. PubMed PMID: 12023785.
834: Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D. Interaction
of pemetrexed disodium (ALIMTA, multitargeted antifolate) and
irradiation in vitro. Int J Radiat Oncol Biol Phys. 2002 Apr
1;52(5):1381-8. PubMed PMID: 11955753.
835: Riviere A. [Does treatment for malignant pleural mesothelioma
exist?]. Rev Pneumol Clin. 2001 Nov;57(5 Pt 2):S3-6. Review. French.
PubMed PMID: 11924240.
836: Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with
multiple targets. Lancet Oncol. 2001 May;2(5):298-306. Review. PubMed
PMID: 11905785.
837: Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ.
Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in
metastatic breast cancer patients previously treated with an
anthracycline and a taxane: an interim analysis. Clin Breast Cancer.
2001 Apr;2(1):47-51. PubMed PMID: 11899382.
838: Misset JL. Brief communication: use of the multitargeted antifolate
pemetrexed (Alimta) in genitourinary cancer. Semin Oncol. 2002 Feb;29(1
Suppl 3):36-9. Review. PubMed PMID: 11894006.
839: Schultz RM, Dempsey JA. Sequence dependence of Alimta (LY231514,
MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells.
Anticancer Res. 2001 Sep-Oct;21(5):3209-14. PubMed PMID: 11848474.
840: Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I,
Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G.
Multiple mechanisms of resistance to methotrexate and novel antifolates
in human CCRF-CEM leukemia cells and their implications for folate
homeostasis. Biochem Pharmacol. 2002 Jan 15;63(2):105-15. PubMed PMID:
11841783.
841: Fizazi K, John WJ, Vogelzang NJ. The emerging role of antifolates
in the treatment of malignant pleural mesothelioma. Semin Oncol. 2002
Feb;29(1):77-81. Review. PubMed PMID: 11836672.
842: Kindler HL, van Meerbeeck JP. The role of gemcitabine in the
treatment of malignant mesothelioma. Semin Oncol. 2002 Feb;29(1):70-6.
Review. PubMed PMID: 11836671.
843: Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti GL, Zoli W.
In Vitro schedule-dependent interactions between the multitargeted
antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell
lines. Clin Cancer Res. 2002 Jan;8(1):233-9. PubMed PMID: 11801564.
844: Backus HH, Wouters D, van der Wilt CL, Kuiper CM, van Groeningen
CJ, Pinedo HM, Peters GJ. Thymidylate synthase inhibition induces p53
dependent and independent cell death. Adv Exp Med Biol. 2000;486:303-6.
PubMed PMID: 11783505.
845: Rivory LP, Clarke SJ, Boyer M, Bishop JF. Highly sensitive analysis
of the antifolate pemetrexed sodium, a new cancer agent, in human plasma
and urine by high-performance liquid chromatography. J Chromatogr B
Biomed Sci Appl. 2001 Dec 25;765(2):135-40. PubMed PMID: 11767306.
846: Norman P. Pemetrexed disodium (Eli Lilly). Curr Opin Investig
Drugs. 2001 Nov;2(11):1611-22. Review. PubMed PMID: 11763166.
847: Novello S, le Chevalier T. ALIMTA (pemetrexed disodium, LY231514,
MTA): clinical experience in non-small cell lung cancer. Lung Cancer.
2001 Dec;34 Suppl 4:S107-9. Review. PubMed PMID: 11742713.
848: Adjei AA. Gemcitabine and pemetrexed disodium combinations in vitro
and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. Review. PubMed
PMID: 11742712.
849: Sayre PH, Finer-Moore JS, Fritz TA, Biermann D, Gates SB, MacKellar
WC, Patel VF, Stroud RM. Multi-targeted antifolates aimed at avoiding
drug resistance form covalent closed inhibitory complexes with human and
Escherichia coli thymidylate synthases. J Mol Biol. 2001 Nov
2;313(4):813-29. Erratum in: J Mol Biol 2002 Mar 1;316(4):1005. PubMed
PMID: 11697906.
850: Mauceri HJ, Seetharam S, Salloum RM, Vokes EE, Weichselbaum RR.
Treatment of head and neck and esophageal xenografts employing Alimta
and concurrent ionizing radiation. Int J Oncol. 2001 Oct;19(4):833-5.
PubMed PMID: 11562763.
851: Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP,
Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R,
Latz J, Schneider M. Pemetrexed disodium in recurrent locally advanced
or metastatic squamous cell carcinoma of the head and neck. Br J Cancer.
2001 Sep 1;85(5):649-55. PubMed PMID: 11531245; PubMed Central PMCID:
PMC2364119.
852: Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a
novel antifolate clinically active against multiple solid tumors.
Oncologist. 2001;6(4):363-73. Review. PubMed PMID: 11524555.
853: Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson
RD, Fisher B, Eisenhauer E. Phase II study of pemetrexed disodium, a
multitargeted antifolate, and cisplatin as first-line therapy in
patients with advanced nonsmall cell lung carcinoma: a study of the
National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001
Aug 1;92(3):595-600. PubMed PMID: 11505404.
854: Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. The impact of p53
status on cellular sensitivity to antifolate drugs. Clin Cancer Res.
2001 Jul;7(7):2114-23. PubMed PMID: 11448931.
855: Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH,
Newell DR, Curtin NJ. In vitro and in vivo properties of novel
nucleoside transport inhibitors with improved pharmacological properties
that potentiate antifolate activity. Clin Cancer Res. 2001
Jul;7(7):2105-13. PubMed PMID: 11448930.
856: Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ. A phase II
study of pemetrexed disodium (LY231514) in patients with locally
recurrent or metastatic breast cancer. Eur J Cancer. 2001
Jul;37(11):1366-71. PubMed PMID: 11435066.
857: Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van
Groeningen CJ, Peters GJ. Differences in the induction of DNA damage,
cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Oncol Res. 2000;12(5):231-9. PubMed PMID: 11417748.
858: Gangjee A, Vidwans A, Elzein E, McGuire JJ, Queener SF, Kisliuk RL.
Synthesis, antifolate, and antitumor activities of classical and
nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J
Med Chem. 2001 Jun 7;44(12):1993-2003. PubMed PMID: 11384244.
859: Taylor EC, Liu B. A new route to 7-substituted derivatives of
n-[4-(2-[2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimidin-5-yl]ethyl)benzoyl]
-L-glutamic acid [ALIMTA (LY231514, MTA)]. J Org Chem. 2001 Jun
1;66(11):3726-38. PubMed PMID: 11374991.
860: van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D,
Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters
GJ. Modulation of both endogenous folates and thymidine enhance the
therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res.
2001 May 1;61(9):3675-81. PubMed PMID: 11325838.
861: Bunn PA Jr. Triplet combination chemotherapy and targeted therapy
regimens. Oncology (Williston Park). 2001 Mar;15(3 Suppl 6):26-32.
Review. PubMed PMID: 11301845.
862: Adjei AA. Gemcitabine and Pemetrexed disodium in treating breast
cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. Review.
PubMed PMID: 11252887.
863: Adjei AA. Pemetrexed: a multitargeted antifolate agent with
promising activity in solid tumors. Ann Oncol. 2000 Oct;11(10):1335-41.
Review. PubMed PMID: 11106124.
864: Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate
(MTA): pharmacokinetics of intraperitoneal administration in a rat
model. Eur J Surg Oncol. 2000 Nov;26(7):696-700. PubMed PMID: 11078617.
865: Cassidy J. Thymidylate synthase inhibitors in colorectal cancer.
Semin Oncol. 2000 Oct;27(5 Suppl 10):83-7. Review. PubMed PMID:
11049037.
866: Ouellet D, Periclou AP, Johnson RD, Woodworth JR, Lalonde RL.
Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients
with cancer. Cancer Chemother Pharmacol. 2000;46(3):227-34. PubMed PMID:
11021740.
867: Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of
transport of the multitargeted antifolate (MTA) and its cross-resistance
pattern in cells with markedly impaired transport of methotrexate. Clin
Cancer Res. 2000 Sep;6(9):3687-95. PubMed PMID: 10999762.
868: Ettinger DS. Gemcitabine/Alimta in locally advanced or metastatic
non-small-cell lung cancer. Oncology (Williston Park). 2000 Jul;14(7
Suppl 4):49-52. PubMed PMID: 10960946.
869: Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL,
Aherne GW. Comparison of thymidylate synthase (TS) protein up-regulation
after exposure to TS inhibitors in normal and tumor cell lines and
tissues. Clin Cancer Res. 2000 Jun;6(6):2538-46. PubMed PMID: 10873110.
870: Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R,
Blatter J, Krejcy K. Front-line treatment of advanced non-small-cell
lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and
cisplatin: a multicenter phase II trial. Ann Oncol. 2000
Apr;11(4):435-40. PubMed PMID: 10847462.
871: Van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream
molecular determinants of response to 5-fluorouracil and antifolate
thymidylate synthase inhibitors. Ann Oncol. 2000 Apr;11(4):385-91.
Review. PubMed PMID: 10847455.
872: Chen VJ, Bewley JR, Smith PG, Andis SL, Schultz RM, Iversen PW,
Tonkinson JL, Shih C. An assessment of the antithymine and antipurine
characteristics of MTA (LY231514) in CCRF-CEM cells. Adv Enzyme Regul.
2000;40:143-54. PubMed PMID: 10828350.
873: van der Wilt CL, Kuiper CM, Peters GJ. Combination studies of
antifolates with 5-fluorouracil in colon cancer cell lines. Oncol Res.
1999;11(8):383-91. PubMed PMID: 10803742.
874: Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM,
Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and
pharmacologic study of sequences of gemcitabine and the multitargeted
antifolate agent in patients with advanced solid tumors. J Clin Oncol.
2000 Apr;18(8):1748-57. PubMed PMID: 10764436.
875: John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK,
Thornton DE, Loehrer PJ. Activity of multitargeted antifolate (pemetrexed
disodium, LY231514) in patients with advanced colorectal carcinoma:
results from a phase II study. Cancer. 2000 Apr 15;88(8):1807-13. PubMed
PMID: 10760756.
876: Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud
T. Treatment regimens including the multitargeted antifolate LY231514 in
human tumor xenografts. Clin Cancer Res. 2000 Mar;6(3):1016-23. PubMed
PMID: 10741729.
877: Patel DH, Allay JA, Belt JA, Sorrentino BP. Retroviral transfer of
the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate
resistance in murine bone marrow cells. Blood. 2000 Apr 1;95(7):2356-63.
PubMed PMID: 10733507.
878: Smith PG, Marshman E, Newell DR, Curtin NJ. Dipyridamole
potentiates the in vitro activity of MTA (LY231514) by inhibition of
thymidine transport. Br J Cancer. 2000 Feb;82(4):924-30. PubMed PMID:
10732767; PubMed Central PMCID: PMC2374405.
879: Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton
D, Rowinsky E, Loehrer PJ Sr. Phase II study of the multitargeted
antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with
advanced pancreatic cancer. Ann Oncol. 2000 Jan;11(1):101-3. PubMed
PMID: 10690396.
880: MTA, A Novel Multitargeted Antifolate: from preclinical to phase I
and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998.
Semin Oncol. 1999 Apr;26(2 Suppl 6):1-110. PubMed PMID: 10610578.
881: Danenberg PV, Malli H, Swenson S. Thymidylate synthase inhibitors.
Semin Oncol. 1999 Dec;26(6):621-31. Review. PubMed PMID: 10606255.
882: Calvert H. MTA, a novel multitargeted antifolate, from preclinical
to phase I and beyond: summary and conclusions. Semin Oncol. 1999
Apr;26(2 Suppl 6):105-8. PubMed PMID: 10598564.
883: O'Dwyer PJ, Nelson K, Thornton DE. Overview of phase II trials of
MTA in solid tumors. Semin Oncol. 1999 Apr;26(2 Suppl 6):99-104. Review.
PubMed PMID: 10598563.
884: Adjei AA, Erlichman C. A phase I trial of MTA and gemcitabine in
patients with locally advanced or metastatic cancer. Semin Oncol. 1999
Apr;26(2 Suppl 6):94-8. PubMed PMID: 10598562.
885: Thödtmann R, Depenbrock H, Blatter J, Johnson RD, van Oosterom A,
Hanauske AR. Preliminary results of a phase I study with MTA (LY231514)
in combination with cisplatin in patients with solid tumors. Semin Oncol.
1999 Apr;26(2 Suppl 6):89-93. PubMed PMID: 10598561.
886: Rinaldi DA. Overview of phase I trials of multitargeted antifolate
(MTA, LY231514). Semin Oncol. 1999 Apr;26(2 Suppl 6):82-8. Review.
PubMed PMID: 10598560.
887: Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA.
Biological activity of the multitargeted antifolate, MTA (LY231514), in
human cell lines with different resistance mechanisms to antifolate
drugs. Semin Oncol. 1999 Apr;26(2 Suppl 6):68-73. PubMed PMID: 10598558.
888: Smith PG, Marshman E, Calvert AH, Newell DR, Curtin NJ. Prevention
of thymidine and hypoxanthine rescue from MTA (LY231514) growth
inhibition by dipyridamole in human lung cancer cell lines. Semin Oncol.
1999 Apr;26(2 Suppl 6):63-7. PubMed PMID: 10598557.
889: Teicher BA, Alvarez E, Liu P, Lu K, Menon K, Dempsey J, Schultz RM.
MTA (LY231514) in combination treatment regimens using human tumor
xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol. 1999
Apr;26(2 Suppl 6):55-62. PubMed PMID: 10598556.
890: Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C,
Mendelsohn LG, Seitz DE, Tonkinson JL. Cellular pharmacology of MTA: a
correlation of MTA-induced cellular toxicity and in vitro enzyme
inhibition with its effect on intracellular folate and nucleoside
triphosphate pools in CCRF-CEM cells. Semin Oncol. 1999 Apr;26(2 Suppl
6):48-54. PubMed PMID: 10598555.
891: Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford
KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA)
on purine biosynthesis. Semin Oncol. 1999 Apr;26(2 Suppl 6):42-7.
Review. PubMed PMID: 10598554.
892: Galivan J, Ryan T, Rhee M, Yao R, Chave K. Glutamyl hydrolase:
properties and pharmacologic impact. Semin Oncol. 1999 Apr;26(2 Suppl
6):33-7. Review. PubMed PMID: 10598552.
893: Calvert H. An overview of folate metabolism: features relevant to
the action and toxicities of antifolate anticancer agents. Semin Oncol.
1999 Apr;26(2 Suppl 6):3-10. Review. PubMed PMID: 10598549.
894: Allegra CJ. Antifolates: the next millennium. Semin Oncol. 1999
Apr;26(2 Suppl 6):1-2. PubMed PMID: 10598548.
895: Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J,
Iglesias J, Fisher B, Eisenhauer EA. Phase II study of first-line
LY231514 (multi-targeted antifolate) in patients with locally advanced
or metastatic colorectal cancer: an NCIC Clinical Trials Group study.
Ann Oncol. 1999 Oct;10(10):1175-9. PubMed PMID: 10586333.
896: Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B,
Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy
for patients with advanced non-small-cell lung cancer: A phase II study.
National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol.
1999 Apr;17(4):1194. PubMed PMID: 10561178.
897: Lansiaux A, Degardin M, Bailly C. [LY231514. A multitargeted
antifolate (MTA)]. Bull Cancer. 1999 Sep;86(9):727-31. French. PubMed
PMID: 10519965.
898: Adjei AA. A review of the pharmacology and clinical activity of new
chemotherapy agents for the treatment of colorectal cancer. Br J Clin
Pharmacol. 1999 Sep;48(3):265-77. Review. PubMed PMID: 10510136; PubMed
Central PMCID: PMC2014335.
899: Thödtmann R, Depenbrock H, Dumez H, Blatter J, Johnson RD, van
Oosterom A, Hanauske AR. Clinical and pharmacokinetic phase I study of
multitargeted antifolate (LY231514) in combination with cisplatin. J
Clin Oncol. 1999 Oct;17(10):3009-16. PubMed PMID: 10506594.
900: Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the
multitargeted antifolate LY231514. Cancer Chemother Pharmacol.
1999;44(5):427-32. PubMed PMID: 10501918.
901: Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG,
Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von
Hoff DD. A phase I evaluation of multitargeted antifolate (MTA,
LY231514), administered every 21 days, utilizing the modified continual
reassessment method for dose escalation. Cancer Chemother Pharmacol.
1999;44(5):372-80. PubMed PMID: 10501910.
902: Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle
modulation by a multitargeted antifolate, LY231514, increases the
cytotoxicity and antitumor activity of gemcitabine in HT29 colon
carcinoma. Cancer Res. 1999 Aug 1;59(15):3671-6. PubMed PMID: 10446980.
903: Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna
C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DD. Activity of the
multitargeted antifolate LY231514 in the human tumor cloning assay.
Cancer Chemother Pharmacol. 1999;44(2):105-10. PubMed PMID: 10412943.
904: Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate
synthase in the antitumor activity of the multitargeted antifolate,
LY231514. Anticancer Res. 1999 Jan-Feb;19(1A):437-43. PubMed PMID:
10226579.
905: Postmus PE, Green MR. Overview of MTA in the treatment of non-small
cell lung cancer. Semin Oncol. 1999 Feb;26(1 Suppl 4):31-6. Review.
PubMed PMID: 10201519.
906: Johnson D, Tonato M. Introduction: the emerging roles of
gemcitabine and MTA in the treatment of non-small cell lung cancer.
Semin Oncol. 1999 Feb;26(1 Suppl 4):1-2. PubMed PMID: 10201514.
907: Gossett LS, Habeck LL, Shackelford KA, Mendelsohn LG, Gates SB,
Worzalla JF, Self TD, Theobald KS, Andis SL, Schultz RM, Shih C. The
synthesis and biological activity of a series of
2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic
and antiarthritic agents. Bioorg Med Chem Lett. 1999 Jan 4;9(1):75-8.
PubMed PMID: 9990460.
908: Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating
the toxicity and efficacy of the multitargeted antifolate, LY231514.
Anticancer Res. 1998 Sep-Oct;18(5A):3235-9. PubMed PMID: 9858888.
909: Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple
folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based
antifolate LY231514 (MTA). Adv Enzyme Regul. 1998;38:135-52. PubMed
PMID: 9762351.
910: Calvert AH, Walling JM. Clinical studies with MTA. Br J Cancer.
1998;78 Suppl 3:35-40. Review. PubMed PMID: 9717989; PubMed Central
PMCID: PMC2062802.
911: Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C,
Mendelsohn LG, Seitz DE, Tonkinson JL. Preclinical cellular pharmacology
of LY231514 (MTA): a comparison with methotrexate, LY309887 and
raltitrexed for their effects on intracellular folate and nucleoside
triphosphate pools in CCRF-CEM cells. Br J Cancer. 1998;78 Suppl
3:27-34. PubMed PMID: 9717988; PubMed Central PMCID: PMC2062799.
912: Von Hoff DD, Goodwin AL, Garcia L. Advances in the treatment of
patients with pancreatic cancer: improvement in symptoms and survival
time. The San Antonio Drug Development Team. Br J Cancer. 1998;78 Suppl
3:9-13. Review. PubMed PMID: 9717985; PubMed Central PMCID: PMC2062801.
913: McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams
T, McCarthy S, Bailey NP, Siddiqui N, Lind MJ, Calvert AH, Twelves CJ,
Cassidy J, Kaye SB. A phase I and pharmacokinetic study of LY231514, the
multitargeted antifolate. Clin Cancer Res. 1998 Mar;4(3):605-10. PubMed
PMID: 9533527.
914: Takimoto CH. Antifolates in clinical development. Semin Oncol. 1997
Oct;24(5 Suppl 18):S18-40-S18-51. Review. PubMed PMID: 9420020.
915: Woodland JM, Barnett CJ, Dorman DE, Gruber JM, Shih C, Spangle LA,
Wilson TM, Ehlhardt WJ. Metabolism and disposition of the antifolate
LY231514 in mice and dogs. Drug Metab Dispos. 1997 Jun;25(6):693-700.
PubMed PMID: 9193870.
916: Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL,
Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR,
Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM.
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits
multiple folate-requiring enzymes. Cancer Res. 1997 Mar
15;57(6):1116-23. PubMed PMID: 9067281.
917: Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C,
Mendelsohn LG. Cell cycle effects of antifolate antimetabolites:
implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol.
1997;39(6):521-31. PubMed PMID: 9118464.
918: Hanauske AR. The development of new chemotherapeutic agents.
Anticancer Drugs. 1996 Aug;7 Suppl 2:29-32. Review. PubMed PMID:
8862708.
919: Jackman AL, Calvert AH. Folate-based thymidylate synthase
inhibitors as anticancer drugs. Ann Oncol. 1995 Nov;6(9):871-81. Review.
PubMed PMID: 8624289.
920: Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR,
Rodriguez G, Corso SW, Fields SM, Langley C, et al. Initial phase I
evaluation of the novel thymidylate synthase inhibitor, LY231514, using
the modified continual reassessment method for dose escalation. J Clin
Oncol. 1995 Nov;13(11):2842-50. PubMed PMID: 7595747.
921: Lu K, Yin MB, McGuire JJ, Bonmassar E, Rustum YM. Mechanisms of
resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-
oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid
(ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8
human ileocecal adenocarcinoma cell line. Biochem Pharmacol. 1995 Jul
31;50(3):391-8. PubMed PMID: 7646540.
922: Hamilton CL, Kirkwood JA. Column-switching high-performance liquid
chromatographic method for the determination of a thymidylate synthase
inhibitor, LY231514, an investigational agent for the treatment of solid
tumors, in human plasma. J Chromatogr B Biomed Appl. 1994 Apr
1;654(2):297-303. PubMed PMID: 8044293.
923: Barnett CJ, Wilson TM, Grindey GB. Synthesis and antitumor activity
of LY288601, the 5,6-dihydro analog of LY231514. Adv Exp Med Biol.
1993;338:409-12. PubMed PMID: 8304146.
924: Taylor EC. Design and synthesis of inhibitors of folate-dependent
enzymes as antitumor agents. Adv Exp Med Biol. 1993;338:387-408. Review.
PubMed PMID: 8304144.
925: Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J,
Jannatipour M, Moran RG. A dideazatetrahydrofolate analogue lacking a
chiral center at C-6,
N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic
acid, is an inhibitor of thymidylate synthase. J Med Chem. 1992 Nov
13;35(23):4450-4. PubMed PMID: 1447744.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
